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Abstract	  
The	  NKG2	  family	  is	  one	  of	  the	  multiple	  families	  of	  immune	  receptors	  encoded	  in	  the	  human	  
genome	   that	   contains	   members	   with	   activating	   and	   inhibitory	   potential.	   The	   CD94/NKG2A	  
inhibiting	  and	  CD94/	  NKG2C	  activating	  receptors	  are	  mainly	  expressed	  on	  NK	  cells	  and	  subsets	  
of	  CD8+	  T	  cells	  and	  have	  been	  shown	  to	  play	  an	  important	  role	  in	  regulating	  immune	  responses	  
against	  infected	  and	  tumour	  cells.	  However	  the	  biology	  of	  other	  members	  of	  the	  NKG2	  family	  
has	   been	   much	   less	   explored.	   Strikingly,	   both	   CD94/NKG2A	   and	   CD94/NKG2C	   can	   bind	   the	  
same	   ligand;	   the	   non-­‐classical	   HLA	   class	   I	   molecule	   HLA-­‐E	   loaded	   with	   nonamer	   peptides	  
derived	   from	  the	  signal	   sequence	  of	  classical	  MHC	  class	   I	  molecules	  or	  with	  peptides	  derived	  
from	   other	   proteins,	   including	   pathogen	   proteins,	   to	   form	   peptide/HLA-­‐E/β2-­‐microglobulin	  
trimers	  that	  can	  be	  recognized	  by	  specific	  T	  cells	  for	  immune	  activation.	  
The	  experiments	  described	   in	   this	   thesis	  have	  addressed	  two	  aspects	  of	   the	  biology	  of	   the	  
CD94/NKG2	  –	  HLA-­‐E	  system:	  
In	  the	  first	  part	  of	  this	  work,	  the	  NKG2H	  receptor,	  an	  as	  yet	  poorly	  characterized	  member	  of	  
the	   NKG2	   family	   has	   been	   studied	   in	   detail.	   NKG2H	   was	   expressed	   on	   low	   numbers	   of	  
peripheral	  blood	  lymphocytes,	  mainly	  on	  CD3+CD56+	  and	  CD3+CD8+	  T	  cells.	  Activation	  of	  NKG2H	  
expressing	   cells	  markedly	   reduced	   the	   activation	   and	  proliferation	  of	   the	  other	   T	   cells	   in	   the	  
culture	  via	  induction	  of	  apoptosis.	  This	  suppressive	  activity	  was	  characteristic	  of	  NKG2H	  but	  not	  
for	  NKG2A	  or	  NKG2C	  expressing	  cells	  and	  did	  not	  depend	  on	  the	  release	  of	  soluble	  factors	  or	  
recognition	  of	  MHC	  class	   I	  molecules.	  A	  marked	   increase	   in	   the	  proportion	  of	   T	   and	  NK	   cells	  
expressing	  NKG2H+	  but	  not	  NKG2A+	  or	  NKG2C+	  cells	  was	  observed	  after	   co-­‐culture	  of	  PBMCs,	  
from	  healthy	  HCMV	  seronegative	  individuals,	  with	  HCMV	  infected	  fibroblasts.	  The	  expansion	  of	  
NKG2H+	   cells	   depended	   on	   contact	   between	   PBMCs	   and	   HCMV	   infected	   fibroblasts	   and	  
separation	  of	  these	  cells	  led	  to	  the	  loss	  of	  NKG2H	  expression.	  
In	   the	   second	   part	   of	   the	   thesis,	   a	   possible	   role	   of	  Mycobacterium	   tuberculosis	   (Mtb)	   –	  
peptide	   specific,	   HLA-­‐E	   restricted	   cells	   in	   the	   immune	   response	   of	   bladder	   cancer	   patients	  
receiving	  BCG	   immunotherapy	  was	   studied.	   Low	   frequencies	  of	  CD8+	  T	   cells	   reactive	  with	   the	  
Mtb-­‐peptide/HLA-­‐E	  tetramers	  were	  observed	  in	  the	  peripheral	  blood	  of	  these	  patients.	  
Our	   data	   are	   the	   first	   to	   describe	   the	   populations	   of	   cells	   that	   express	   the	   CD94/NKG2H	  
receptor,	  the	  effects	  on	  lymphocyte	  function	  elicited	  by	  receptor	  ligation	  and	  a	  possible	  role	  for	  
CD94/NKG2H	   in	   immune	   responses	   to	   viral	   infection.	   Further,	   the	   HLA-­‐E	   tetramer	   staining	  
method	  has	  been	  shown	  to	  be	  applicable	  for	  the	  detection	  and	  characterization	  of	  Mtb	  specific	  
HLA-­‐E	  restricted	  T	  cells	  during	  BCG	  therapy	  in	  bladder	  cancer	  patients,	  although	  this	  approach	  
could	  be	  improved	  by	  use	  of	  a	  larger	  library	  of	  Mtb-­‐peptide/HLA-­‐E	  complexes.	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Presentación	  
NKG2	  es	  una	   familia	  de	   receptores	   inmunes	  que	  engloba	  algunos	  miembros	   con	  potencial	  
activador	   y	   otros	   inhibidores,	   como	   sucede	   con	   otras	   muchas	   otras	   familias	   de	   receptores	  
inmunes	  codificadas	  en	  el	  genoma	  humano.	   Los	  heterodímeros	  CD94/NKG2A	  y	  CD94/NKG2C,	  
inhibidor	  y	  activador	   respectivamente,	   se	  han	  estudiado	  en	  profundidad	  en	   los	  últimos	  años.	  
Estos	   receptores	   se	   expresan	   sobre	   todo	   en	   células	   Natural	   Killer	   (NK)	   y	   subpoblaciones	   de	  
linfocitos	  T	  CD8+	  y	  se	  ha	  demostrado	  que	  desempeñan	  un	  importante	  papel	  en	  la	  regulación	  de	  
la	  respuesta	  inmune	  generada	  frente	  a	  células	  infectadas	  y	  tumorales.	  Sin	  embargo,	  la	  biología	  
de	  algunos	  miembros	  de	  la	  familia	  NKG2	  no	  se	  ha	  estudiado	  todavía.	  Tanto	  CD94/NKG2A	  como	  
CD94/NKG2C	   reconocen	   	   el	  mismo	   ligando:	   la	  molécula	   de	  MHC	  de	   clase	   I	   no	   clásica	  HLA-­‐E,	  
cargada	   con	   péptidos	   nonaméricos	   derivados	   de	   la	   secuencia	   señal	   de	   otras	   moléculas	   de	  
histocompatibilidad	   clásicas;	   aunque	   también	   se	   ha	   descrito	   que	   HLA-­‐E	   puede	   presentar	  
péptidos	  derivados	  de	  otras	  proteínas,	  incluyendo	  proteínas	  de	  patógenos,	  formando	  trímeros	  
péptido/HLA-­‐E/β2-­‐	  microglobulina	  que	  pueden	  ser	  reconocidos	  por	  células	  T	  específicas.	  
Los	   experimentos	   descritos	   en	   esta	   tesis	   estudian	   dos	   aspectos	   de	   la	   biología	   del	   sistema	  
CD94/NKG2	  –	  HLA-­‐E:	  	  
En	  la	  primera	  parte	  de	  este	  trabajo,	  se	  estudia	  en	  detalle	  el	  todavía	  poco	  conocido	  receptor	  
NKG2H.	  Se	  muestra	  que	  este	  receptor	  se	  expresa	  en	  la	  superficie	  celular	  de	  un	  porcentaje	  muy	  
bajo	  de	  células	  efectoras,	  principalmente	  CD3+CD56+	  y	  T	  CD3+CD8+.	  La	  activación	  de	  linfocitos	  a	  
través	  de	  NKG2H	  redujo	  de	  manera	  considerable	  la	  activación	  y	  la	  proliferación	  de	  otras	  células	  
T	   en	   el	   cultivo,	   mediante	   inducción	   de	   apoptosis.	   Este	   efecto	   supresor	   era	   característico	   de	  
NKG2H	  pero	  no	  de	  células	  que	  expresaban	  NKG2A	  o	  NKG2C,	  y	  no	  dependía	  de	  la	  liberación	  de	  
factores	  solubles	  o	  del	  reconocimiento	  de	  MHC	  de	  clase	  I.	  Tras	  el	  cultivo	  de	  células	  de	  sangre	  
periférica,	   proveniente	   de	   donantes	   sanos	   seronegativos	   para	   HCMV	   con	   fibroblastos	  
infectados	  con	  HCMV,	  se	  observó	  un	   incremento	  notable	  en	   la	  proporción	  de	  células	  NK	  que	  
expresaban	  NKG2H	   pero	   no	  NKG2A	   o	  NKG2C.	   La	   expansión	   de	   células	   positivas	   para	  NKG2H	  
dependía	  del	  contacto	  entre	   las	  células	  de	  sangre	  periférica	  y	   los	   fibroblastos	   infectados,	  y	   la	  
separación	  de	  ambas	  células	  daba	  lugar	  a	  la	  pérdida	  de	  expresión	  de	  NKG2H.	  
En	   la	   segunda	   parte	   de	   esta	   tesis,	   se	   estudia	   el	   posible	   papel	   de	   péptidos	   específicos	   de	  
Mycobacterium	   tuberculosis,	   restringidos	   por	   HLA-­‐E,	   en	   la	   respuesta	   inmune	   generada	   por	  
pacientes	  de	  cáncer	  de	  vejiga	  recibiendo	  inmunoterapia	  basada	  en	  BCG.	  Utilizando	  tetrámeros	  
HLA-­‐E/	  péptido	  Mtb	  se	  encontraron	  frecuencias	  bajas	  de	  células	  positivas	  en	  sangre	  periférica	  
de	  los	  pacientes.	  
Nuestros	  datos	  son	  los	  primeros	  en	  describir	  el	  fenotipo,	  las	  características	  funcionales	  y	  el	  
posible	   papel	   en	   las	   respuestas	   inmunes	   frente	   a	   infecciones	   virales	   desempeñadas	   por	   el	  
receptor	  CD94/NKG2H.	  Más	  aún,	  se	  demuestra	  que	  el	  uso	  de	  tetrámeros	  de	  HLA-­‐E	  constituye	  
un	  método	  aplicable	  para	  teñir	  células	  de	  sangre	  periférica	  y	  evaluar	  la	  presencia	  de	  células	  T	  
restringidas	   por	   péptidos	   específicos	   de	  Mtb	   en	   el	   caso	   de	   los	   pacientes	   y	   cáncer	   de	   vejiga,	  
aunque	   este	   procedimiento	   se	   puede	   mejorar	   utilizando	   un	   repertorio	   más	   amplio	   de	  




	  	   21	  
Abbreviations	  
7-­‐AAD	   7-­‐aminoactinomycin	  d	  
APC	   Allophycocyanin	  
CD	   Cluster	  of	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The Inhibition / activation paradigm in immunology	  
	  1. Introduction	  
	  
NK	   cells	   were,	   for	   a	   long	   time,	   thought	   to	   be	   regulated	   by	   the	   ‘missing-­‐self’	   hypothesis	  
(Ljunggren	   and	   Karre,	   1990).	   	   This	   theory	   proposed	   that	   NK	   cells	   were	   constitutively	   active,	   but	  
inhibited	  via	   inhibiting	  receptors	  and	  their	   interaction	  with	  MHC	  class	  I.	   	   In	  the	  case	  of	  down-­‐
regulation	  of	  MHC	  class	  I	  such	  as	  in	  virally	  infected	  cells	  and	  cancerous	  cells,	  inhibition	  would	  be	  
lost,	   leading	   to	   activation	   of	   the	  NK	   cell’s	   function,	   namely,	   killing	   infected	   or	   defective	   cells	  
within	   the	  body.	   	  However,	  eventually	   it	  was	  discovered	   that	  NK	  cells	   also	  express	  activating	  
receptors,	  and	  that,	  additionally,	  inhibiting	  receptors	  were	  not	  restricted	  to	  the	  NK	  cell	  subset,	  
but	   were	   expressed	   on	   many	   other	   immune	   cell	   subsets	   such	   as	   B	   cells,	  
monocyte/macrophages,	  dendritic	  cells	  (DCs)	  and	  T	  cells.	  	  Further,	  it	  was	  discovered	  that	  there	  
were	  specialized	  families	  of	  receptor	  pairs/families	  with	  both	  activating	  and	  inhibiting	  members	  
(Fig.	  1).	  This	  has	  led	  to	  a	  new	  paradigm	  of	  homeostasis	  where	  any	  given	  cell	  is	  controlled	  by	  a	  
balance	  of	  both	  inhibiting	  and	  activating	  signals.	  	  When	  the	  balance	  is	  tipped	  to	  one	  side	  or	  the	  
other,	  the	  cell	  is	  moved	  into	  action,	  with	  inhibition	  or	  activation	  being	  dependent	  on	  which	  way	  
the	  balance	  swings.	  
	  1.1 ¨Paired	  receptors¨	  
Cell	   surface	   receptors	   are	   integral	   membrane	   proteins	   that	   interact	   with	   either	   soluble	  
factors	  or	  ligands	  on	  other	  target	  cells	  and	  regulate	  cell	  function.	  The	  term	  ¨Paired	  receptors¨	  
refers	   to	   closely	   related	   membrane	   proteins	   often	   expressed	   on	   immune	   cells.	   They	   are	  
generally	  encoded	  by	  different	  genes,	  but	  have	  very	  similar	  extracellular	  ligand-­‐binding	  regions	  
and	   have	   both	   activating	   and	   inhibitory	   members	   (Akkaya	   et	   al.	   2013).	   CD28	   and	   CTLA-­‐4	   are	  
probably	   the	   best-­‐studied	   example	   of	   paired	   co-­‐activating/co-­‐inhibitory	   receptors.	   These	  
molecules	  are	  expressed	  on	  T	  cells	  and	  bind	  the	  same	  ligands	  (i.e.,	  CD80	  and	  CD86)	  to	  deliver	  
opposing	   positive	   and	  negative	   signals	   (Lenschow	  et	   al.	   1996;	  Krummel	   et	   al.	   1996(1)(2);	   Chambers	  et	   al.	  
1999).	  For	  NK	  cells,	  the	  inhibitory	  receptors	  usually	  contain	  an	  immunoreceptor	  tyrosine-­‐based	  
inhibitory	  motif	   (ITIM)	  within	  the	  cytoplasmic	  region.	  Upon	   ligand	  binding,	   immune	   inhibitory	  
receptors	   are	   phosphorylated	   on	   the	   tyrosine	   residue,	   recruit	   phosphatases	   and	   inhibit	   the	  
propagation	  of	  activation	  signals	   in	   the	   lymphocyte	  on	  which	  they	  are	  expressed.	   In	  contrast,	  
the	  activating	  receptors	  have	  a	  short	  cytoplasmic	  region	  lacking	  ITIM	  elements,	  but	  containing	  a	  
charged	  amino	  acid	   residue	   (usually	  Arg	  or	   Lys)	   in	   the	   transmembrane	   region,	   that	  mediates	  
association	  with	  transmembrane	  adaptor	  proteins	  bearing	  either	  an	  immunoreceptor	  tyrosine-­‐
based	   activation	   motif	   (ITAM)	   (CD247,	   FcεRγ,	   DAP12),	   or	   a	   PI3	   kinase/Grb2	   binding	   motif	  
(DAP10).	   ITAM	  motifs,	  upon	  ligand	  binding,	   lead	  to	  the	  association	  of	  kinases	  such	  as	  Syk	  and	  
Zap	  70	  and	   transmitting	  of	  activating	  signals	   into	   the	  cell	   (Lanier	  et	  al.	  2000;	  Love	  et	  al.	  2000).	  The	  
extracellular	   regions	   of	   NK	   receptors	   usually	   contain	   either	   immunoglobulin	   superfamily	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MHC	  class	  I	  ligands,	  contain	  both	  activating	  and	  inhibitory	  receptors	  within	  the	  families	  (Lanier	  et	  
al.	  1998).	  Paired	  activating	  and	   inhibitory	  receptors	  families	  have	  also	  been	   identified	  on	  other	  
cell	  types	  (Ali	  et	  al.	  2014).	  So,	  the	  immune	  system	  can	  be	  considered	  to	  be	  tightly	  regulated	  by	  the	  
balance	  between	  the	  activating	  and	   inhibitory	  signals	   initiated	  by	  these	  paired	  receptors,	  and	  














Fig.	   1:	   Paired	   receptors.	   Paired	   receptors	   consist	   of	   activating	   and	   inhibitory	   receptors	   having	   highly	  
homologous	   extracellular	   ligand	   binding	   regions.	   The	   inhibitory	   receptors	   possess	   an	   immunoreceptor	  
tyrosine-­‐based	   inhibitory	   motif	   (ITIM)	   within	   the	   cytoplasmic	   region.	   In	   contrast,	   the	   activating	   receptors	  
have	  short	  cytoplasmic	  regions	  and	  a	  positively	  charged	  residue	  (Arg	  or	  Lys)	  in	  the	  transmembrane	  domain,	  
which	   allows	   association	  with	   an	   adaptor	  protein	  possessing	   an	   immunoreceptor	   tyrosine-­‐based	   activation	  
motif	   (ITAM).	   	   The	   left	   panel	   displays	   the	   C-­‐type	   lectin-­‐like	   receptors	   including	   the	   inhibitory	   heterodimer	  
CD94/NKG2A	  and	  activating	  heterodimer	  CD94/NKG2C.	  The	  right	  panel	  illustrates	  the	  two-­‐Ig-­‐like	  domain	  KIR	  
proteins	  including	  KIR2DS	  activating	  and	  KIR2DL	  inhibitory	  receptor.	  The	  ITIM	  motif	  is	  shown	  in	  red	  whereas	  
the	  ITAM	  motif	  is	  shown	  in	  black.	  
	  1.2 Integration	  of	  signals	  in	  NK	  cells	  
In	   the	   1970s,	   a	   population	   of	   lymphocytes	   able	   to	   “spontaneously”	   mediate	   cytotoxicity,	  
without	  prior	  exposure	  to	  the	  target,	  was	  described	  in	  the	  spleen	  of	  unmanipulated	  mice	  and	  
rats	  and	   in	  the	  peripheral	  blood	  of	  humans	  (Rosenberg	  et	  al.	  1974;	  Herberman	  et	  al.	  1975(1)(2)).	  These	  
initial	  observations	  were	  rapidly	  confirmed	  and	  the	  term	  natural	  killer	   (NK)	  cell	  was	  added	  to	  
the	   immunological	   lexicon	   (Kiessling	   et	   al.	   1975).	   	   NK	   cells	   are	   a	   population	   of	   lymphocytes	  
(approximately	  10%	  of	  peripheral	  blood	  mononuclear	  cells,	  PBMCs),	  distinct	  from	  B	  and	  T	  cells	  
and	   located	   at	   the	   crossroads	   between	   innate	   and	   adaptive	   immunity.	   They	   play	   important	  
roles	  in	  the	  coordination	  of	  both	  tumour	  immunosurveillance	  and	  the	  immune	  response	  against	  
pathogens.	  Diverse	  functional	  activities	  have	  been	  associated	  with	  NK	  cells,	  including	  ¨natural¨	  
cytotoxicity	   and	   antibody-­‐dependent	   cell-­‐mediated	   cytotoxicity	   both	   dependent	   on	  
perforin/granzyme	  release,	  as	  well	  as	  the	  capacity	  of	  NK	  cells	  to	  produce	  a	  range	  of	  cytokines	  
including	  tumour-­‐necrosis	   factor	  (TNF-­‐α)	  and	   interferon-­‐γ	  (IFNγ)	  and	  chemokines	  that	  help	  to	  
CD94/NKG2A	   CD94/NKG2C	  
DAP12	  





	   27	  
Introduction	  
generate	   and	   sustain	   an	   inflammatory	   environment	   (Trinchieri	   et	   al.	   1989).	   NK	   cells	   thus	  
participate	  in	  an	  early	  defence	  system	  via	  direct	  elimination	  of	  virally	   infected	  or	  transformed	  
cells	   through	   target-­‐cell	   lysis,	   via	  activation	  of	  dendritic	   cells	   (DCs)	  and	  via	  modulation	  of	   the	  
response	  of	  adaptive	   lymphocytes	   (T	  cells	  and	  B	  cells)	   through	   the	   release	  of	   soluble	   factors.	  
Human	  NK	  cells	  are	  phenotypically	  and	  functionally	  heterogeneous.	  Approximately	  10%	  of	  NK	  
cells	  found	  in	  blood	  express	  high	  levels	  of	  surface	  CD56	  and	  are	  classified	  as	  CD56bright.	  These	  NK	  
cells	  do	  not	  express	  CD16	  (also	  known	  as	  FcγRIIIA),	  can	  produce	  abundant	  amounts	  of	  cytokines	  
(IFNγ,	  TNF-­‐α,	  granulocyte/macrophage	  colony-­‐stimulating	  factor	  (GM-­‐CSF),	  IL-­‐10	  and	  IL-­‐13)	  and	  
various	  chemokines,	  but	  have	  little	  ability	  to	  spontaneously	  kill	  tumour	  cell	  targets	  (Nagler	  et	  al.	  
1989;	  Caligiuri	  et	  al.	  1990;	  Cooper	  et	  al.	  2001).	   In	  contrast,	  the	  majority	  of	  circulating	  human	  NK	  cells	  
show	   low	  surface	  density	  or	   ¨dim¨	  expression	  of	  CD56	   (CD56dim),	  do	  express	  CD16	  at	   the	   cell	  
surface,	  are	  less	  efficient	  cytokine	  producers	  (per	  cell)	  in	  response	  to	  activation	  by	  monokines,	  
but	  are	  highly	  cytotoxic	  and	  can	  spontaneously	  lyse	  many	  tumours	  and	  virally	  infected	  targets	  
(Lanier	  et	  al.	  1986;	  Jacobs	  et	  al.	  2001;	  Walzer	  et	  al.	  2007).	  
The	   prevalent	   view	   of	   NK	   cell	   activation	   is	   that	   specific	   NK	   recognition	   of	   infected	   or	  
transformed	  cells	  while	  maintaining	  tolerance	  for	  ¨self¨,	  depends	  on	  a	  balance	  of	  signals	  from	  
activating	  and	   inhibitory	  receptors.	  According	  to	  the	  ¨missing	  self¨	  hypothesis	   (Karre	  et	  al.	  1986;	  
Ljunggren	  et	  al.	  1990),	  the	  binding,	  or	  not,	  of	  NK	  cell	  inhibitory	  receptors	  to	  target	  cell	  MHC	  class	  I	  
(cognate	   ligands	  for	  many	  NK	   inhibitory	  receptors	  and	  expressed	  by	  virtually	  every	  cell	   in	  the	  
body)	  determines	  NK	  cell	  specificity	  (Karlhofer	  et	  al.	  1992;	  Wagtmann	  et	  al.	  1995;	  Dohring	  et	  al.	  1996).	  The	  
recognition	  of	  MHC	  class	  I	  molecules	  by	  the	  NK	  cell	  inhibitory	  receptor	  leads	  to	  the	  recruitment	  
of	  phosphatases	   that	  block	   the	  propagation	  of	   signals	  which	   lead	   to	   target	  cell	   killing.	  Down-­‐
regulation	   of	   the	   expression	   of	   MHC	   class	   I	   molecules	   on	   the	   target	   cell	   surface,	   with	   the	  
consequent	   lack	  of	  engagement	  of	  the	   inhibitory	  receptor	  and	  absence	  of	  an	   inhibitory	  signal	  
favours	  NK	  cell	  activation	  and	  killing	  of	  the	  target	  cell	  (Moretta	  et	  al.	  1992(1);	  Moretta	  et	  al.	  1997;	  Ploegh	  
et	  al.	  1998;	  Algarra	  et	  al.	  2000).	  This	  point	  of	  view	  has	  been	  modified	  recently	  as	  it	  has	  become	  clear	  
that	  a	  threshold	   for	  NK	  cell	   responsiveness	  exists	  and	  that	  the	  definition	  of	   this	  checkpoint	   is	  
regulated	  by	  a	  licensing	  or	  education	  process	  (Shifrin	  et	  al.	  2014).	  During	  this	  process	  NK	  cells	  not	  
only	   acquire	   receptor	   expression	   and	   become	   self-­‐tolerant,	   but	   they	   are	   also	   licensed	   for	  
effector	   function.	   The	   molecular	   mechanisms	   underlying	   NK	   cell	   licensing	   are	   poorly	  
understood,	   but	   it	   is	   generally	   agreed	   that	   interactions	   between	  MHC	   class	   I	  molecules	   and	  
inhibitory	  receptors	  are	  critical	  for	  this	  process	  (Hoglundet	  al.	  2010).	  
The	  recognition	  that	  NK	  cells	  express	  a	  variety	  of	  activating	  receptors	  led	  to	  a	  modification	  of	  
the	  missing-­‐self	  hypothesis	  to	  include	  the	  idea	  that	  NK	  cells	  were	  not	  constitutively	  active,	  but	  
rather	   required	   specific	   signals	   for	   activation	   that	   could	   then	  be	   subject	   to	   the	   action	  of	   the	  
inhibitory	   receptors	   (Yokoyama	   et	   al.	   1993).	   It	   is	   now	  widely	   appreciated	   that	   host	   cells	   can	   be	  
modified	   as	   a	   result	   of	   cellular	   stress,	   viral	   infection	   or	   tumour	   transformation	   leading	   to	  
induction	  or	  up	  regulation	  at	  the	  cell	  surface	  of	  molecules	  that	  at	  physiological	  conditions	  are	  
low/not	  expressed.	  These	  molecules	  can	  engage	  activating	  receptors,	  such	  as	  NKG2D	  (Bauer	  et	  al.	  




	   28	  
Introduction	  
Activating	   receptors	   associated	   with	   ITAM-­‐containing	   adaptor	   proteins	   (CD3ζ,	   FcεRIγ	   and	  
DAP12)	  transmit	  strong	  activation	  signals	  into	  the	  cell	  through	  recruitment	  of	  tyrosine	  kinases	  
Syk	   and	   ζ-­‐associated	   protein	   (ZAP-­‐70).	   Such	   receptors	   can	   be	   further	   subdivided	   into	   two	  
groups.	   The	   first	   group	   comprises	   KIRs	   and	  CD94/NKG2	   family	  members	   that	   are	   specific	   for	  
MHC	   class	   I	   molecules,	   and	   includes	   KIR2DS,	   KIR3DS	   (binding	   classical	   MHC	   class	   I),	  
CD94/NKG2C	  (binding	  HLA-­‐E)	  and	  CD94/NKG2E.	  These	  receptors	  belong	  to	  the	  group	  of	  “paired	  
receptors¨	  and	  associate	  with	  the	  ITAM-­‐containing	  adaptor	  molecule	  DAP12.	  The	  second	  group	  
of	   ITAM-­‐associated	   receptors	   includes	   the	   activating	   receptors	  mainly	   expressed	   on	  NK	   cells	  
(and	   responsible	   for	   NK-­‐cell	   non-­‐MHC-­‐restricted	   natural	   cytotoxicity):	   NKp46,	   NKp30	   and	  
NKp44,	  referred	  to	  as	  natural	  cytotoxicity	  receptors	  (NCR)	  by	  their	  discoverers	  (Sivori	  et	  al.	  1997;	  
Vitale	  et	  al.	  1998;	  Pessino	  et	  al.	  1998;	  Sivori	  et	  al.	  1999;	  Pende	  et	  al.	  1999;	  Cantoni	  et	  al.	  1999).	  NKp44	  couples	  
with	  DAP12,	  while	  NKp30	  and	  NKp46	  interact	  with	  hetero	  or	  homodimers	  of	  CD3ζ	  and	  FcεRIγ.	  
Another	   receptor	   in	   this	   group	   is	   CD16.	   This	   receptor	   mediates	   antibody-­‐dependent	   cell-­‐
mediated	   cytotoxicity	   (ADCC)	   (Perussia	  et	  al.	  1983;	  Takai	  et	  al.	  1994)	   and	  associates	  with	  CD3ζ	   and	  
FcεRIγ.	  
Another	   category	   of	   activating	   receptors	   on	   NK	   cells	   is	   the	   ITAM	   independent	   receptors,	  
which	   include	   NKG2D,	   CD2,	   2B4	   and	   DNAM-­‐1.	   In	   humans,	   the	   NKG2D	   receptor	   associates	  
specifically	  with	  the	  adaptor	  protein	  DAP10	  (Wu	  et	  al.	  1999),	  containing	  a	  phosphatidylinositol-­‐3	  
kinase	  (PI3K)	  binding	  motif.	  NKG2D	  expression	  is	  not	  confined	  only	  to	  NK	  cells,	  since	   it	   is	  also	  
expressed	   by	   virtually	   all	   T-­‐cell	   receptor	   (TCR)	   γ/δ+	  and	   CD8+	   TCR	   α/β+	   cells.	   The	   ligands	   for	  
NKG2D,	  the	  MHC	  class	  I	  chain	  related	  gene	  A	  (MICA),	  MHC	  class	  I	  chain	  related	  gene	  B	  (MICB),	  
and	   UL16-­‐binding	   protein	   (ULBP),	   are	   expressed	   on	   some	   tumour	   cells	   and	   on	   infected	   or	  
stressed	  cells	  (Nausch	  and	  Cerwenka.	  2008).	  2B4	  (CD244),	  receptor	  is	  expressed	  by	  NK	  cells	  but	  also	  
can	   be	   found	   on	   activated	   CD8+	   T	   cells,	   monocytes	   and	   granulocytes.	   Binding	   of	   its	   ligand	  
(CD48),	   leads	   to	   recruitment	   of	   SLAM-­‐associated	   protein	   (SAP)	   and	   Fyn	   through	   cytoplasmic	  
immunotyrosine-­‐based	  switch	  motifs	  (ITSMs).	  (Moretta	  et	  al.	  1992(1);	  Nakajima	  et	  al.	  1999;	  Tangye	  et	  al.	  
1999;	  Nakajima	  et	  al.	  2000;	  Sivori	  et	  al.	  2000;	  Chuang	  et	  al.	  2001).	  
As	  mentioned	  previously,	  to	  avoid	  killing	  “self”	  cells	  NK	  cells	  also	  express	  receptors	  that	  can	  
trigger	  inhibiting	  signals.	  These	  receptors	  can	  also	  recognize	  MHC	  class	  I	  molecules.	  In	  humans,	  
three	  families	  of	  such	  inhibitory	  NK	  receptors	  have	  been	  described.	  One	  major	  group	  is	  referred	  
to	  as	  killer	  immunoglobulin	  (Ig)-­‐like	  receptors	  (KIR).	  They	  possess	  two	  or	  three	  Ig-­‐domains	  and	  
each	  member	  interacts	  with	  a	  different	  group	  of	  closely	  related	  classical	  HLA	  class	  I	  molecules	  
(HLA-­‐A,	  HLA-­‐B	  or	  HLA-­‐C).	   For	   example,	  HLA-­‐C	  molecules	   are	   the	   ligands	   for	   KIR2D	   receptors,	  
while	  subsets	  of	  HLA-­‐B	  and	  HLA-­‐A	  molecules	  are	  the	   ligands	  for	  KIR3D	  receptors	   (Valiante	  et	  al.	  
1993;	  Litwin	  et	  al.	  1994;	  Colonna	  et	  al.	  1995;	  Dohring	  et	  al.	  1996;	  Pende	  et	  al.	  1996;	  Valés-­‐Gómez	  et	  al.	  1998;	  Baba	  
et	  al.	  2000;	  Fan	  et	  al.	  2001;	  Ivarsson	  et	  al.	  2014).	  A	  second	  group	  of	  receptors	  known	  as	  LILR	  (leukocyte	  
immunoglobulin-­‐like	  receptors)	  (LIR-­‐1,	  ILT2)	  are	  also	  members	  of	  the	  Ig	  superfamily.	  The	  third	  
major	  group	  of	   inhibitory	  receptors	  expressed	  on	  NK	  cells	   is	  the	  heterodimeric	  CD94/NKG2	  C-­‐
type	  lectin	  proteins	  (Houchins	  et	  al.	  1991;	  Chang	  et	  al.	  1995;	  Lazetic	  et	  al.	  1996;	  Brooks	  et	  al.	  1997;	  Carretero	  
et	  al.	  1997;	  Borrego	  et	  al.	  1998;	  Braud	  et	  al.	  1998(1);	  Lee	  et	  al.	  1998(2);	  Bellón	  et	  al.	  1999;	  López-­‐Botet	  et	  al.	  1999;	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inhibitory	  receptors	  from	  each	  group	  possess	  immunoreceptor	  tyrosine-­‐based	  inhibitory	  motifs	  
(ITIM)	  in	  their	  cytoplasmic	  tails	  (Bolland	  et	  al.	  1999;	  Long	  et	  al.	  1999;	  Daëron	  et	  al.	  2008;	  Long	  et	  al.	  2008).	  
	  1.3 Integration	  of	  signals	  in	  T	  cells	  
The	  1950s,	  60s	  and	  70s	  were	  an	  exciting	  time	  for	  immunologists,	  as	  major	  discoveries	  were	  
made	  in	  the	  field	  of	  immunology;	  the	  importance	  of	  recirculating	  lymphocytes	  as	  mediators	  of	  
immunity	   (Gowans	   et	   al.	   1959;	   Gowans	   et	   al.	   1962;	   Miller	   et	   al.	   1967),	   definition	   of	   the	   role	   of	   the	  
thymus	   (Cooper	   et	   al.	   1967;	   Cooper	   et	   al.	   1973)	   and	   the	   existence	   of	   two	   distinct	   but	   interacting	  
lymphocyte	  subsets,	  one	  derived	  from	  the	  thymus	  (T	  cells)	  and	   involved	   in	  cellular	   immunity,	  
and	   the	  other	  derived	   from	  the	  bone	  marrow	   (B	  cells),	   that	  produces	  antibodies	   (Claman	  et	  al.	  
1966;	   Miller	   et	   al.	   1968;	   Mitchell	   et	   al.	   1968;	   Howard	   et	   al.	   1972;	   Scott	   et	   al.	   1972;	   Bromberg	   et	   al.	   2004).	  
Immunological	   compatibility	   was	   also	   defined	   in	   the	   1970s	   by	   the	   definition	   of	   the	  
transplantation	   antigens	   –	   now	   known	   as	   the	   molecules	   encoded	   by	   the	   major	  
histocompatibility	   complex	   (MHC).	   The	   true	   physiological	   function	   of	   these	   antigens	   was	  
unknown	  up	   to	   the	   point	  when	  MHC	   restriction	   of	   T	   cell	   recognition	  was	   discovered	   by	   two	  
young	   immunologists	   Rolf	   Zinkernagel	   and	   Peter	   Doherty,	   a	   discovery	   for	   which	   they	   were	  
awarded	  the	  Nobel	  Prize	  in	  Physiology	  and	  Medicine	  in	  1996	  (Zinkernagel	  et	  al.	  1973;	  Oldstone	  et	  al.	  
1973;	  Zinkernagel	  et	  al.	  1974;	  Zinkernagel	  et	  al.	  1975;	  Doherty	  et	  al.	  1975;	  Zinkernagel	  et	  al.	  1976;	  Townsend	  et	  al.	  
1986;	   Bjorkman	   et	   al.	   1987).	   The	   intense	   efforts	   to	   discover	   the	  molecule	   that	  mediated	   specific	  
MHC	  recognition	  culminated	  with	  the	  identification	  of	  the	  TCR	  proteins	  in	  late	  1982	  and	  early	  
1983	  by	   the	  groups	  of	   Jim	  Allison,	  Ellis	  Reinherz,	   John	  Kappler	  and	  Philippa	  Marrack.	  A	  T	   cell	  
clone-­‐specific	  disulfide-­‐linked	  heterodimer	  of	  about	  45-­‐50	  kDa	  was	   identified,	   that	  comprised	  
an	  alpha	  and	  beta	  chain	  and	  where	  each	  chain	  contained	  variable	  and	  constant	  regions	  (Allison	  
et	   al.	   1982;	  Meuer	   et	   al.	   1983;	  Haskins	   et	   al.	   1983;	   Acuto	   et	   al.	   1983;	   Bigler	   et	   al.	   1983;	   Samelson	   et	   al.	   1983;	  
Hendrick	  et	  al.	  1984(1)(2);	  Chien	  et	  al.	  1984).	  Soon,	  a	  second	  TCR	  with	  structural	  properties	  very	  similar	  
to	  TCRαβ	  was	  identified	  and	  called	  TCRγδ	  (Brenner	  et	  al.	  1986).	  The	  finding	  that	  T	  cells	  recognize	  
antigen	   presented	   by	   MHC	   molecules	   and	   the	   development	   of	   monoclonal	   antibody	  
technology,	   rapidly	   led	   to	   the	   generation	   of	   monoclonal	   antibodies	   against	   the	   CD3	  
polypeptides,	  showing	  their	  involvement	  in	  antigen	  recognition	  (Reinherz	  et	  al.	  1982).	  Monoclonal	  
antibodies	   recognizing	   the	   TCR,	  which	   inhibited	   antigen	   recognition	   in	   an	   antigen-­‐dependent	  
fashion,	  were	  first	  described	  in	  1983,	  as	  was	  the	  physical	  and	  functional	  relationship	  between	  
the	  TCR	  and	  the	  CD3	  polypeptides.	  The	  mature	  TCR/CD3	  complexes	  are	  formed	  by	  6	  different	  
polypetides;	  the	  TCRαβ	  or	  the	  TCRγδ	  chains	  and	  the	  CD3γ,	  δ,	  ε	  and	  ζ	  polypeptides	  (Marrack	  et	  al.	  
1986;	  Clevers	  et	  al.	  1988).	  	  
Each	  T	  lymphocyte	  circulating	  in	  peripheral	  blood	  expresses	  a	  unique	  TCR	  on	  the	  surface	  as	  
the	   result	   of	   developmental	   selection	   upon	  maturation	   in	   the	   thymus.	   Two	   types	   of	   T	   cells	  
appear	  after	  this	  selection	  according	  to	  the	  TCR	  expression;	  the	  majority	  express	  antigen	  (Ag)-­‐
binding	   αβ	   chains	   in	   the	   TCR,	   which	   are	   disulfide-­‐linked	   heterodimers	   of	   Ig	   superfamily	  
proteins.	   αβTCR	   T	   cells	   have	   a	   very	   diverse	   repertoire	   of	   Ag	   recognition	   receptors	   and	  
represent	  mature	  T	  cells	  that	  play	  key	  roles	  in	  driving	  the	  adaptive	  immune	  response.	  A	  small	  




	   30	  
Introduction	  
αβTCR	  T	  cells	  and	  play	  specific	  roles	  in	  determined	  aspects	  of	  the	  innate	  immune	  response	  to	  
certain	  pathogens.	  
Two	  major	  surface	  co-­‐receptor	  molecules,	  CD4	  and	  CD8,	  define	  two	  separate	  T	  cell	  lineages	  
with	   different	   functions.	   CD4+	   T	   cells	   recognize	   Ag	   in	   the	   context	   of	  MHC	   class	   II	   molecules	  
[expressed	   on	   so-­‐called	   antigen	   presenting	   cells	   (APC),	   such	   as	   B	   cells,	   macrophages	   and	  
dendritic	   cells	   (DC)]	   and	   their	   key	   function	   is	   to	   produce	   cytokines	   as	   effector	   T	   helper	   cells.	  
CD8+	  lymphocytes	  are	  activated	  by	  Ag-­‐peptides	  presented	  by	  MHC	  class	  I	  molecules	  (expressed	  
on	  all	  nucleated	  cells)	  and	  act	  as	  effector	  cytotoxic	  T	  lymphocytes	  (CTL).	  
The	   functional	   properties	   of	   the	   T	   cells	   allow	   classification	   as	   naive,	   effector	   and	  memory	  
cells,	   each	   of	   which	   displays	   considerable	   diversity	   in	   terms	   of	   phenotype,	   function	   and	  
anatomic/tissue	  distribution.	  Naive	  T	  cells	  have	  not	  yet	  encountered	  foreign	  Ag	  and	  have	  not	  
been	  yet	  activated.	  When	  activated,	  CD4+	  T	  helper	  cells	  (Th)	  can	  be	  subdivided	  into	  Th1,	  Th2,	  
Th17,	  follicular	  helper	  T	  cell	   (Tfh),	   induced	  T-­‐regulatory	  cells	   (iTreg)	  and	  the	  regulatory	  type	  1	  
cells	  (Tr1)	  as	  well	  as	  the	  potentially	  distinct	  T-­‐helper	  9	  (Th9)	  based	  on	  the	  complex	  network	  of	  
specific	   cytokine	   signalling	   and	  production.	   (Del-­‐Prete	  et	   al.	   1991;	   Trinchieri	   et	   al.	   2003;	  Afkarian	  et	   al.	  
2002;	  Thieu	  et	  al.	  2008;	  Kaplan	  et	  al.	  1996;	  Glimcher	  et	  al.	  2000;	  Veldhoen	  et	  al.	  2006;	  Bettelli	  et	  al.	  2006;	  Chen	  et	  
al.	  2003;	  Yoshimura	  et	  al.	  2011;	  Vinuesa	  et	  al.	  2005;	  Vogelzang	  et	  al.	  2008;	  Nurieva	  et	  al.	  2008).	  CD8+	  T	   cells	  
also	  called	  cytotoxic	  T	   lymphocytes	   (CTL)	  can	  be	  divided	   into	   two	  cell	   subpopulations	   termed	  
Tc1	   (T	   cytotoxic	   1)	   and	   Tc2	   (T	   cytotoxic	   1),	   based	   on	   their	   potential	   to	   produce	   cytokines	  
(Salgame	  et	  al.	  1991;	  Maggi	  et	  al.	  1994;	  Croft	  et	  al;	  1994).	  Tc1	  cells	  secrete	  IFN-­‐γ	  and	  Tc2	  produce	  IL-­‐4,	  
IL2	  and	  TNF-­‐α	  (Mosmann	  et	  al.	  1997).	  Once	  the	  antigenic	  agent	  is	  eliminated,	  most	  of	  the	  effector	  
T	  cells	  will	  undergo	  apoptosis,	  although	  other,	  few	  lymphocytes	  will	  survive	  and	  become	  long-­‐
lived	  memory	  T	  cells	  (Jacob	  et	  al.	  1999;	  Opferman	  et	  al.	  1999;	  Dai	  et	  al.	  2000;	  Lanzavecchia	  et	  al.	  2000;	  Hu	  et	  
al.	  2001;	  Kaech	  et	  al.	  2001;	  Sprent	  et	  al.	  2001;	  Bourgeois	  et	  al.	  2002;	  Schluns	  et	  al.	  2002;	  Sprent	  et	  al.	  2002;	  Janssen	  
et	  al.	  2003;	  Shedlock	  et	  al.	  2003).	  Memory	  T	   cells,	   both	  CD4	  and	  CD8,	   can	  be	   further	  divided	   into	  
central	  and	  effector	  memory	  cells	  (Sallusto	  et	  al.	  1999).	  
The	  activation	  of	  T	  cells	  is	  determined	  by	  the	  presence	  of	  distinct	  signals.	  The	  engagement	  of	  
TCR	  by	   antigenic	  peptides	  bound	   to	  MHC	  molecules	  on	   the	   surface	  of	  APCs	  provides	   the	   so-­‐
called	  ´signal-­‐1´.	  This	  signal	  by	  itself	  is	  not	  only	  insufficient	  for	  T	  cell	  activation	  but	  also	  can	  lead	  
to	   apoptosis	   or	   a	   state	   of	   antigen-­‐specific	   non-­‐responsiveness	   (anergy).	   For	   optimal	   T	   cell	  
proliferation	  and	  acquisition	  of	  effector	  functions	  a	  second	  costimulatory	  ´signal	  2´	  is	  required,	  
provided	  by	  a	  range	  of	  surface	  molecules	  expressed	  on	  APCs.	  Indeed	  T	  cell	  activation	  after	  T	  cell	  
receptor	   engagement	   is	   influenced	   by	   signals	   from	   both	   positive	   and	   negative	   regulatory	  
molecules	  that	  can	  either	  enhance	  or	  inhibit	  the	  TCR	  mediated	  immune	  response	  (Mueller	  et	  al.	  
1989).	  Four	  different	  families,	  each	  of	  which	  contains	  costimulatory	  and	  coinhibitory	  molecules,	  
are	  able	  to	  modulate	  T	  cell	  activation:	  1.	  B7-­‐CD28	  family	  including:	  CD28	  (Jenkins	  et	  al.	  1991;	  Boise	  
et	  al.	  1995;	  Rudd	  et	  al.	  2003),	   cytotoxic	   T-­‐lymphocyte	  antigen-­‐4	   (CTLA-­‐4;	  CD152)	   (Brunet	  et	  al.	  1987;	  
Krummel	   et	   al.	   1996(1)(2);	  Walunas	   et	   al.	   1996),	   programmed	   death-­‐1	   (PD-­‐1;	   CD279)	   (Ishida	   et	   al.	   1992;	  
Dong	   et	   al.	   1999;	   Freeman	   et	   al.	   2000;	   Latchman	   et	   al.	   2001),	   inducible	   costimulatory	  molecule	   (ICOS;	  
CD278)	  (Hutloff	  et	  al.	  1999;	  Yoshinaga	  et	  al.	  1999),	  and	  B-­‐	  and	  T-­‐lymphocyte	  attenuator	  (BTLA;	  CD272)	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CTLA-­‐4	  bind	  to	  the	  same	  ligands,	  B7-­‐1	  (CD80)	  and	  B7-­‐2	  (CD86)	  but	  the	  first	  transmits	  activating	  
and	  the	  second	  inhibitory	  signals	  (Linsley	  et	  al.	  1994;	  Collins	  et	  al.	  2002);	  2.	  CD2	  signalling	  lymphocyte	  
activation	  molecule	  (SLAM)	  family	  including:	  SLAM	  (CD150),	  2B4	  (CD244),	  and	  CD48	  (Boles	  et	  al.	  
2001;	  Wang	  et	  al.	  2001);	  3.	   Ig	   family	   including:	   T	   cell	   immunoglobulin	  mucin-­‐3	   (TIM-­‐3)	   (Rodriguez-­‐
Manzanet	  et	  al.	  2009;	  Zhu	  et	  al.	  2011),	  CD160	  (Anumanthan	  et	  al.	  1998;	  Agrawal	  et	  al.	  1999;	  Cai	  et	  al.	  2008;	  Cai	  
et	  al.	  2009),	  and	  lymphocyte-­‐activation	  gene	  3	  (Lag-­‐3)	  (Triebel	  et	  al.	  1990;	  Huard	  et	  al.	  1994;	  Workman	  et	  
al.	  2004;	  Grosso	  et	  al.	  2007);	  and	  4.	   TNF-­‐receptor	   superfamily	   including:	  CD27	   (Denoeud	  et	  al.	  2011).	  
Studies	  have	  shown	  that	  CD8+	  T	  lymphocyte	  activation	  can	  also	  be	  modulated	  by	  receptors	  that	  
are	  perhaps	  more	  often	  associated	  with	  NK	  cell	  activity	  (Vilches	  et	  al.	  2002;	  Raulet	  et	  al.	  2004).	  These	  
receptors	  include	  members	  of	  the	  KIR	  family	  (Huard	  et	  al.	  2000),	  NKG2D	  (Bauer	  et	  al.	  1999;	  Groh	  et	  al.	  
2001)	  and	  the	  CD94/NKG2	  receptors	  (Mingari	  et	  al.	  1998(1)(2);	  Uhrberg	  et	  al.	  2001;	  Young	  et	  al.	  2001;	  Jabri	  et	  
al.	  2002;	  Vivier	  et	  al.	  2004,	  Mónica	  et	  al.	  2005).	  
As	   a	   complex	   biological	   element,	   each	   step	   of	   the	   signalling	   pathway	   initiated	   by	   TCR	  
engagement	  is	  subjected	  to	  both	  positive	  and	  negative	  regulation.	  For	  example,	  one	  of	  the	  first	  
biochemical	  consequences	  of	  TCR	  binding	  is	  activation	  of	  Lck	  (Veillette	  et	  al.	  1988)	  and	  Fyn,	  an	  Src-­‐
family	   protein	   tyrosine	   kinases	   (PTK)	   (Hermiston	   et	   al.	   2002).	   Lck	   itself	   is	   further	   regulated	  
positively	  and	  negatively	  by	  CD45	  protein	  tyrosine	  phosphatase	  and	  COOH-­‐terminal	  Src	  kinase	  
(CSK)	   respectively	   (Thomas	  et	  al.	  1995;	  Latour	  et	  al.	  2001).	  Once	  Lck	   is	  activated,	   ITAMs	  of	   the	  CD3	  
chain	  are	  phosphorylated	  creating	  docking	  sites	  for	  the	  tandem	  Src	  homology	  2	  (SH2)	  domains	  
of	   the	  Syk	  PTK	  ZAP-­‐70	   (Reth	  1989;	  Chan	  et	  al.	  1991;	  Chan	  et	  al.	  1992).	  After	   recruitment	   to	   the	  TCR,	  
Zap-­‐70	   is	   also	   phosphorylated	   and	   activated	   by	   SRC-­‐family	   kinases.	   Active	   Zap-­‐70	   then	  
phosphorylates	  several	  downstream	  substrates,	  initiating	  a	  cascade	  of	  signalling	  pathways	  that	  
result	   in	   nuclear	   transcriptional	   changes.	   Molecules,	   called	   adaptor	   proteins	   are	   another	  
important	   players	   in	   these	   signalling	   cascades	   (Peterson	   et	   al.	   1998;	   Rudd.	   1999;	   Samelson.	   1999).	  
These	   adaptors	   lack	   enzymatic	   activity,	   but	   possess	  multiple	   binding	   sites	   and	  modules	   that	  
bind	   to	   other	   proteins	   and	   can	   function	   as	   either	   positive	   or	   negative	   regulators	   of	   T	   cell	  
signalling.	   Examples	  of	   adaptors	  with	  a	  positive	  effect	   include:	   growth	   factor	   receptor-­‐bound	  
protein-­‐2	  (GRB-­‐2),	  the	  linker	  for	  activation	  of	  T	  cell	  (LAT)	  (Finco	  et	  al.	  1998;	  Zhang	  et	  al.	  1998;	  Weber	  et	  
al.	   1998),	   GRB-­‐2-­‐related	   adaptor	   downstream	   of	   Shc	   (GADS)	   (Yoder	   et	   al.	   2001)	   and	   the	   SH2-­‐
domain-­‐containing	   leukocyte	   protein	   of	   76	   kDa	   (SLP-­‐76)	   (Jackman	   et	   al.	   1995;	   Motto	   et	   al.	   1996).	  
Adaptors	   with	   negative	   regulatory	   functions	   include:	   phosphoproteins	   associated	   with	  
(glycosphingolipid-­‐enriched	  micro	  domains)	  GEMs	  (PAG)	  (Brdickova	  et	  al.	  2001;	  Davidson	  et	  al.	  2003),	  
the	   SH-­‐2-­‐interacting	   transmembrane	   adaptor	   protein	   (SIT)	   (Hubener	   et	   al.	   2001)	   and	   the	  
downstream	  of	  tyrosine	  kinases	  (DOK).	  A	  number	  of	  others	  adaptors	  such	  as	  the	  adhesion	  and	  
degranulation	   promoting	   adaptor	   protein	   (ADAP)	   (Geng	   et	   al.	   2001),	   the	   Src	   kinase-­‐associated	  
phosphoprotein	  of	  55	  kDa	  (SKAP-­‐55)	  (Marie-­‐Cardine	  et	  al.	  1997)	  and	  the	  Wiskott-­‐Aldrich	  syndrome	  
protein	  (WASP)	  have	  regulatory	  effect	  on	  the	  cytoskeleton,	  on	  adhesion	  and	  on	  the	  ability	  of	  T	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2. The	  CD94/NKG2	  C-­‐Type	  lectin	  family	  of	  receptors.	  
	  
CD94	   (20-­‐30	   kDa)	   is	   a	   type	   II	   membrane	   glycoprotein	   that	   forms	   disulphide-­‐linked	  
heterodimers	  with	  different	  members	  of	  the	  NKG2	  family.	  CD94/NKG2	  receptor	  complexes	  are	  
expressed	  predominantly	  on	  NK	  cells	  and	  a	  subset	  of	  CD8+	  T	  cells	  and	  heterodimers	  containing	  
NKG2A	  and	  NKG2C	  recognize	  and	  bind	  the	  non-­‐classical	  MHC	  class	  I	  molecule	  HLA-­‐E	  (HLA	  class	  I	  
histocompatibillity	   antigen,	   alpha	   chain	   E).	   Orthologous	   of	   the	   CD94/NKG2	   family	   of	   NK	   cell	  
receptors	   have	   been	   identified	   in	   humans,	   chimpanzees,	   orangutans,	   rheus	   monkeys,	   and	  
rodents	  (Lanier	  et	  al.	  1998;	  Long	  et	  al.	  1997;	  Guethlein	  et	  al.	  2002;	  Houchins	  et	  al.	  1991;	  Lohwasser	  et	  al.	  1999;	  
Berg	  et	  al.	  1998;	  La	  Bonte	  et	  al.	  2000;	  La	  Bonte	  et	  al.	  2001;	  Khakoo	  et	  al.	  2000).	  These	  receptors,	   together	  
with	  KIR,	  include	  some	  members	  that	  can	  either	  initiate	  or	  inhibit	  cellular	  activation	  therefore	  
by	   functional	   criteria	   they	   are	   divided	   into	   activating	   and	   inhibitory	   receptors.	   CD94/NKG2	  
receptors	  have	  been	  proposed	  to	  be	  important	  in	  NK	  cell	  tolerance	  to	  self,	  to	  play	  an	  important	  
role	   in	   NK	   cell	   development,	   and	   to	   contribute	   to	   NK	   cell-­‐mediated	   immunity	   to	   certain	  
infections	  including	  human	  cytomegalovirus.	  
	  2.1 CD94/NKG2	  	  gene	  cluster	  
Human	   NK	   cells	   express	   a	   number	   of	   receptors	   that	   belong	   to	   the	   C	   type	   lectin-­‐like	  
superfamily,	  such	  as	  NKR-­‐P1	  (Lanier	  et	  al.	  1994),	  members	  of	  the	  NKG2	  family	  (Houchins	  et	  al.	  1991;	  
Yabe	  et	  al.	  1993),	  CD69	  (Lopez-­‐Cabrera	  et	  al.	  1993),	  and	  CD94	  (Chang	  et	  al.	  1995).	  The	  genes	  coding	  for	  
these	  molecules	  form	  part	  of	  the	  NK	  cell	  complex	  (NKC)	  and	  are	  clustered	  together,	  in	  humans,	  
on	   the	  short	  arm	  of	   chromosome	  12p13	   (Fig.	  2).	  The	  distal	   to	  proximal	  position	  of	   these	   loci	  
are:	   NKR-­‐P1,	   CD69,	   CD94,	   NKG2D,	   NKG2F,	   NKG2E/H,	   NKG2C	   and	   NKG2A/B.	   The	   physical	  
distance	  spanned	  by	  the	  NK	  gene	  complex	  in	  humans	  ranges	  between	  0.7	  and	  2.4	  megabases	  
and	  is	  flanked	  by	  genetic	  markers	  D12S397	  and	  D1S89	  (Renedo	  et	  al.	  1997;	  Suto	  et	  al.	  1997;	  Glienke	  et	  
al.	  1998;	  Sobanov	  et	  al.	  1999;).	  
In	   1990,	   Houchins	   and	   coworkers	   identified	   a	   number	   of	   genes	   that	   were	   expressed	  
preferentially	  in	  NK	  cells,	  especially	  those	  encoding	  membrane	  receptors	  (Houchins	  et	  al.	  1990).	  In	  
this	   report,	   they	   identified	   12	   groups	   of	   cross-­‐hybridizing	   cDNA	   clones	   and	   one	   of	   these,	  NK	  
group	   2	   (NKG2),	  was	   shown	   to	   be	   expressed	   only	   in	   NK	   cells	   of	   the	   panel	   of	   cells	   that	   they	  
examined.	   One	   year	   later,	   they	   reported	   that	   NKG2	   was	   actually	   a	   group	   of	   closely	   related	  
transcripts	  that	  encode	  a	  series	  of	  type	  II	  membrane	  proteins,	  designated	  NKG2-­‐A,	  -­‐B,	  -­‐C,	  -­‐E	  and	  
–D	  (Houchins	  et	  al.	  1991).	  Comparison	  of	  the	  peptides	  encoded	  by	  each	  member	  of	  these	  group,	  
showed	   that	   NKG2-­‐A	   and	   NKG2-­‐C	   had	   high	   homology	   in	   the	   extracellular	   part	   but	   less	  
throughout	   the	   intracellular	   and	   transmembrane	   segments,	   NKG2-­‐B	   peptide	   was	   a	   splice	  
variant	  of	  NKG2-­‐A	  and	  NKG2-­‐E	  that	  encodes	  a	  261	  amino	  acid	  long	  protein,	  was	  95%	  similar	  to	  
NKG2C	  over	   the	   first	  191	  amino	  acid	   residues	   (Adamkiewich	  et	  al.	  1993).	   Finally	  NKG2-­‐D	  was	   the	  
most	  distantly	  related	  of	  all,	  having	  only	  20%	  sequence	  homology	  with	  the	  other	  members	  of	  






























Fig.	  2:	  Chromosomal	  location	  of	  the	  CD94/NKG2	  gene	  cluster	  in	  humans.	  The	  CD94/NKG2	  family	  gene	  cluster	  
is	  located	  on	  the	  short	  arm	  of	  chromosome	  12p13.	  Five	  NKG2	  genes	  give	  rise	  to	  seven	  proteins,	  two	  of	  which	  
NKG2D	  and	  NKG2F	  do	  not	   form	  a	  heterodimer	  with	  CD94	  molecule.	  NKG2D	  is	  structurally	  the	  most	  different	  
from	  the	  other	  members	  of	   this	   family	  and	   is	  expressed	  at	   the	  cell	   surface	  as	  homodimer.	  NKG2B	   is	  a	   splice	  
variant	  of	  NKG2A	  and	  both	  function	  as	  inhibitory	  receptors	  making	  heterodimers	  with	  CD94	  molecule.	  NKG2H	  
is	  an	  alternatively	  spliced	  variant	  of	   the	  NKG2E	  transcript	  and	  together	  with	  NKG2C	  protein	  all	   three	  possess	  
activating	  potential.	  The	  putative	  NKG2F	  protein	  has	  a	  short	  extracellular	  region,	  which	  does	  not	  contain	  a	  C-­‐
type	  lectin	  domain,	  but	  it	  is	  similar	  to	  NKG2C	  in	  that	  a	  lysine	  residue	  is	  found	  in	  the	  transmembrane	  region.	  	  
	  
	  
lectin	  domain	  proteins	  possessing	  a	  type	  II	  membrane	  orientation.	  The	  basic	  structure	  of	  these	  
proteins	   is	   that	   of	   an	   intracellular	   N-­‐terminal	   domain,	   a	   transmembrane	   domain	   and	   an	  
extracellular	  carbohydrate-­‐recognition	  domain,	  which	  is	  the	  ligand	  binding	  part	  of	  the	  molecule	  
(Adamkiewicz	  et	  al.	  1994).	  NKG2A	  and	   its	   splice	  variant	  NKG2B	  have	  been	   shown	   to	  possess	   two	  
ITIMs	   in	   their	   cytoplasmic	   domains.	   The	   NKG2C	   molecule	   lacked	   ITIMs,	   but	   instead	   had	   a	  
positively	  charged	  residue	  within	  the	  transmembrane	  region	  that	  allowed	  association	  with	  the	  
ITAM-­‐containing	   adaptor	   molecule	   DAP12	   (Lanier	   et	   al.	   1998).	   In	   1997,	   a	   new	   member	   of	   the	  
NKG2	   family	   of	   receptors	  was	   identified	  by	   Plougastel	   et	   al.	   The	  NKG2F	   gene	   localizes	   25	   kb	  
from	   NKG2A,	   does	   not	   contain	   any	   lectin	   domain	   but	   has	   a	   charged	   residue	   in	   the	  
transmembrane	  region	  allowing	  interaction	  with	  DAP12	  (Kim	  et	  al.	  2004)	  and	  an	  ITIM	  like	  motif	  in	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the	   cytoplasmic	   tail.	   Shortly	   afterwards,	   Bellón	   et	   al.	   1999	   published	   results	   describing	   a	  
TCRαβ+,	  CD8+	  T	  cell	   clone	   (TCC;	  K14B06)	   that	  expressed	  an	  activating	  CD94	  heterodimer	   that	  
could	   trigger	   redirected	   lysis	   in	   a	   TCR-­‐independent	   manner.	   Biochemical	   and	   molecular	  
characterization	   of	   the	   heterodimer	   identified	   a	   novel	   NKG2	   molecule,	   named	   NKG2H.	  
Comparison	   of	   the	   nucleotide	   sequence	   of	   the	  NKG2H	   cDNA	  with	  NKG2	   genomic	   sequences	  
revealed	   that	  NKG2H	   is	   an	   alternative	   splice	   form	  of	  NKG2E	   in	  which	   intron	  VI	   has	  not	  been	  
removed	   and	   that	   does	   not	   contain	   exon	   VII	   (Fig.	   3).	   Like	   NKG2C,	   NKG2H	   has	   a	   short	  
cytoplasmic	   tail,	   lacks	   ITIMs	  but	  does	  possess	  a	  charged	   lysine	  residue	   in	   the	  transmembrane	  

















Fig.	  3:	  	  Alignment	  of	  NKG2	  family	  members	  and	  CD94.	  (*)	  indicate	  identical	  residues;	  (:)	  indicate	  highly	  similar	  




Earlier,	  in	  1990,	  immunological	  studies,	  carried	  out	  in	  parallel	  to	  the	  cloning	  studies	  outlined	  
above,	  led	  to	  the	  description	  of	  a	  novel	  cell	  surface	  disulfide-­‐linked	  dimer	  initially	  called	  Kp43,	  
that	   was	   preferentially	   expressed	   by	   NK	   cells,	   TCRγδ+	   T	   lymphocytes	   and	   some	  
CD8+CD56+TCRαβ+	   T	   cell	   clones	   (Aramburu	   et	   al.	   1990;	   Aramburu	   et	   al.	   1991).	   Functionally,	  
monoclonal	   antibodies	   specific	   for	   Kp43	   could	   modulate	   NK	   cell-­‐mediated	   cytotoxicity	   and	  
cytokine	  production	   (Aramburu	  et	  al.	  1993).	  Molecular	   cloning	  of	   the	  cDNA	  encoding	  Kp43	   (now	  
termed	   CD94)	   (Chang	   et	   al.	   1995),	   led	   to	   the	   identification	   of	   a	   single-­‐copy	   gene,	   located	   in	  
chromosome	   12p13.1,	   encoding	   a	   type	   II	   membrane	   glycoprotein	   with	   a	   C-­‐type	   lectin-­‐like	  
domain	  and	  a	  short	  cytoplasmic	   tail.	   	  All	   the	  cDNA	  clones	   isolated	  displayed	  an	   identical	  ORF	  
(open	  reading	  frame),	  encoding	  for	  a	  180-­‐amino	  acid	  polypeptide	  with	  a	  short	  intra-­‐cytoplasmic	  
domain	  (7	  amino	  acids),	  which	  contains	  a	  charged	  residue	  (Lys)	  in	  the	  transmembrane	  region.	  
However,	  the	  biochemical	  studies	  in	  polyclonal	  NK	  cells	  indicated	  that	  Kp43	  was	  assembled	  as	  a	  
NKG2E           MSKQRGTFSEVSLAQDPKWQQRKPKGNKSSISGTEQEIFQVELNLQNASLNHQGIDKIYDCQGLLPPPEKLTAE 115 
NKG2H           MSKQRGTFSEVSLAQDPKWQQRKPKGNKSSISGTEQEIFQVELNLQNASLNHQGIDKIYDCQGLLPPPEKLTAE 60 
NKG2C           MNKQRGTFSEVSLAQDPKRQQRKPKGNKSSISGTEQEIFQVELNLQNPSLNHQGIDKIYDCQGLLPPPEKLTAE 60 
NKG2A           MDNQGVIYSDLNLPPNPKRQQRKPKGNKSSILATEQEITYAELNLQKASQDFQGNDKTYHCKDLPSAPEKLIVG 60 
CD94            ------------------------------------------------------------MAVFKTTLWRLISG  
                                                                               : ..  :*    
 
NKG2E           VLGIICIVLMATV—LKTIVLIPFL              EQ--NNSSPNARTQKARHCG 
NKG2H           VLGIICIVLMATV—LKTIVLIPFL              EQ--NNSSPNARTQKARHCG 
NKG2C           VLGIICIVLMATV—LKTIVLIPFL              EQ--NNFSPNTRTQKARHCG 
NKG2A           ILGIICLILMASV—VTIVVIPSTLI             -QRHNNSSLNTRTQKARHCG 
CD94            TLGIICLSLMATLGILL             KNSFTKLSIEPAFTPGPNIELQKDSDCC 
                  *****: ***::  :                      :   . . * . **  .* 
 
NKG2E           HCPEEWITYSNSCYYIGKERRTWEESLQACASKNSSSLLCIDNEEEMKFLASILPSSWIGVFRNSSHHPWVTINGLAFKHEIKDSDH-- 177 
NKG2H           HCPEEWITYSNSCYYIGKERRTWEESLQACASKNSSSLLCIDNEEEMKFLASILPSSWIGVFRNSSHHPWVTINGLAFKHEIKDSDH-- 177 
NKG2C           HCPEEWITYSNSCYYIGKERRTWEESLLACTSKNSS-LLSIDNEEEMKFLASILPSSWIGVFRNSSHHPWVTINGLAFKHKIKDSDN-- 176 
NKG2A           HCPEEWITYSNSCYYIGKERRTWEESLLACTSKNSS-LLSIDNEEEMKFLSIISPSSWIGVFRNSSHHPWVTMNGLAFKHEIKDSDN-- 178 
CD94            SCQEKWVGYRCNCYFISSEQKTWNESRHLCASQKSS-LLQLQNTDELDFMSSSQQFYWIGLSYSEEHTAWLWENGSALSQYLFPSFETF 120 
                 * *:*: *  .**:*..*::**:**   *:*::** ** ::* :*:.*::      ***:  ...* .*:  ** *:.: :  * .   
 
NKG2E           AERNCAMLHVRGLISDQ-CGSSRIIRRGFIMLTRLVLNS----------------- 240 
NKG2H           AERNCAMLHVRGLISDQ-CGSSRIIVSISFRIKALELAVHQIKFYICSNRNDIMIA 257 
NKG2C           AELNCAVLQVNRLKSAQ-CGSSMIYHCKHKL------------------------ 231 
NKG2A           AELNCAVLQVNRLKSAQ-CGSSIIYHCKHKL------------------------ 233 
CD94            NTKNCIAYNPNGNALDESCEDKNRYICKQQLI----------------------- 179 
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disulfide-­‐linked	   dimer,	   comprising	   two	   subunits	   (Lopez-­‐Botet	   et	   al.	   1995).	   In	   addition,	  
immunoprecipitation	  analysis	  of	  NK	  cells	  obtained	  from	  different	  donors	  showed	  two	  forms	  of	  
CD94	   molecule	   corresponding	   to	   molecular	   size	   of	   43kDa	   (p43)	   and	   39kDa	   (p39),	   providing	  
further	  evidence	   for	   the	  structural	  heterogeneity	  of	   these	  proteins	   (Perez-­‐Villar	  et	  al.	  1995;	  Perez-­‐
Villar	   et	   al.	   1996).	   These	   observations	   were	   consistent	   with	   functional	   data	   showing	   that	   the	  
specific	   anti-­‐Kp43	   (CD94)	   mAb	   might	   either	   inhibit	   or	   activate	   NK	   cell	   function,	   but	   were	  
difficult	  to	  reconcile	  with	  the	  invariant	  nature	  of	  the	  cloned	  CD94	  transcript.	  	  
A	   solution	   to	   this	   dilemma	   was	   provided	   by	   Phillips	   et	   al.	   1996,	   who	   reported	   that	   a	  
polyclonal	  antiserum	  raised	  against	  the	  cloned	  CD94	  protein	  did	  not	  react	  in	  Western	  blotting	  
with	  Kp43,	  strongly	  suggesting	  that	  CD94	  and	  Kp43	  were	  different	  molecules;	  Kp43	  (CD94)	  was	  
renamed	   ¨CD94-­‐associated	   protein¨.	   A	   plausible	   candidate	   for	   43kDa	   glycoprotein	   (p43)	  was	  
the	   recently	   identified	   C-­‐type	   lectin	   protein	   NKG2A,	   the	   only	   molecule	   of	   this	   family	   that	  
contained	  cytoplasmic	  ITIMs	  and	  had	  the	  predicted	  molecular	  weight.	  Subsequent	  experiments	  
confirmed	  that	  the	  p43	  subunit	  was	  encoded	  by	  NKG2A	  that	  assembled	  with	  CD94	  to	  constitute	  
the	  functional	  receptor	  complex	  (Plougastel	  et	  al.	  1996;	  Lazetic	  et	  al.	  1996;	  Carretero	  et	  al.	  1997).	  
NKG2B,	  the	  splice	  variant	  of	  NKG2A,	  as	  well	  as	  other	  members	  of	  the	  NKG2	  multigene	  family	  
including	   NKG2C	   (corresponding	   to	   the	   previously	   detected	   p39	   subunit)	   and	   NKG2E/H	   also	  
require	   assembly	   with	   CD94	   to	   generate	   functional	   heterodimeric	   receptors.	   NKG2D,	   as	  
mentioned	  previously,	   is	  distantly	  related	  to	  the	  other	  members	  of	  the	  NKG2	  family	  and	  does	  
not	  dimerize	  with	  CD94,	   rather	   it	   is	   expressed	  as	  homodimer	  and	  associates	  with	   the	  DAP10	  
adaptor	  protein	  (Wu	  et	  al.	  1999).	  
A	  common	  structural	  feature	  of	  the	  inhibitory	  receptors	  is	  the	  presence	  of	  cytoplasmic	  ITIM	  
(I/V/L/SxYxxL/V	   sequences)	   that	   after	   tyrosine	   phosphorylation,	   recruit	   protein	   tyrosine	  
phosphatases	  (SHP-­‐1	  and	  SHP-­‐2)	  involved	  in	  the	  downregulation	  of	  NK	  cell	  activity	  (Burshtyn	  et	  al.	  
1996;	   Campbell	   et	   al.	   1996;	   Fry	   et	   al.	   1996;	   Olcese	   et	   al.	   1996).	   CD94/NKG2A/-­‐B	   complex	   contain	  
cytoplasmic	   ITIMs	   and	   are	   generally	   considered	   to	   be	   inhibitory	   receptors.	   CD94/NKG2C	   and	  
CD94/NKG2E/-­‐H	  are	  homologous	  to	  NKG2A/-­‐B	  but	  lack	  ITIMs,	  possess	  a	  charged	  amino	  acid	  in	  
the	  transmembrane	  region	  and	  exert	  activating	  functions.	  
	  2.2 Ligands	  for	  CD94/NKG2	  	  receptors	  
Moretta	  and	  co-­‐workers,	   in	  1994	  proposed	  that	  the	  CD94	  receptor	  could	  recognize	  certain	  
HLA	  molecules	  on	  the	  target	  cell.	  Moreover,	  the	  hypothesis	  that	  the	  CD94/NKG2	  C-­‐type	  lectin	  
receptor	  complex	  may	  be	   involved	   in	  NK	  cell	  mediated	   recognition	  of	  different	  HLA	  allotypes	  
was	   further	  supported	  by	  the	   functional	  data	  reported	  by	  Sivori	  et	  al.	  1996	  and	  Phillips	  et	  al.	  
1996.	  However,	  although	  NK	  cells	  expressing	  these	  C-­‐type	  lectin	  receptors	  could	  recognize	  in	  a	  
CD94	  dependent	  way,	  target	  cells	  expressing	  HLA-­‐A,	  HLA-­‐B,	  HLA-­‐C	  or	  HLA-­‐G,	  it	  was	  not	  possible	  
to	   demonstrate	   a	   direct	   interaction	   between	   these	   ligands	   and	   the	   receptors.	   Subsequent	  
experiments	   revealed	   that	   the	   true	   ligand	   bound	   by	   the	   CD94/NKG2A/B	   as	   well	   as	   the	  
CD94/NKG2C	   complex	   was	   HLA-­‐E,	   a	   non-­‐classical	   MHC	   class	   I	   molecule,	   that	   binds	   leader	  
peptides	  derived	   from	  the	   signal	   sequences	  of	   classical	  HLA-­‐A,	  HLA-­‐B,	  HLA-­‐C	  or	  HLA-­‐G	  alleles	  




	   36	  
Introduction	  
E	   expression	   depends	   on	   the	   availability	   of	   classical	   MHC	   class	   I	   leader	   peptides,	  
downregulation	   of	   MHC	   class	   I	   expression	   consequently	   leads	   to	   a	   reduction	   of	   HLA-­‐E	  
expression	   at	   the	   cell	   surface.	   Accordingly,	   although	   indirect,	   the	   interaction	   between	  
CD94/NKG2	  and	  HLA-­‐E	  is	  one	  of	  the	  central	  mechanisms	  by	  which	  NK	  cells	  monitor	  the	  overall	  
expression	  level	  of	  multiple	  MHC	  class	  I	  molecules.	  
	  2.2.1 HLA-­‐E	  molecule	  
Major	   histocompatibility	   class	   I	  molecules	   (MHC-­‐I)	   are	   classified	   into	   two	   groups;	   classical	  
MHC-­‐I	  or	  class	  Ia	  proteins	  (HLA-­‐A,	  HLA-­‐B	  and	  HLA-­‐C)	  which	  are	  encoded	  by	  highly	  polymorphic	  
genes	  and	  are	  expressed	  in	  most	  nucleated	  cells,	  and	  non-­‐classical	  MHC-­‐I	  or	  class	  Ib	  molecules	  
(HLA-­‐E,	  HLA-­‐F	  and	  HLA-­‐G),	  encoded	  by	  genes	  which	  are	  much	  less	  polymorphic	  and	  often	  have	  
restricted	  patterns	  of	  expression.	  In	  humans,	  the	  best	  understood	  of	  these	  class	  Ib	  antigens	  is	  
human	   leukocyte	   antigen	   (HLA)-­‐E.	   Unlike	   the	   other	   MHC	   class	   Ib	   molecules,	   HLA-­‐E	   is	  
transcribed	  virtually	  in	  all	  human	  tissues	  and	  cell	  lines,	  although	  at	  lower	  levels	  than	  MHC	  class	  
Ia	  antigens	  (Wei	  et	  al.	  1990;	  Braud	  et	  al.	  1997).	  The	  gene	  encoding	  HLA-­‐E	  is	  located	  between	  HLA-­‐A	  
and	  HLA-­‐C	  on	  the	  short	  arm	  of	  chromosome	  6.	  With	  only	  nine	  alleles	  encoding	  three	  different	  
proteins,	   HLA-­‐E	   is	   the	   least	   polymorphic	   of	   all	  MHC	   class	   I	  molecules.	   Two	  HLA-­‐E	  molecules,	  
encoded	  by	  HLA-­‐E*01:01	  and	  HLA-­‐E*01:03,	   exist	  with	   about	   equal	   frequencies	   in	   the	  human	  
population	  (Geraghty	  et	  al.	  1992;	  Strong	  et	  al.	  2003;	  Antoun	  et	  al.	  2009).	  The	  two	  confirmed	  alleles,	  HLA-­‐
E*01:01	   and	   HLA-­‐E*01:03	   have	   been	   referred	   as	   HLA-­‐ER	   and	   HLA-­‐EG	   respectively	   since	   they	  
differ	  in	  one	  amino	  acid,	  having	  either	  arginine	  (HLA-­‐E*01:01)	  or	  glycine	  (HLA-­‐E*01:03)	  located	  
at	  position	  107	  on	  the	  α2	  domain	  of	  the	  HLA-­‐E	  heavy	  chain	  (Grimsley	  et	  al.	  2002).	  Recently,	  a	  novel	  
HLA-­‐E	   allele,	   HLA-­‐E*01:03:05	   was	   identified	   in	   two	   Brazilian	   individuals.	   This	   novel	   HLA-­‐E	  
variant	  has	   a	   synonymous	   substitution	  with	  a	  G	   to	  C	   transversion	  at	   the	  position	  1625,	   third	  
base	  of	  codon	  189	  in	  exon	  4	  (Veiga-­‐Castelli	  et	  al.	  2012).	  The	  extremely	  high	  degree	  of	  conservation	  
between	  species	  at	  the	  HLA-­‐E	  locus,	  especially	  in	  the	  peptide-­‐binding	  region	  (Connolly	  et	  al.	  1993;	  
Boyson	  et	  al.	  1995)	  is	  consistent	  with	  an	  important,	  conserved,	  biological	  function	  of	  the	  peptide-­‐
HLA-­‐E	  complex	  (Aldrich	  et	  al.	  1994;	  Braud	  et	  al.	  1997).	  
Like	  other	  MHC	  class	   I	  molecules,	  HLA-­‐E	   is	   a	  heterodimer	   consisting	  of	  a	  α	   heavy	   chain,	   a	  
type	   I	   integral	  membrane	   glycoprotein	   and	   a	   light	   chain,	  β-­‐2	  microglobulin	   (β2m)	  which	   is	   a	  
soluble	  protein	   (Adams	  et	  al.	  2013).	   The	  extracellular	   region	  of	   the	  heavy	   chain	   folds	   into	   three	  
domains	  (α1,	  α2	  and	  α3),	  with	  β2m	  contributing	  a	  fourth	  domain.	  As	  in	  MHC	  class	  Ia	  molecules,	  
the	  α1	  and	  α2	  domains	   form	   the	  peptide-­‐binding	   site:	   a	   groove	  on	   the	  upper	   surface	  of	   the	  
MHC	  class	   I	  molecule,	  which	  bind	  antigenic	  peptides.	  However,	  this	  peptide	  binding	  groove	   is	  
highly	  specialized	  to	  mediate	  an	  exquisitely	  specific	  association	  with	  9	  amino-­‐acid	  long	  peptides	  
derived	  from	  MHC	  class	  I	  signal	  sequences	  (Braud	  et	  al.	  1997;	  O´Callaghan	  et	  al.	  1998(1)(2)).	  
	  2.2.2 Processing	  of	  MHC	  class	  I	  molecules.	  Generation	  of	  HLA-­‐E	  epitopes.	  
Unlike	   classical	   MHC	   class	   I	   molecules,	   HLA-­‐E	   associates	   with	   a	   narrow	   set	   of	   nonameric	  
peptides,	  mostly	  derived	  from	  the	  leader	  sequences	  of	  classical	  MHC	  class	  Ia	  molecules.	  These	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hydrophobic	  segments	  to	  target	  the	  newly	  synthesized	  proteins	  to	  the	  endoplasmatic	  reticulum	  
(ER).	  Once	   in	  the	  ER,	   the	  N-­‐terminal	  signal	  peptide	   is	   released	  from	  the	  class	   I	  protein	  by	  the	  
signal	  peptidase	  (SPase)	  (Martoglio	  et	  al.	  1998).	  The	  native	  class	  I	  protein	  is	  chaperoned	  by	  calnexin	  
and	  incorporated	  into	  a	  protein	  complex	  responsible	  for	  peptide	  loading,	  the	  so-­‐called	  peptide	  
loading	   complex	   (PLC)	   (Cresswell	   et	   al.	   2005).	   The	   cleaved	   signal	   peptide	   of	   MHC	   I	   molecule,	  
usually	  24	  amino	  acids	  long,	  remains	  in	  the	  ER	  membrane	  due	  to	  its	  hydrophobicity	  and	  needs	  a	  
second	  cleavage	  to	  be	  liberated	  from	  the	  membrane.	  This	  second	  cleavage	  is	  mediated	  by	  the	  
signal	   peptide	   peptidase	   (SSPase),	   an	   aspartic	   protease,	  which	   acts	  within	   the	   ER	  membrane	  
(Lemberg	  et	  al.	  2001).	  SSpase	  mediated	  cleavage	  results	  in	  release	  of	  the	  epitope-­‐containing	  leader	  
peptide	   to	   the	   cytosol.	   This	   leader	   peptide	   gets	   rewarded	   with	   a	   second	   life	   becoming	   a	  
peptide,	   which	   could	   be	   presented	   by	   an	   HLA-­‐E	   molecule.	   To	   be	   loaded	   onto	   the	   HLA-­‐E	  
molecule,	   the	  precursor	  peptide	   is	   further	   shaped	  by	   the	  proteasome	   to	  make	   it	   suitable	   for	  
transport	   back	   into	   the	   ER,	   a	   function	  performed	  by	   the	   transporter	   associated	  with	   antigen	  
processing	   (TAP)	   (Bland	   et	   al.	   2003).	   ER	   resident	   chaperones	   facilitate	   the	   folding	   of	   the	   HLA-­‐E	  
molecule	  heavy	  chain	  and	  β2m,	  which	  bind	  TAP	  in	  a	  complex	  where	  tapasin	  plays	  a	  critical	  role,	  
bridging	  HLA-­‐E	  and	  TAP.	  Tapasin	  is	  also	  required	  to	  facilitate	  the	  binding	  and	  loading	  of	  the	  high	  
affinity	  peptide	  to	  the	  HLA-­‐E	  molecule	  (Ulbrecht	  et	  al.	  1998;	  Braud	  et	  al.	  1998(2);	  Lee	  et	  al.	  1998(1)).	  After	  
peptide	  loading,	  MHC	  class	  I	  molecules	  dissociate	  from	  TAP	  and	  cluster	  at	  the	  export	  site	  on	  the	  
ER	  membrane	  where	  they	  are	  selectively	  recruited	  into	  cargo	  vesicles	  for	  transport	  to	  the	  Golgi	  
apparatus.	  HLA-­‐E	  molecules	  then	  traffic	  through	  the	  Golgi	  apparatus	  to	  the	  plasma	  membrane	  
where	  it	  can	  serve	  as	  a	  ligand	  for	  particular	  receptors.	  
	  2.2.3 Peptides	  presented	  by	  HLA-­‐E	  molecule.	  
The	   peptide-­‐binding	   groove	   of	   HLA-­‐E	   has	   similar	   dimensions	   to	   that	   of	   the	   classical	  MHC	  
class	   I	   molecules,	   but	   its	   surface	   features	   are	   distinctive.	   The	   groove	   is	   highly	   hydrophobic,	  
which	  favours	  binding	  of	  hydrophobic	  leader	  peptides.	  Pockets	  along	  the	  length	  of	  the	  groove	  
are	  well	  adapted	  to	  bind	  specific	  amino	  acids.	  Three	  hydrophobic	  pockets	  at	  peptide	  position	  1,	  
7	  and	  9	  bind	  methionine,	  valine	  and	  leucine	  respectively	  and	  two	  pockets	  at	  positions	  3	  and	  6,	  
which	  bind	  alanine	  and	  threonine	  respectively.	  A	  number	  of	  hydrophobic	   interactions,	  as	  well	  
as	   hydrogen	   bonds,	   between	   residues	   in	   the	   groove	   and	   atoms	   of	   the	   peptide	   chain,	   occur	  
along	  the	   length	  of	   the	  peptide	   ligand.	  For	  these,	  and	  other	  specific	   interactions	  to	  occur	  the	  
peptide	  needs	  to	  have	  a	  correct	  conformation	  and	  length.	  This	  restricts	  the	  ability	  of	  peptides	  
to	  bind	  and	  stabilize	  the	  HLA-­‐E	  molecule.	  	  
A	  standard	   leader	  sequence	   is	  well	  conserved	  throughout	  MHC	  class	   I	  molecules,	  and	   is	  of	  
the	   form	  MAVMAPRTVLLLSGALALTQTWA.	   The	   first	   structure	   of	   HLA-­‐E	   in	   a	   complex	  with	   the	  
leader	   sequence	   peptide	   from	   HLA-­‐B*08	   (VMAPRTVLL)	   was	   described	   by	   O´Callaghan	   et	   al.	  
1998.	  This	  study	  demonstrated	  that	  leader	  peptide	  specificity	  is	  a	  highly	  developed	  property	  of	  
HLA-­‐E.	  Due	  to	  the	  extensive	  repertoire	  of	  human	  HLA-­‐class	  I	  molecules,	  the	  exact	  sequence	  of	  
the	  leader	  peptide	  especially	  at	  the	  positions	  2,	  7	  and	  8	  differs,	  but	  most	  of	  them	  bind	  to	  HLA-­‐E	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threonine	  at	  position	  2	  of	   the	  peptide,	  as	  well	   as	   the	   leader	  peptide	  derived	   from	   the	  HLA-­‐E	  
itself	  (Lee	  et	  al.	  1998(2);	  Stevens	  et	  al.	  2001;	  Strong	  et	  al.	  2003).	  
Although,	  HLA-­‐E	   is	  normally	  found	  associated	  with	  a	   limited	  peptide	  repertoire,	  other	   lines	  
of	  evidence	  have	  revealed	   that	  peptides	   from	  proteins	  other	   than	  MHC	  class	   I	  molecules	  can	  
bind	  HLA-­‐E.	  These	  peptides	  include	  the	  VMAPRTLVL	  and	  the	  VMAPRTLIL	  peptides	  derived	  from	  
the	  UL40	  glycoprotein	  leader	  sequences	  of	  two	  different	  human	  cytomegalovirus	  (CMV)	  strains	  
(Toledo	  and	  AD169),	  matching	  exactly	   the	   leader	  sequence	  peptides	  of	  various	  HLA-­‐A	  and	  –C	  
alleles	   (VMAPRALVL	   and	   VMAPRTLIL	   respectively)	   (Heatley	   et	   al.	   2013).	   Importantly,	   unlike	   the	  
MHC	  class	   I	   leader	  peptides,	   the	  gpUL40-­‐derived	  peptides	  are	  assembled	  on	  HLA-­‐E	   in	   a	   TAP-­‐
independent	   manner	   (Tomasec	   et	   al.	   2000).	   Peptides	   derived	   from	   the	   heat	   shock	   protein	   60	  
(hsp60,	   QMRPVSRVL)	   (Michaëlsson	   et	   al.	   2002),	   the	   ATP-­‐binding	   cassette	   transporter	   multidrug	  
resistance-­‐associated	   protein	   7	   the	   (MRP7,	   ALALVRMLI)	   (Wooden	   et	   al.	   2005),	   the	   Salmonella	  
enterica	   serovar	   TyphiGroEL	   protein	   (GroEL,	   KMLRGVNVL)	   (Salerno-­‐Goncalves	   et	   al.	   2004),	   the	  
human	  immunodeficiency	  virus	  (HIV)	  gag	  protein	  (HIVp24,	  AISPRTLNA)	  (Naterrmann	  et	  al.	  2005(1)),	  
and	  gliadin	  (gliadin	  α2	  chain,	  SQQPYLQLQ)	  (Terrazzano	  et	  al.	  2007)	  have	  also	  been	  shown	  to	  bind	  to	  
the	  HLA-­‐E	  molecule.	  Recently,	  multiple	  peptides	  derived	  from	  Mycobacterium	  tuberculosis	  have	  
been	  described	  as	  having	  the	  capacity	  to	  bind	  and	  be	  presented	  by	  HLA-­‐E	  (Joosten	  et	  al.	  2010).	  
The	  binding	  of	  viral	  protein	  peptides,	  as	   is	   typical	   for	  classical	  MHC	  class	   Ia	  molecules,	  has	  
also	  been	  demonstrated	  for	  HLA-­‐E	  and	  examples	  of	  these	  include	  peptides	  from	  the	  influenza	  
matrix	   protein	   (InflM,	   ILGFVFTLT)	   (Ulbrecht	   et	   al.	   1998),	   Epstein-­‐Barr	   virus	   (EBV)	   BZLF-­‐1	   protein	  
(BZLF-­‐1,	   SQAPLPCVL)	   (Jorgensen	   et	   al.	   2012)	   and	   the	   Hepatitis	   C	   virus	   (HCV)	   core	   protein	   (HCV	  
Core,	   YLLLPRRGPRL)	   (Nattermann	   et	   al.	   2005(2);	   Orr	   et	   al.	   2010;	   Cheent	   et	   al.	   2013).	   Interestingly,	   two	  
alternative	  splicing	  isoforms	  of	  mutant	  peroxiredoxin	  5	  (Prdx5)	  encode	  two	  nonapeptides	  Prdx5	  
splice	   variant	   (Prdx5Δ2,	   AMAPIKTHL)	   and	   Prdx5	   splice	   variant	   (Prdx5Δ2,	   3,	   AMAPIKVRL)	   also	  
able	  to	  bind	  HLA-­‐E	  (Sensi	  et	  al.	  2009).	  
	  2.3 Presentation	   of	   HLA-­‐E-­‐bound	   peptides	   to	   CD94/NKG2	   receptors	   and	  receptor	  response	  
The	   identification	   of	   HLA-­‐E	   as	   a	   ligand	   for	   CD94/NKG2	   receptors	  was	   achieved	   essentially	  
simultaneously	  by	  several	  groups.	  Two	  groups	  showed	  that	  stabilization	  of	  HLA-­‐E	  expression	  at	  
the	  cell	   surface	  by	   incubation	  with	  synthetic	  peptides	  derived	   from	  the	  signal	   sequences	  of	  a	  
number	  of	  HLA	  class	   I	  molecules	   led	  to	  protection	  of	  these	  peptide-­‐treated	  cells	   from	  NK	  cell	  
lysis.	  Further,	  treatment	  with	  CD94-­‐specific	  but	  not	  killer	  cell	   inhibitory	  receptor	  (KIR)-­‐specific	  
mAbs	   could	   block	   this	   HLA-­‐E-­‐mediated	   protection	   of	   target	   cells	   (Borrego	   et	   al.	   1998;	   Lee	   et	   al.	  
1998(2)).	  In	  contrast,	  the	  experiments	  of	  Braud	  et	  al.	  depended	  on	  the	  utilization	  of	  new	  method	  
for	   identifying	   antigen	   specific	   T	   cells;	   peptide-­‐HLA	   tetrameric	   complexes,	   a	   technique	  
developed	  by	  Mark	  Davis´	  laboratory	  in	  1996	  (Altman	  et	  al.	  1996;	  O´Callaghan	  et	  al.	  1999;	  McMichael	  et	  
al.	   1998).	   Tetramers	   of	   HLA-­‐E,	   loaded	   with	   MHC	   I	   leader	   peptides,	   bound	   to	   a	   significant	  
population	   of	   peripheral	   blood	   lymphocytes	   expressing	   CD56	   and	   CD16,	   both	   of	   which	   are	  
markers	  for	  NK	  cells	  (Braud	  et	  al.	  1998).	  The	  identification	  of	  mAbs	  able	  to	  block	  the	  binding	  of	  the	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CD94/NKG2A,	   as	   well	   as	   NKG2B	   or	   -­‐C	   surface	   molecules.	   These	   proteins	   were	   specific	   and	  
selective	   receptors	   for	   HLA-­‐E,	   that	   could	   trigger	   inhibitory	   (CD94/NKG2A-­‐B	   receptor)	   or	  
activating	  (CD94/NKG2C	  receptor)	  signals	  in	  the	  NK	  cells.	  The	  finding	  that	  CD94/NKG2	  receptors	  
can	  recognize	  and	  directly	  bind	  HLA-­‐E	  has	  been	  later	  confirmed	  by	  other	  groups	  (Llano	  et	  al.	  1998;	  
Vales-­‐Gomez	  et	  al.	  1999;	  Brooks	  et	  al.	  1999).	  
Based	  on	  the	  structure	  of	  MICA	  bound	  to	  NKG2D,	  Li	  and	  coworkers	  (Li	  et	  al.	  2001(2))	  proposed	  
that	   CD94/NKG2A	  would	   bind	   HLA-­‐E	   with	   CD94	   oriented	   over	   the	  α1	   helix	   of	   HLA-­‐E	   and	   C-­‐
terminal	   part	   of	   the	   peptide,	   and	   NKG2A	   over	   the	   α2	   helix.	   Subsequent	   binding	   and	  
mutagenesis	  studies	  of	  HLA-­‐E	  helices	  (Kaiser	  et	  al.	  2005;	  Sullivan	  et	  al.	  2007;	  Wada	  et	  al.	  2004)	  coupled	  
with	  the	  resolution	  of	  the	  structure	  of	  the	  non	  ligated	  CD94/NKG2A	  heterodimer	  (Sullivan	  et	  al.	  
2007)	  provided	  further	  support	  for	  this	  orientation,	  indicating	  that	  CD94	  is	  likely	  responsible	  for	  
reading	  out	  the	  C	  terminus	  of	  the	  peptide	  and	  that	  the	  two	  most	  critical	  peptide	  contact	  points	  
for	  CD94/NKG2	  are	  positions	  P5,	   an	   invariant	  Arg,	   and	  P8,	   a	  hydrophobic	   residue	   that	   varies	  
between	   class	   I	   leader	  peptides	   (Miller	  et	  al.	  2003;	  Sullivan	  et	  al.	  2007).	   Finally,	   the	   solution	  of	   the	  
crystal	  structure	  of	  the	  complex	  between	  CD94/NKG2A	  and	  HLA-­‐E	  (Kaiser	  et	  al.	  2008)	  has	  provided	  
detailed	  insight	  into	  the	  recognition	  mechanisms	  of	  this	  family	  of	  immunoreceptors,	  accounting	  
for	   the	   affinity	   differences	   between	   NKG2A	   and	   NKG2C	   for	   HLA-­‐E	   and	   between	   different	  
peptides	   for	  NKG2x	   receptors.	   Sequence	   differences	   in	  NKG2x	   residues	   167-­‐170,	  which	   form	  
part	  of	  the	  heterodimer	  interface,	  account	  for	  the	  affinity	  difference	  between	  CD94/NKG2A	  and	  
CD94/NKG2C	  for	  given	  HLA-­‐E-­‐peptide	  complexes.	  
Several	   proteins	  other	   than	  MHC	   class	   I	   leader	  peptides	  have	  also	  been	   shown	   to	  encode	  
peptides	   that	   can	   bind	   to	   HLA-­‐E	   (Nattermann	   et	   al.	   2005(2);	   Ulbrecht	   et	   al.	   2000;	  Wooden	   et	   al.	   2005).	  
Taking	   into	   account	   the	   particular	   differences	   of	   these	   peptides	   from	   canonical	  MHC	   class	   I	  
leader	   peptides,	   it	   seems	   reasonable	   to	   assume	   that	   CD94/NKG2x	   complex	  will	   interact	  with	  
HLA-­‐E	  with	  a	  reduced	  affinity	  but	  this	  remains	  to	  be	  confirmed.	  	  
In	  addition	  to	  being	  a	  ligand	  for	  the	  CD94/NKG2	  receptors,	  HLA-­‐E	  can	  also	  present	  peptides	  
for	  recognition	  by	  CD8+	  T	  cells	  expressing	  conventional	  αβTCRs	  (Heinzel	  et	  al.	  2002;	  Pietra	  et	  al.	  2003;	  
Romagnani	  et	  al.	  2004;	  Salerno-­‐Concalves	  et	  al.	  2004).	  The	  footprint	  of	  an	  HLA-­‐E	  restricted	  TCR	  on	  HLA-­‐E	  
closely	  overlaps	  that	  of	  CD94/NKG2A	  on	  HLA-­‐E	  (Sullivan	  et	  al.	  2007;	  Petrie	  et	  al.	  2008).	  
	  2.3.1 Affinity	  
There	   is	   a	   precise	   correlation	   between	   the	   nature	   of	   the	   peptide	   bound	   by	   HLA-­‐E	   and	  
immune	   recognition	   for	   function	   (Llano	   et	   al.	   1998;	   Brooks	   et	   al.	   1999;	   Vales-­‐Gomez	   et	   al.	   1999).	   In	  
cellular	  systems,	  Llano	  and	  coworkers	  confirmed	  that	  there	  is	  a	  good	  correlation	  between	  the	  
presence	  of	   a	   leader	  peptide	  with	  methionine	   at	   position	  2	   and	   recognition	  by	  CD94/NKG2A	  
receptors,	  while	  Brooks	  et	  al.	  used	  recombinant	  receptor	  protein	  to	  examine	  the	  interaction	  of	  
HLA-­‐E	   with	   CD94/NKG2A	   and	   observed	   that	   at	   26oC	   HLA-­‐E	   could	   reach	   the	   surface	   without	  
peptide	  and	  that	  peptides	  with	  threonine	  at	  position	  2	  could	  also	  promote	  surface	  expression	  
of	   HLA-­‐E,	   although	   with	   less	   efficiency	   than	   those	   peptides	   with	   a	   methionine	   at	   the	   same	  
position.	  At	  37oC,	   the	   stability	  of	   the	  HLA-­‐E	   complex	   containing	  peptides	  with	  a	   threonine	  at	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surface	  when	  cells	  were	  warmed	  from	  26	  to	  37oC.	  The	  efficiency	  of	  receptor	  binding	  was	  shown	  
to	   be	   similar	   in	   both	   cases.	   These	   workers	   also	   showed	   that	   the	   presence	   of	   an	   alanine	   at	  
position	   6	   in	   HLA-­‐Cw*0702,	   slightly	   reduced	   the	   stability	   of	   HLA-­‐E	   at	   the	   cell	   surface	   and	  
markedly	  reduced	  the	  binding	  of	  the	  receptor	  to	  HLA-­‐E.	  Again	  in	  1999,	  Vales-­‐Gomez	  et	  al.	  using	  
an	   in	   vitro	   system	   allowing	   direct	   measurement	   of	   the	   binding	   of	   soluble	   HLA-­‐E	   to	   soluble	  
CD94/NKG2	  receptors,	  addressed	  the	  importance	  of	  the	  peptide	  bound	  to	  HLA-­‐E	  for	  interaction	  
with	  the	  CD94/NKG2A	  and	  CD94/NKG2C	  receptors.	  These	  data	  confirmed	  that	  leader	  peptides	  
with	  threonine	  at	  P2	  could	  refold	  HLA-­‐E,	  but	  that	  these	  complexes	  were	  less	  stable	  than	  those	  
where	  HLA-­‐E	  was	  refolded	  using	  peptides	  with	  methionine	   in	  this	  position	  and	  these	  workers	  
were	  the	  first	  to	  show	  that	  CD94/NKG2A	  –	  HLA-­‐E-­‐peptide	  interactions	  had	  kinetic	  parameters	  
similar	  to	  those	  of	  the	  p58	  KIR	  binding	  to	  HLA-­‐C	  (Vales-­‐Gomez	  et	  al.	  1998).	  Moreover,	  the	  activating	  
receptor	   (CD94/NKG2C)	  was	   found	   to	   bind	   to	   the	   peptide	  MHC	   complex	  with	   a	  much	   lower	  
affinity	   than	   the	   inhibitory	   receptor	   (CD94/NKG2A)	   and	   that	   the	   major	   factor	   for	   the	   final	  
outcome	  of	  the	  interaction	  between	  HLA-­‐E	  and	  the	  CD94/NKG2-­‐A/-­‐C	  receptors	  is	  the	  nature	  of	  
the	   bound	   peptide.	   Changes	   in	   the	   peptide	   sequence	   at	   residues	   P6	   and	   P8,	   at	   least,	   may	  
directly	  influence	  binding	  to	  CD94/NKG2,	  whereas	  substitutions	  at	  P2,	  P3	  and	  P7	  are	  more	  likely	  
to	  affect	  binding	  indirectly	  by	  influencing	  peptide	  binding	  to	  MHC.	  
	  2.3.2 CD94/NKG2A-­‐C	  ambivalence	  
NK	   cells	   form	   two	   distinct	   types	   of	   immunological	   synapse:	   a	   cytotoxic	   synapse	   (cNKIS)	  
resulting	   in	   cell	   killing,	   and	  NK	   activation	   for	   cytokine	   and	   granule	   release,	   and	   an	   inhibitory	  
synapse	   (iNKIS)	   that	   suppresses	   these	   functions.	   The	   nature	   and	   molecular	   composition	   of	  
these	  synapses	  are	  very	  different	  (Bromley	  et	  al.	  2001;	  Davies	  et	  al.	  2001;	  McCann	  et	  al.	  2002;	  Vyas	  et	  al.	  
2002).	   The	   formation	   and	   aggregation	   of	   activating	   receptors	   in	   a	   cNKIS	   requires	   an	   intact	  
cytoskeleton	  and	  ATP	  (Lou	  et	  al.	  2000;	  Bromley	  et	  al.	  2001;	  McCann	  et	  al.	  2002;	  Vyas	  et	  al.	  2001;	  Vyas	  et	  al.	  
2002;	   Davis	   et	   al.	   2004)	   whereas	   an	   iNKIS,	   polarizes	   to	   the	   site	   of	   contact	   in	   a	   cytoskeleton	  
independent	   fashion	   (Fassett	   et	   al.	   2001;	  Masilamani	   et	   al.	   2006).	   Other	   data	   have	   shown	   that	   the	  
majority	  of	  the	  CD94/NKG2A	  molecules	  exist	  as	  a	  membrane-­‐mobile	  fraction	  and	  move	  freely	  
within	   the	   plasma	   membrane	   (Lippincott-­‐Schwartz	   et	   al.	   2001;	   Sanni	   et	   al.	   2004).	   However,	   after	  
ligation,	   CD94/NKG2A	   is	   enriched	   at	   the	   site	   of	   the	   contact	   with	   the	   target	   and	   becomes	  
markedly	  immobile	  (Sanni	  et	  al.	  2004).	  
The	  ability	  of	  CD94/NKG2A	  receptor	  and	  its	  splice	  variant	  CD94/NKG2B	  to	  transmit	  inhibitory	  
signals	  depends	  on	  the	  two	  ITIMs	  in	  the	  cytoplasmic	  tail	  of	  NKG2A	  and	  -­‐B.	  After	  interaction	  with	  
the	   ligand,	  the	  tyrosine	  residue	   in	  each	   ITIM	  becomes	  phosphorylated	  thereby	  facilitating	  the	  
binding	   and	   activation	   of	   the	   SHP-­‐1	   and	   SHP-­‐2	   tyrosine	   phosphatases,	   which	   lead	   to	   the	  
suppression	   of	   NK	   cell	   activation	   (Kabat	   et	   al.	   2002;	   Le	   Drean	   et	   al.	   1998).	   These	   receptors	   inhibit	  
activation	   signals	  by	   interfering	  with	   the	  actin	   cytoskeleton-­‐dependent	   recruitment	  of	   ligated	  
activating	  receptors	  into	  lipid	  rafts	  at	  the	  target	  contact	  sites	  (Stebbins	  et	  al.	  2003;	  Watzl	  et	  al.	  2003;	  
Masilamani	  et	  al.	  2006)	  and	  phosphorylated	  Vav1	  has	  been	  described	  as	  a	  major	  target	  for	  the	  SHP-­‐
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In	  general,	  the	  inhibitory	  effect	  generated	  by	  CD94/NKG2A	  ligation	  can	  override	  the	  effect	  of	  
activating	  signals,	  thereby	  preventing	  the	  killing	  of	  target	  cells	  and	  cytokine	  release.	  However,	  if	  
the	   activation	   signals	   are	   very	   strong,	   CD94/NKG2A	   inhibitory	   signalling	   can	   be	   overridden	  
(McMahon	   et	   al.	   2002;	   Lanier	   et	   al.	   2005;	   Ortaldo	   et	   al.	   2005).	   Importantly,	   these	   effects	   are	  
topographically	  restricted	  so	  that	  NK	  cells	  can	  simultaneously	  form	  both	  activating	  (aNKIS)	  and	  
inhibitory	  synapses	  (iNKIS)	  with	  a	  susceptible	  or	  a	  resistant	  target	  cell	  and	  indeed	  lyse	  only	  the	  
susceptible	  target	  but	  spare	  the	  resistant	  target	  respectively	  (Eriksson	  et	  al.	  1999).	  
CD94/NKG2C-­‐E-­‐H	   activating	   receptors	   lack	   intrinsic	   sequences	   required	   for	   cellular	  
activation.	  However,	  these	  receptors	  associate	  with	  the	  DAP12	  adaptor	  protein	  that	  has	  ITAMs	  
and	   can	   transmit	   activation	   signals	   upon	   ligand	   binding	   (Bellón	   et	   al.	   1999;	   Lanier	   et	   al.	   1998).	  
Moreover,	   association	   of	   these	   receptors	   with	   DAP12	   significantly	   enhances	   receptor	   cell	  
surface	   expression	   levels	   (Lanier	   et	   al.	   1998).	   In	   the	   CD94/NKG2C	   cNKIS,	   the	   kinase	   PYK-­‐2,	  
microtubule	   organizing	   center	   (MTOC)	   and	   paxillin	   translocate	   to	   the	   area	   of	   NK-­‐target	   cell	  
contact	   (Sancho	   et	   al.	   2000).	   Further,	   it	   has	   been	   shown	   that	   the	   MAPK	   pathway	   of	   cellular	  
activation	  is	  also	  involved	  in	  the	  CD94/NKG2C-­‐mediated	  signalling	  (Carretero	  et	  al.	  2000).	  	  
Under	  physiological	  conditions,	  all	  nucleated	  cells	  continuously	  express	  the	  HLA-­‐E	  molecule,	  
and	   ligation	   of	   its	   receptors	   leads	   to	   their	   down-­‐regulation.	   A	   continuous	   supply	   of	  
CD94/NKG2A	  receptors	  on	  the	  plasma	  membrane	  is	  maintained	  by	  the	  recycling	  of	  internalized	  
receptors	   between	   the	   plasma	   membrane	   and	   endosomal	   compartment	   in	   a	   ligand	  
independent	  manner	  (Borrego	  et	  al.	  2002;	  Mellman	  et	  al.	  1996).	  Although	  not	  much	   is	  known	  about	  
intracellular	  CD94/NKG2C	   trafficking,	   it	   can	  be	  distinguished	   from	   that	  of	  CD94/NKG2A	  by	   its	  
sensitivity	  to	  brefeldin	  A	  treatment	  (Borrego	  et	  al.	  2002).	  
	  2.3.3 NKG2C:	  ¨Memory¨/¨memory-­‐like¨	  marker	  on	  NK	  cells?	  
Guma	  et	  al.	  2004	  published	  the	  very	  first	  data	  indicating	  that	  HCMV	  infection,	  but	  not	  other	  
herpesvirus	   infections	   [Epstein-­‐Barr	   virus	   (EBV),	   and	   herpes	   simplex	   virus	   (HSV)]	   could	   shape	  
the	   NKR	   repertoire	   of	   healthy	   individuals	   by	   selectively	   promoting	   an	   expansion	   of	  
CD94/NKG2C+	  NK	  and	  T	  cells.	  Later,	  co-­‐culture	  of	  PBMCs	  from	  HCMV	  seropositive	  donors	  with	  
HCMV	  infected	  fibroblasts	  was	  shown	  to	  produce	  a	  preferential	  expansion	  of	  CD94/NKG2C+	  NK	  
cells	  by	  a	  mechanism	  that	  probably	  involved	  the	  interaction	  of	  the	  CD94/NKG2C	  receptor	  with	  
the	   infected	   cell	   (Guma	  et	  al.	  2006(1)).	   In	   studies	  with	  other	   viral	   infections,	   like	  Hantavirus,	   and	  
Chikungunya	  virus,	  a	  similar	  expansion	  of	  NKG2C+	  NK	  cells	  was	  described	   (Bjorkstrom	  et	  al.	  2011;	  
Petitdemange	  et	  al.	  2011),	  although	  an	  influence	  of	  previous	  exposure	  to	  HCMV	  infection	  could	  not	  
be	  completely	  excluded	  in	  these	  patients.	  An	  increased	  frequency	  of	  NKG2C+	  NK	  cells	  was	  also	  
detected	  in	  HCMV	  seropositive	  individuals	  infected	  with	  HIV	  	  (Brunetta	  et	  al.	  2010)	  and	  Hepatitis	  B	  
virus	   (HBV)	   (Beziat	   et	   al.	   2012).	   Importantly,	   the	   HLA-­‐E	   molecule,	   a	   known	   ligand	   for	   the	  
CD94/NKG2C	   receptor	   has	   been	   shown	   to	   be	   upregulated	   in	   HCMV	   (Prodhomme	   et	   al.	   2012),	  
Hantavirus	   (Bjorkstrom	  et	  al.	  2011)	  and	  HIV	   (Nattermann	  et	  al.	  2005(1))	   infections.	   It	  has	  been	  shown	  
that	   NK	   cell	   education	   (ie,	   expression	   of	   a	   self-­‐specific	   KIR)	   is	   required	   for	   the	   efficient	  
expansion	  of	  NKG2C+	  NK	  cells,	  at	   least	   in	  vitro	   (Beziat	  et	  al.	  2013).	  Moreover	   these	   in	  vitro	  data	  




	   42	  
Introduction	  
proliferation	   and	  differentiation	  of	   CD57-­‐	  NK	   cells,	   rather	   than	   the	  pre-­‐existing	  differentiated	  
CD57+	   NK	   cell	   subset.	   In	   some	   rare	   HCMV+	   but	   NKG2C-­‐	   donors	   NK	   expansions	   involving	  
educated	  NK	  cells	  expressing	  activating	  KIRs	  (KIR2DS4,	  KIR2DS2	  and	  KIR3DS1)	  (Beziat	  et	  al.	  2013),	  
as	  well	  as	  receptor	  KIR2DL2/3	  (Foley	  et	  al.	  2011;	  Bjorkstrom	  et	  al.	  2011;	  Petitdemange	  et	  al.	  2011;	  Bezait	  et	  
al.	  2012)	  have	  been	  described.	  
In	  the	  setting	  of	  solid-­‐organ	  transplantation,	  allogenic	  hematopoietic	  stem	  cell	  or	  umbilical	  
cord	  blood	  transplantation	  HCMV	  reactivation	  results	  in	  the	  induction	  of	  functional	  CD57+	  and	  
NKG2C+	   NK	   cells	   (Della	   et	   al.	   2011;	   Foley	   et	   al.	   2012;	   Lopes-­‐Verges	   et	   al.	   2011).	   In	   humans,	   CD57	   is	  
expressed	  preferentially	  by	  a	  subset	  of	  NK	  cells	  with	  a	  highly	  mature	  phenotype	  (Bezlat	  et	  al.	  2010;	  
Bjorkstrom	  et	  al.	  2010;	  Lopez-­‐Vergez	  et	  al.	  2010)	  suggesting	  that	  CD57	  might	  mark	  NK	  cells	   that	  have	  
been	   clonally	   expanded	   by	   infections.	   Interestingly,	   the	   expanded	   NKG2C+	   cells	   did	   not	   just	  
express	   the	   CD57	  marker,	   but	   were	   also	  more	   potent	   producers	   of	   IFN-­‐γ	   than	   their	   NKG2C-­‐	  
counterparts.	   Similarly,	   another	   study	   demonstrated	   that	   after	   hematopoietic	   cell	  
transplantation,	  NKG2C+	  NK	  cells	  from	  CMV-­‐positive	  donors	  expanded	  only	  in	  CMV+	  recipients,	  
whereas	  NKG2C+	  NK	  cells	  from	  CMV-­‐negative	  donors	  did	  not,	  consistent	  with	  the	  existence	  of	  a	  
secondary	   response	   against	   HCMV	   (Bjorkstom	   et	   al.	   2011).	   However	   expansions	   of	   NKG2C+	  
lymphocytes	   do	   not	   always	   correlate	   with	   HCMV	   infection	   since	   the	   frequencies	   of	  
CD94/NKG2C+	  peripheral	  blood	  NK	  and	  T	  cells	  are	  increased	  in	  patients	  during	  the	  acute	  phase	  
of	   Steven	   Johnson	   syndrome	   (SJS)	   and	   Toxic	   epidermal	   necrolysis	   (TEN)	   and	   these	   cells	   can	  
degranulate	  in	  response	  to	  HLA-­‐E+	  cells	  in	  an	  NKG2C-­‐dependent	  manner	  (Morel	  et	  al.	  2010).	  
In	  summary,	  all	  of	  these	  data	  suggest	  that	  the	  NKG2C	  receptor	  is	  actively	  participating	  in	  the	  
immune	   response	   against	   HCMV.	   However,	   further	   investigations	   are	   needed	   to	   fully	   define	  
how	  NKG2C	  participates	  in	  processes	  underlying	  the	  generation	  of	  NK	  memory.	  It	  is	  important	  
to	  note	  that	  although	  recently	  it	  has	  been	  suggested	  that	  human	  NK	  cells	  can	  exhibit	  a	  memory-­‐
like	   response,	   at	   present	   this	   has	   not	   been	   confirmed	   definitively.	   Moreover,	   it	   is	   still	   not	  
entirely	  clear	  whether	  the	  phenomenon	  of	  NK	  memory	  depends	  on	  antigen	  driven	  expansion	  of	  
NK	   cell	   subpopulations,	   or	   whether	   these	   cells	   are	   a	   variant	   of	   human	   cytokine-­‐induced	  
memory	  like	  NK	  cells	  (Cooper	  et	  al.	  2009;	  Lee	  et	  al.	  2012;	  Ni	  et	  al.	  2012;	  Romee	  et	  al.	  2012).	  
	  2.3.4 Non-­‐classical	  MHC	  class	  I	  restricted	  T	  cells	  
Under	   usual	   homeostatic	   conditions	   the	   peptide	   repertoire	   bound	   to	   HLA-­‐E	   is	   highly	  
restricted	  to	  self,	  MHC	  derived	  signal	  sequences.	  However,	  under	  cellular	  stress	  conditions	  such	  
as	   malignant	   cell	   transformation	   or	   intracellular	   infection	   with	   chronic	   pathogens,	   a	   new	  
peptide	   repertoire	   can	  be	   loaded	  onto	  HLA-­‐E	  molecules	  and	  presented	   to	  CD8+	  T	   cells	   (CTLs)	  
able	  to	  kill	  tumour	  cells	  or	   infected	  cells.	  Thus,	  while	  HLA-­‐E	  was	  first	  described	  as	  a	   ligand	  for	  
CD94/NKG2A	  (inhibitory)	  and	  CD94/NKG2C	  (activating)	  NK	  cell	  receptors,	  it	  is	  now	  clear	  that	  it	  
can	  also	  present	  peptides	  for	  αβ	  TCR-­‐mediated	  recognition	  (Li	  et	  al	  2001(1);	  Pietra	  et	  al.	  2001;	  Garcia	  et	  
al.	  2002;	  Heinzel	  et	  al.	  2002).	   Several	  observations	  have	  also	   raised	   the	  possibility	   that	  activation-­‐
induced	   expression	   of	   CD94/NKG2	   on	   a	   subset	   of	   CTLs	  may	   critically	   influence	   CTL	   function	  
(Mingari	  et	  al.	  1998(2)).	  Specifically,	  cross-­‐linking	  of	  KIRs	  or	  CD94/NKG2A	  receptors	  expressed	  on	  T	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1995)	  indicating	  that	  these	  inhibitory	  MHC-­‐recognizing	  receptors	  could	  contribute	  to	  the	  down-­‐
regulation	  of	  a	  CTL	  response.	  	  
A	   number	   of	   examples	   of	   HLA-­‐E	   dependent	   presentation	   of	   bacterial	   and	   viral	   peptide	  
antigens	  to	  human	  αβ	  TCR	  CD8+	  T	  cells	  have	  been	  documented.	  Several	  pathogens	  known	  to	  
encode	   HLA-­‐E	   binding	   peptides	   are:	  Mycobacterium	   tuberculosis	   (Mtb),	   Salmonella	   enterica,	  
Listeria	  monocytogenes,	  CMV,	  HIV,	  HBV,	  EBV	  and	  HCV	  (Rodgers	  et	  al.	  2005).	  
Mycobacterium	  tuberculosis	  (Mtb)	  represents	  a	  leading	  cause	  of	  infectious	  disease	  morbidity	  
and	   mortality	   worldwide.	   Both,	   CD4+	   and	   CD8+	   T	   lymphocytes	   appear	   to	   be	   important	   for	  
immune	  defence	  against	  mycobacterial	  infection.	  The	  importance	  of	  HLA-­‐E	  restricted	  T	  cells	  in	  
the	  host	  cell	  response	  to	  Mtb	  infection	  was	  first	  described	  in	  2002	  (Heinzel	  et	  al.	  2002).	  These	  data	  
represent	   the	   first	   demonstration	   of	   CTL	   recognition	   of	   a	   pathogen-­‐derived	   antigen	   being	  
presented	  in	  the	  context	  of	  HLA-­‐E.	  Presentation	  of	  the	  Mtb-­‐derived	  peptide	  was	  shown	  to	  be	  
TAP	   independent	   and	   to	   require	   proteasomal	   processing.	   Another	   finding	   shows	   that	  
mycobacteria	  reside	  in	  phagosomes	  of	  antigen	  presenting	  cells	  (APC),	  especially	  macrophages,	  
and	   that	   these	   phagosomes	   enriched	   in	   HLA-­‐E	   probably	   facilitates	   presentation	   of	  
mycobacterial	   peptides	   to	   human	   HLA-­‐E	   (Grotzke	   et	   al.	   2009).	   Recently,	   a	   number	   of	   HLA-­‐E	  
restricted	  peptide	  epitopes	   from	  Mtb	   recognized	  by	  CD8+	  T	   cells	  have	  been	   identified.	   In	   this	  
study	  in	  silico	  analyses	  of	  the	  Mtb	  genome	  predicted	  candidate	  HLA-­‐E	  epitopes	  for	  recognition	  
by	   human	   T	   cells	   (Joosten	   et	   al.	   2010).	   Subsequently,	   a	   combination	   of	   HLA-­‐E	   peptide	   binding	  
studies	  and	  assays	  of	   the	  proliferation	  of	  human	  CD8+	  T	  cells	   from	  PPD-­‐responsive	  adults	  and	  
BCG-­‐vaccinated	  infants	  established	  which	  of	  those	  peptides	  were	  true	  epitopes.	  The	  responding	  
CD8+	   T	   cells	   had	   cytotoxic	   activity,	   and	   lysed	   the	   target	   cells	   in	   a	   peptide	   specific	   and	  HLA-­‐E	  
dependent	   manner,	   strongly	   suggesting	   HLA-­‐E-­‐peptide	   engagement	   by	   the	   TCR.	   However,	  
these	  Mtb-­‐reactive	   T	   cell	   lines	   also	   exhibited	   strong	   immunosuppressive	   properties,	   as	   they	  
inhibited	  the	  proliferation	  of	  unrelated	  responder	  T	  cells,	  suggesting	  that	  this	  dual	  activity	  could	  
be	  mediated	  by	   the	   same	  HLA-­‐E-­‐peptide	   induced	  T	   cells.	   Further	   studies	  need	   to	  be	  done	   to	  
understand	   whether,	   HLA-­‐E	   mediated	   antigen	   presentation	   in	   tuberculosis	   preferentially	  
activates	  T	   cells	  with	   regulatory	  properties	  as	   compared	   to	  T	   cells	  with	   cytolytic	   activity.	   It	   is	  
interesting	  to	  note	  that	  CD8+	  T	  cells	  specific	  for	  Hsp60sp	  bound	  to	  HLA-­‐E	  play	  an	  important	  role	  
in	   maintaining	   peripheral	   self-­‐tolerance	   (Jiang	   et	   al.	   2010)	   and	   also	   that	   murine	   CD8+	   T	   cells	  
specific	   for	   the	   unconventional	   MHC	   class	   I	   molecule	   Qa-­‐1	   (the	   murine	   homolog	   of	   HLA-­‐E)	  
bound	   to	   peptides	   derived	   from	   the	   signal	   sequence	   of	   Hsp60	   have	   also	   been	   reported	   to	  
contribute	  to	  self/nonself	  discrimination	  (Sarantopoulos	  et	  al.	  2004;	  Leavenworth	  et	  al.	  2013).	  
In	  the	  context	  of	  the	  viral	  infections,	  one	  of	  the	  most	  common	  viruses	  infecting	  the	  human	  
population	   is	   HCMV,	   causing	   a	   life-­‐long	   persistent	   asymptomatic	   infection,	   which,	   however,	  
may	   cause	   severe	   morbidity	   in	   immunocompromised	   individuals.	   HCMV	   has	   evolved	   an	  
impressive	   variety	   of	   strategies	   to	   escape	   from	   recognition	  mediated	   by	   conventional	   (MHC	  
class	   Ia-­‐restricted)	   CTLs.	   Different	   CMV	   viral	   proteins	   are	   well	   known	   to	   inhibit	   MHC	   class	   I	  
expression	  by	  the	  infected	  cells.	   	  Viral	  proteins,	  like	  US2	  and	  US11	  bind	  to	  nascent	  HLA	  class	  I	  
chains	  to	  shuttle	  them	  from	  the	  ER	  to	  the	  cytosol,	  where	  they	  undergo	  proteasome-­‐dependent	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binds	   TAP	   and	   blocks	   TAP-­‐mediated	   transport	   of	   antigenic	   peptides	   to	   the	   ER.	   As	   a	  
consequence,	  surface	  expression	  of	  MHC	  class	  I	  molecules,	  presenting	  possible	  viral	  proteins	  is	  
down	  regulated,	   leading	  to	   inefficient	  antigen	  presentation	  to	  CTLs	  and	  viral	  escape	  from	  the	  
adaptive	   immune	   system.	   On	   the	   other	   hand,	   human	   CMV	   itself,	   through	   the	   expression	   of	  
gpUL40	   protein,	   can	   supply	   peptides	   that	   can	   bind	   and	   be	   presented	   by	   HLA-­‐E	   at	   the	   cell	  
surface	   in	   a	   TAP	   independent	   manner	   (Ulbrecht	   et	   al.	   2003;	   Hoare	   et	   a.	   2006).	   This	   augmented	  
surface	  expression	  of	  HLA-­‐E	  via	  interaction	  with	  the	  inhibitory	  CD94/NKG2A	  receptor	  will	  allow	  
escape	  from	  NK-­‐cell	  attack.	  Interestingly,	  Pietra	  and	  coworkers	  in	  2003,	  provided	  evidence	  that	  
some	  human	  CD8+	  TCRαβ+	  T	  cells	  can	  recognize	  HLA-­‐E	  when	  loaded	  with	  peptides	  derived	  from	  
HCMV.	  These	  HLA-­‐E	  restricted	  CD8+	  T	  cells	  could	  represent	  an	  additional	  type	  of	  effector	  cells	  
playing	   a	   role	   in	   defence	   against	   a	   virus,	   which	   has	   evolved	   to	   escape	   recognition	   by	   both	  
adaptive	   and	   innate	   immunity.	   Indeed,	   these	   HLA-­‐E	   restricted	   CD8+	   T	   cells	   are	   capable	   of	  
prompt	  production	  of	  IFN-­‐γ	  and	  can	  kill	  infected	  cells	  (Mazzarino	  et	  al.	  2005).	  The	  UL40	  protein	  of	  
HCMV,	  that	  supplies	  the	  viral	  peptides	  loaded	  onto	  HLA-­‐E,	  is	  variable	  and	  strikingly,	  the	  ability	  
of	   individuals	   to	  develop	  effective	  HLA-­‐E	  restricted	  CD8+	  T	  cell	  defence	  against	  CMV	   infection	  
depends	   on	   the	   genotypes	   of	   the	   infecting	   HCMV	   strain	   as	   well	   as	   the	   HLA-­‐A	   and	   HLA-­‐Cw	  
haplotype	  of	  the	  infected	  individual.	  
That	  HLA-­‐E	  can	  play	  an	  important	  role	  in	  regulating	  antiviral	  immunity	  has	  also	  been	  shown	  
for	   hepatitis	   C	   virus	   (HCV).	   Infection	  with	   this	   virus	   is	   associated	  with	   enhanced	   intrahepatic	  
HLA-­‐E	  expression	   (Nattermann	  et	  al.	  2005(2))	  where	  HCV	  gives	   rise	   to	  a	  peptide,	  corresponding	   to	  
amino	   acids	   35-­‐44	   of	   the	   core	   protein,	   that	   binds	   HLA-­‐E,	   to	   stabilise	   and	   promote	   surface	  
expression	  where	  it	  protects	  cells	  from	  NK	  cell	  mediated	  cytotoxicity.	  Apart	  from	  its	  interaction	  
with	   NK	   cell	   receptors,	   it	   has	   also	   been	   demonstrated	   that	   peptide	   loaded	   HLA-­‐E	  molecules	  
could	  also	  be	  recognized	  by	  CD8+	  T	  cells	  via	  their	  TCR	  (Schulte	  et	  al.	  2009).	  Schulte	  and	  coworkers	  
also	  provided	  the	  first	  evidence	  for	  the	  different	  functional	  role	  of	  the	  two	  allelic	  variants	  (HLA-­‐
ER	  and	  HLA-­‐EG)	  of	  HLA-­‐E	  in	  HCV	  infection.	  
HLA-­‐E	   expression	   by	   tumour	   cells	   has	   been	   recently	   reported	   in	   several	   types	   of	   human	  
cancers.	   For	   example,	   HLA-­‐E	   is	   overexpressed	   in	   fresh	   lymphoma	   (Marin	   et	   al.	   2003),	   ovarian	  
carcinomas	  (Malmberg	  et	  al.	  2002),	  gliomas	  (Wischhusen	  et	  al.	  2005),	  melanomas	  (Derre	  et	  al.	  2006)	  and	  
colon	  cancer	  (Bianchini	  et	  al.	  2006).	  Expression	  of	  HLA-­‐E	  at	  the	  cell	  surface,	  that	  can	  bind	  inhibitory	  
CD94/NKG2A	  receptor	  expressed	  by	  NK	  and	  T	  cells,	  would	  seem	  to	  favour	  tumour	  cells	  escape	  
from	   the	   immune	   system.	   To	   date,	   the	   potential	   role	   of	   HLA-­‐E	   as	   an	   antigen-­‐presenting	  
molecule	   for	   tumour	   specific	   CD8+	   T	   cells	   is	   poorly	   understood,	   but	   in	  murine	  models	   it	   has	  
been	   shown	   that	  Qa-­‐1b,	  a	  nonclassical	  major	  histocompatibility	   complex	  molecule	   that	  binds	  
MHC	   class	   I	   derived	   leader	   peptides	   and	   functions	   as	   a	   ligand	   for	   germ	   line	   receptors	  
CD94/NKG2,	   dominates	   the	   immune	   response	   to	   tumours	  with	  defects	   in	   antigen	  processing	  
(Oliveira	  et	  al.	  2010).	  The	  basis	  of	   this	  phenomenon	  seems	   to	  be	   that	  deficiencies	   in	   the	  normal	  
processing	  pathway	  leads	  to	  the	  replacement	  of	  the	  normally	  loaded	  HLA	  leader	  peptides	  by	  a	  
novel	   peptide	   repertoire	   that	   contains	   immunogenic	   neoantigens	   for	   CD8+	   T	   cells.	   Thus,	   in	  




	   45	  
Introduction	  
through	   CD94/NKG2A	   while	   presentation	   of	   a	   novel	   repertoire	   of	   immunogenic	   peptides,	  
stimulates	  cytotoxic	  CD8+	  T	  cells.	  
Interestingly,	  peptides	  derived	  from	  alternative	  splicing	  events	  of	  the	  peroxiredoxin5	  (Prdx5)	  
gene	  can	  be	  presented	  by	  HLA-­‐E	  (Sensi	  et	  al.	  2009).	   Increased	  levels	  of	  Prdx5	  can	  be	  detected	  in	  
several	  diseases,	  such	  as	  osteoarthritis	  and	  tendon	  degeneration	  as	  well	  as	   in	  melanoma	  cells	  
as	  a	  result	  of	  different	  forms	  of	  cellular	  stress.	  Although	  no	  evidence	  for	  immune	  recognition	  of	  
the	   Prdx5	   peptide-­‐HLA-­‐E	   complex	   was	   shown,	   perhaps	   the	   endogenous	   and	   environmental	  
stress	   conditions	   alter	   the	   normal	   cellular	   processes	   and	   lead	   to	   cellular	   damage	   that	   could	  
contribute	   to	   HLA-­‐E	   stabilization	   leading	   to	   CD8+	   mediated	   recognition	   and	   elimination	   of	  
tumour-­‐stressed	  cells.	  In	  contrast,	  recent	  analyses	  of	  ovarian	  and	  cervical	  cancer	  samples	  have	  
indicated	  that	  the	  HLA-­‐E	  molecule	   is	  frequently	  over	  expressed	  in	  these	  two	  tumour	  types.	   In	  
situ	   analyses	   of	   inhibitory	   CD94/NKG2A	   and	   activating	   CD94/NKG2C	   expression,	   revealed	   a	  
frequent	  expression	  of	  the	  inhibitory	  receptor	  on	  intraepithelial	  CD8+	  T	  cells,	  whereas	  NK	  cells,	  
the	  predominant	  cell	  type	  expressing	  these	  two	  receptors,	  were	  hardly	  found	  in	  both	  tumour	  
types.	   Importantly,	   the	   beneficial	   prognostic	   effect	   associated	   with	   the	   presence	   of	   high	  
numbers	   of	   infiltrating	   CTLs	   in	   ovarian	   cancer	   was	   completely	   neutralized	   by	   the	   strong	  
expression	   of	   HLA-­‐E,	   indicating	   that	   CTL	   infiltration	   in	   this	   type	   of	   cancer	   is	   associated	   with	  
better	  survival	  only	  when	  HLA-­‐E	  expression	  is	  low	  and	  that	  intratumoural	  CTLs	  are	  inhibited	  by	  
the	  CD94/NKG2A	  receptor	  expressed	  on	  their	  surface	  (Gooden	  et	  al.	  2011).	  
	  2.3.5 CD94/NKG2	  receptors	  modulate	  antigen-­‐specific	  T	  cell	  activity	  
CD94/NKG2	   receptors,	   as	  mentioned	  previously,	   are	  expressed	  by	   small	   subpopulations	  of	  
αβ	  and	  γδ	  T	  cells	  as	  well	  as	  by	  NK	  cells.	  About	  5	  %	  of	  peripheral	  human	  CD8+	  T	  cells	  express	  the	  
inhibitory	  CD94/NKG2A	  receptor	  and	   interestingly,	  CD94/NKG2+αβCD8+	  T	  cells	  are	  oligoclonal	  
populations	   characterized	   by	   an	   effector	  memory	   phenotype	   (McMahon	   et	   al.	   2001).	   Generally,	  
the	  NK	  receptors	  expressed	  by	  CTLs	  are	  characterized	  by	  their	  capacity	  to	  modulate,	  positively	  
or	  negatively,	  TCR	  signalling	  but	  T	  cell	  activation	  remains	  under	  the	  control	  of	  the	  TCR	  (the	  TCR	  
primacy	   rule)	   (Jabri	   et	   al.	   2006).	   However	   some	   important	   exceptions	   to	   this	   rule	   have	   been	  
described.	   For	   example	   during	   CMV	   infection,	   CTLs	   express	   surface	   NKG2C	   and	   similar	  
observations	  have	  been	  made	  in	  conditions	  of	  chronic	  T	  cell	  inflammation.	  While	  these	  T	  cells	  
could	   benefit	   the	   host	   in	   the	   case	   of	   infection,	   NKG2C+	   T	   cells	   have	   been	   suggested	   to	   be	  
detrimental	   in	   chronic	   inflammation	   and	   may	   contribute	   to	   severe	   immunopathology,	   as	  
suggested	  in	  celiac	  disease.	  
Transcripts	  for	  NKG2E	  and	  NKG2H	  have	  been	  also	  detected	  in	  primary	  human	  CTLs	  (Jabri	  et	  al.	  
2002),	  but	  their	  expression	  remains	  to	  be	  confirmed	  by	  specific	  antibodies.	  Both,	  CD94/NKG2A	  
and	   CD94/NKG2C	   recognize	   and	   bind	   HLA-­‐E	   molecule.	   Because	   CD94/NKG2C	   is	   poorly	  
expressed	  by	  CTLs,	   ligand	   induction	   should	  generally	   translate	   into	  an	   inhibitory	   signal	   in	   the	  
normal	   target	   cell	   conditions.	   In	   the	  case	  of	  disease	  conditions	   such	  as	  CMV	   (Guma	  et	  al.	  2004)	  
and	   severe	   celiac	   disease	   CTLs	   (Meresse	  et	   al.	   2006)	   can	   express	   CD94/NKG2C,	   but	   they	   do	   not	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TCR	   stimulation,	   in	   a	   combination	   with	   various	   cytokines	   including	   interleukin-­‐15	   (IL15),	  
transforming	  growth	   factor-­‐β	   (TGF-­‐β),	   IL-­‐2,	   IL-­‐12	  or	   IL-­‐10,	  has	  been	  shown	  to	  up-­‐regulate	   the	  
surface	  expression	  of	  NKG2A	  on	  T	  cells	   (Mingari	  et	  al.	  1998(1)(2);	  Bertone	  et	  al.	  1999;	  Derre	  et	  al.	  2002),	  
suggesting	  that	  NKG2A	  might	  be	  an	  activation	  induced	  event	  not	  dependent	  on	  TCR	  specificity.	  
However,	   although	   the	   microenvironment	   might	   alter	   CD94/NKG2A	   surface	   expression,	   TCR	  
interaction	   with	   cognate	   antigen	   seems	   to	   be	   a	   prerequisite	   for	   its	   induction	   in	   vivo.	  
Importantly,	   IL-­‐15,	   TGF-­‐β,	   and	   IL-­‐12	   could	   induce	   CD94	   but	   not	   NKG2A	   in	   the	   absence	   of	  
concomitant	  TCR	  stimulation,	  further	  suggesting	  control	  of	  TCR	  over	  NKG2A	  expression.	  NKG2A	  
may	   therefore	  participate	   in	   a	   negative	   feedback	   loop	   in	  which	   TCR	   stimulation	  up-­‐regulates	  
NKG2A	  and,	  in	  turn,	  NKG2A	  down-­‐modulates	  TCR	  activation.	  
There	  is	  strong	  evidence	  indicating	  that	  CD94/NKG2	  receptors	  on	  CTLs	  play	  essential	  roles	  in	  
the	   control	   of	   these	   cells	   during	   important	   disease	   processes.	   The	   presence	   of	   abundant	  
melanoma-­‐specific	   CTLs	   in	   patients	   with	   progressive	   tumour	   has	   been	   correlated	   with	  
expression	  of	  inhibitory	  NKG2A	  (Speiser	  et	  al.	  1999),	  expansion	  of	  CD94/NKG2C/DAP12	  expressing	  
CTLs,	   as	  mentioned	  before,	  occurs	   in	   some	  pathological	   situations	  and	  ultimately,	   the	   loss	  of	  
TCR	   control	   over	   proliferation	  might	   be	   involved	   in	   the	  malignant	   transformation	  of	   CTLs,	   as	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The	  main	  objectives	  of	  the	  work	  presented	  in	  this	  thesis	  were:	  
	  
1. Phenotypic	  and	  functional	  characterization	  of	  the	  orphan	  receptor	  CD94/NKG2H.	  
	  	  
1.1 Identify	  and	  characterize	  the	  cell	  types	  that	  express	  NKG2H	  protein.	  
	  
1.2 Determine	  the	  possible	  biological	  role	  of	  the	  NKG2H+	  cells	  in	  viral	  infections.	  
	  
1.3 To	  explore	  the	  function	  of	  NKG2H-­‐expressing	  cells	  after	  specific	  stimulation	  of	  the	  
receptor	  via	  monoclonal	  antibody	  
	  
2. Identification	   and	   analysis	   of	  Mycobacterium	   tuberculosis	   specific	   T	   cell	   clones,	   using	  
HLA-­‐E	  tetramers	  loaded	  with	  specific	  peptide	  epitopes	  from	  mycobacteria,	   in	  the	  blood	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PBMCs.	  	  
Peripheral	  blood	  mononuclear	  cells	  (PBMC)	  were	  isolated	  from	  healthy	  volunteers	  by	  Ficoll-­‐
Hypaque	   (GE	  Healthcare)	  density	  gradient	   centrifugation.	  The	  blood	  was	  collected	   in	  a	  50	  ml	  
falcon	  tube	  containing	  (1/1000)	  heparin	  (Sigma	  Aldrich),	  then	  diluted	  1:2	  with	  PBS,	  layered	  over	  
an	   equal	   volume	   of	   Ficoll	   and	   centrifuged	   for	   30	   min	   at	   1800	   rpm	   without	   brake.	   PBMCs,	  
accumulated	  at	  the	  interface	  between	  the	  plasma	  and	  the	  ficoll,	  were	  recovered,	  washed	  twice	  
with	  PBS,	  and	  resuspended	  in	  RPMI	  supplemented	  with	  10%	  human	  serum	  (HS)(Sigma	  Aldrich),	  
2	   mM	   L-­‐glutamine,	   10	   mM	   HEPES,	   100	   U/ml	   penicillin,	   100	   U/ml	   streptomycin,	   50	   µM	   β-­‐
mercaptoethanol	  and	  incubated	  in	  a	  humidified	  incubator	  at	  37oC	  and	  5%	  CO2.	  	  Cell	  lines,	  virus	  stocks	  and	  infections.	  
All	   cell	   lines	  were	   cultivated	  at	  37oC	  and	  5%	  CO2	  in	   a	  humidified	   incubator	  and	   split	  when	  
necessary.	   Human	   telomerase	   reverse	   transcriptase	   (hTERT)	   immortalized	   fibroblasts	   (HLA-­‐
type:	  HLA-­‐A*01,	  B*08/*41,	  C*07/*17,	  DRB1*03/*07.	  DRB3+,	  DRB4+)	  were	  cultured	  in	  complete	  
Dulbecco´s	   minimal	   essential	   medium	   (DMEM)	   supplemented	   with	   10%	   fetal	   bovine	   serum	  
(FBS),	  2	  mM	  L-­‐glutamine,	  10	  mM	  HEPES,	  100	  U/ml	  penicillin,	  100	  U/ml	  streptomycin	  and	  50	  µM	  
β-­‐mercaptoethanol.	  
Stocks	   of	   HCMV	   strains	   Merlin,	   AD169,	   Toledo,	   TB/40	   were	   prepared	   and	   titrated	   using	  
standard	  methods	   (William	   J.	   Britt.	   2010).	   In	   some	   experiments,	   preparations	   of	  Herpes	   simplex	  
virus	  type	  1	  (HSV-­‐1)	  or	  Vaccinia	  virus	  propagated	  and	  quantified	  as	  described	  previously	  (Earl	  et	  
al.	  2001;	  Blaho	  et	  al.	  2005).	  hTERT	   fibroblasts	  were	   infected	  with	  HCMV,	  HSV-­‐1,	  or	  Vaccinia	   in	  24	  
well	  plates	  at	  70%	  confluence	  in	  DMEM	  supplemented	  with	  2%	  fetal	  bovine	  serum.	  	  The	  mock	  
controls	  were	  not	  exposed	  to	  virus.	  After	  18-­‐20	  hours	  of	  infection,	  the	  virus	  containing	  media	  
was	  removed	  and	  cells	  were	  cultured	  in	  DMEM	  supplemented	  with	  2%	  fetal	  bovine	  serum	  up	  to	  
the	  point	  when	  used	  for	  the	  necessary	  experiment.	  Lymphocyte	  co-­‐cultures.	  
PBMCs	   were	   incubated	   in	   24	   well	   plates	   (1.5-­‐2.106/well)	   in	   complete	   RPMI	   medium,	  
supplemented	  with	  5%	   fetal	  bovine	  serum	  and	  5%	  human	  serum	   in	   the	  presence	  of	  mock	  or	  
HCMV	   infected	   fibroblasts.	   Recombinant	   human	   IL-­‐2	   (50	  U/ml)	   (Peprotech)	  was	   added	   to	   all	  
cultures	  at	  day	  3.	  Cells	  were	  then	  incubated	  for	  3,	  7	  or	  10	  days.	  Some	  experiments	  were	  done	  in	  
a	  Transwell	  (0.4μm)	  permeable	  support	  where	  PBMCs	  were	  incubated	  separately	  in	  the	  upper	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Flow	  cytometry.	  
For	  immunofluorescence	  staining	  of	  PBMCs,	  cells	  were	  washed	  with	  PBS	  containing	  1%	  FBS,	  
0.5%	  BSA,	  and	  0.05%	  sodium	  azide	  (S-­‐PBS),	  pretreated	  with	  1%	  normal	  human	  serum	  to	  block	  
FcR,	  and	  subsequently	  stained	  with	  the	  fluorescently	  labeled	  and/or	  unlabeled	  mAb	  specified	  in	  
each	  experiment,	  using	  the	  concentrations	  recommended	  by	  the	  manufacturer.	  After	  staining,	  
the	   labelled	   cells	   were	   analysed	   by	   flow	   cytometry	   [Gallios	   (Beckman	   Coulter)	   or	   Cytomics	  
FC500	   (Beckman	  Coulter)].	  All	   the	   staining	  was	  performed	   for	  20	  min	  on	   ice	  and	   in	   the	  dark,	  
maintaining	  the	  cells	  at	  4oC	  until	  analysis.	  	  
For	  tetramer	  staining,	  100	  µl	  of	  heparinized	  blood	  were	  transferred	  to	  cytometry	  tubes.	  For	  
all	  tetramers,	  a	  concentration	  of	  0.5	  µg	  per	  100	  µl	  of	  blood	  was	  used.	  The	  tetramer	  conjugated	  
with	  streptavidin-­‐PE	  was	  added	  and	  the	  sample	  was	  incubated	  for	  20	  min	  at	  room	  temperature	  
before	  adding	  the	  mixture	  of	  mAbs.	  1ml	  of	  lysing	  solution	  (VersaLyse,	  Beckman	  Coulter)	  in	  2%	  
paraformaldehyde	  (PFA)	  was	  added	   into	  the	  tubes	  and	  samples	  were	  vortexed,	   incubated	  for	  
30	  min	  at	  room	  temperature	  and	   left	  at	  4oC	  for	  overnight	   (o/n).	  Samples	  were	  analysed	  on	  a	  
Gallios	   (Beckman	   Coulter)	   flow	   cytometer	   and	   the	   acquisition	  was	   performed,	   gating	   on	   the	  
lymphocyte	  population.	  
Flow	   cytometry	   data	   were	   analysed	   using	   either	   Kaluza	   v1.2	   or	   FlowJo	   V9.6.2	   cytometry	  
analysis	  programs.	  	  














Molecule	   Clone	   Supplier	  
	   	   	  
CD3	   CRL-­‐8001	   ATCC	  	  
CD3-­‐FITC	   UCHT1	   BioLegend	  
CD3-­‐PacificBlue	   OKT3	   BioLegend	  
CD4-­‐APC	   OKT4	   BioLegend	  
CD8-­‐PeCy7	   RPA-­‐T8	   BioLegend	  
CD28	   CD28.2	   BD	  Biosciences	  
CD56-­‐PE	   MEM-­‐188	   BioLegend	  
CD56-­‐PerCP/Cy5.5	   N901	   BeckmanCoulter	  
CD56-­‐APC	   CMSSB	   eBioscience	  
CD69-­‐APC/Cy7	   FN50	   BioLegend	  
CD161-­‐Violet	  421	   HP-­‐3G10	   BioLegend	  
CD107a-­‐APC	   H4A3	   BioLegend	  
Mouse	  IgG1	   MOPC-­‐21	   Sigma	  
NKG2A-­‐PE	   Z199	   BeckmanCoulter	  
NKG2C-­‐PE	   134591	   R&D	  systems	  
NKG2H	   633810	   R&D	  systems	  
Annexin-­‐V-­‐FITC	   731725	   Beckman	  
7AAD	   /	   Beckman	  Coulter	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RNA	  isolation,	  cDNA	  synthesis	  and	  Quantitative	  RT-­‐PCR.	  
Total	  cellular	  RNA	  was	  extracted	  from	  PBMC	  cultured	  with	  mock	  or	  HCMV	  Merlin	   infected	  
fibroblasts	  at	  day	  0,	  day	  3	  and	  day	  7	  using	  RNA	  extraction	  kit	  (Qiagen).	  Reverse	  transcription	  to	  
generate	   first	   strand	   cDNA	   was	   performed	   by	   standard	   protocols	   using	   random	   hexamers	  
(Roche)	   and	   SuperScript	   II	   Reverse	   Transcriptase	   (Invitrogen)	   in	   the	   presence	   of	   RNase	  
inhibitors	  (Promega).	  
cDNA	  was	  used	  as	  a	  template	  to	  quantify	  nkg2h	  gene	  expression	  using	  the	  following	  primers	  
5´-­‐TGTGCAATGCTACATGTACGTG	   and	   5´-­‐TGATGCACTGCAAGCTCAAGC.	   qPCR	   reactions	   were	  
carried	  using	  Hot	  FIRE	  Pol	  EvaGreen	  qPCR	  Mix	  Plus	  (ROX),	  (Solis	  BioDyne),	  in	  a	  final	  volume	  of	  
8µl.	   Reactions	   were	   run	   with	   Applied	   Biosystems	   7900HT.	   Amplification	   was	   performed	   as	  
follows:	  50oC	  for	  10´,	  95oC	  for	  2´,	  40	  cycles	  at	  95oC	  for	  15´´and	  60oC	  for	  1´.	  	  
Each	  experiment	  was	  performed	  in	  triplicates	  and	  repeated	  3	  times.	  The	  relative	  expression	  
was	  calculated	  using	  the	  2–(ΔΔCt)	  method	  using	  β	  actin	  for	  normalisation.	  Degranulation	  assay.	  
Lysosome-­‐Associated	   Membrane	   Protein	   1	   (LAMP-­‐1,	   CD107a)	   is	   a	   protein	   present	   in	   the	  
membrane	  of	  the	  multi-­‐vesicular	  bodies	  that	  store	  lytic	  granules	  inside	  cytotoxic	  lymphocytes.	  
Subsequent	  to	  cell	  activation,	  cytotoxic	  granules	  are	  released	  and	  LAMP-­‐1	  is	  transferred	  to	  the	  
cell	   surface	   during	   the	   fusion	   of	   these	   lytic	   granules	   with	   the	   cell	   plasma	  membrane.	   Thus,	  
degranulation	  can	  be	  measured	  by	  quantification	  of	  increases	  in	  surface	  LAMP-­‐1	  expression.	  	  
After	  a	  7	  day	  culture	  period	  of	  PBMCs	  with	  mock	  or	  HCMV	  infected	  fibroblasts,	  Monensin	  at	  
2	  µM	  final	  concentration	  together	  with	  APC-­‐labelled	  mAb	  against	  CD107a	  (Lamp1)	  at	  3	  µg/well	  
was	  added	  to	  the	  media	   in	  all	  wells	  and	  incubated	  for	  an	  additional	  5.30	  h	  at	  37oC	   in	  5%	  CO2	  
supplemented	  incubator.	  Monensin	  prevents	  the	  acidification	  of	  endocytic	  vesicles	  avoiding	  the	  
degradation	  of	  re-­‐internalized	  LAMP-­‐1	  proteins	  from	  the	  surface	  and	  allowing	  the	  visualization	  
of	  this	  marker	  following	  stimulation.	  After	  the	  incubation	  period,	  cells	  were	  surface	  stained	  as	  
described	  previously	  for	  the	  CD3-­‐FITC	  and	  CD56-­‐PE	  markers.	  The	  percentage	  of	  single	  Lamp-­‐1	  
positive	   or	   CD56/Lamp-­‐1	   and	   CD3/Lamp-­‐1	   double	   positive	   cells	   was	   determined	   by	   flow	  
cytometry.	  Stimulation	  of	  PBMC	  using	  immobilized	  antibody	  
To	   immobilize	   stimulating	   antibody,	   24	   well	   plates	   were	   pre-­‐coated	   with	   purified	   human	  
anti-­‐CD3,	  anti-­‐CD3/CD28	  or	  anti-­‐CD3/NKG2H	  mAbs	   in	  PBS	  and	   incubated	   for	  2-­‐3	  hours	  at	  RT.	  
The	   mAb	   concentration	   is	   specified	   in	   each	   experiment.	   Unbound	   mAb	   was	   removed	   by	  
washing	  the	  plate	  once	  with	  PBS.	  PBMCs,	  at	  1.5-­‐2.106	  cells/well	  were	  added	  to	  the	  mAb	  coated	  
plates	   in	  RPMI	  containing	  10%	  HS	  and	   incubated	   for	  48	  or	  72	  hours	  at	  37oC	  and	  5%	  CO2	  in	  a	  
humidified	  incubator.	  After	  this	  period	  of	  incubation,	  cells	  were	  collected,	  washed	  with	  S-­‐PBS,	  
stained	  with	  CD3-­‐Pacific	  Blue	  and	  CD69-­‐APC/Cy7	  mAbs	  and	  analysed	  by	  flow	  cytometry.	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Proliferation	  assay.	  
CFSE	  (5-­‐(and	  6)-­‐Carboxyfluorescein	  succcinimidyl	  ester)	  (Invitrogen)	   is	  a	  cell-­‐permeable	  dye	  
widely	   used	   to	   stain	   cells	   and	  monitor	   cell	   proliferation,	   both	   in	   vivo	   and	   in	   vitro.	   CFSE	   is	   a	  
colourless	  and	  non-­‐fluorescent	  dye	  that	  can	  easily	  cross	  the	  intact	  cell	  membrane.	  Once	  inside	  
the	   cell,	   intracellular	   esterases	   cleave	   the	   acetate	   groups	   to	   yield	   the	   fluorescent	  
carboxyfluorescein	  molecule	  which	   forms	   stable	   conjugates	  with	  membrane	   and	   intracellular	  
proteins	  (Lyons	  et	  al.	  1999).	  After	  each	  round	  of	  cell	  division	  the	  CFSE	  fluorescence	  intensity	  within	  
daughter	  cells	  is	  halved,	  thus	  the	  number	  of	  rounds	  of	  cell	  division	  undergone	  by	  a	  cell	  can	  be	  
followed	  by	  measuring	  the	  progressive	  halving	  of	  CFSE	  intensity.	  
PBMCs	  were	  resuspended	  in	  RPMI	  and	  incubated	  for	  5-­‐7	  min	  at	  37oC	  in	  the	  incubator	  with	  
the	   intracellular	   fluorescent	   dye	   CFSE	   at	   a	   final	   concentration	   of	   2.5	  µM.	   After	   two	  washes,	  
CFSE	  labelled	  PBMCs	  were	  cultured	  in	  24-­‐well	  plates	  to	  which	  mAb	  had	  been	  pre-­‐absorbed	  as	  
described.	   CFSE	   labelled	   cells	   were	   further	   stained	   for	   surface	   markers	   and	   flow	   cytometry	  
analyses	  were	  performed	  on	  days	  2,	  3	  and	  4	  after	  stimulation.	  Cell	  viability	  assay.	  
Loss	   of	   plasma	   membrane	   integrity	   is	   one	   of	   the	   earliest	   features	   changes	   detected	   in	  
apoptotic	  cells,	  resulting	  in	  the	  translocation	  of	  the	  phospholipid	  phosphatidylserine	  (PS)	  from	  
the	  inner	  to	  the	  outer	  leaflet	  of	  the	  membrane.	  Annexin-­‐V	  has	  a	  high	  affinity	  for	  PS,	  so	  it	  binds	  
to	  cells	  with	  exposed	  PS,	  marking	  cells	  undergoing	  early	  apoptotic	  changes.	   	  At	   late	  stages	  of	  
apoptosis	  or	  when	  necrosis	  occurs,	  the	  integrity	  of	  the	  plasma	  membrane	  is	  damaged.	  7AAD	  is	  
a	   dye	   that	   does	   not	   pass	   through	   an	   intact	  membrane,	   but	   can	   get	   into	   dead	   and	   damaged	  
cells.	  Thus	  7AAD	  stains	  cells	  that	  are	  in	  late	  apoptosis	  or	  necrotic.	  
Anti-­‐CD3,	   anti-­‐CD3/CD28	   or	   anti-­‐CD3/NKG2H	   stimulated	   PBMCs	   were	   collected,	   washed	  
with	   S-­‐PBS	   and	   surface	   stained	  with	   CD3-­‐Pacific	   Blue	   and	   CD69-­‐APC/Cy7	   specific	   antibodies.	  
Cells	   were	   washed	   with	   PBS	   and	   stained	   with	   Annexin-­‐V	   FITC	   and	   7AAD	   in	   annexin	   binding	  
buffer	  (Invitrogen)	  following	  the	  instruction	  of	  the	  manufacture.	  	  Antibody	  blocking	  assay	  
Purified	  PBMCs	  were	  cultured	  with	  immobilized	  anti-­‐CD3	  or	  anti-­‐CD3/NKG2H	  antibody	  pre-­‐
coated	  plates	  as	  described	  above.	  10	  µg/ml	  of	  soluble,	  purified	  anti	  MHC	  class	  I	  antibody	  (HP-­‐
1F7,	  Perez-­‐Villar	  et	  al.	  1997)	  was	  added	  in	  RPMI	  containing	  10%	  HS	  and	  incubated	  for	  48	  hours	  at	  
37oC	  and	  5%	  CO2	  in	  a	  humidified	  incubator.	  
For	   supernatant	   transfer	   experiments	   paired	   set	   of	   ¨donor¨	   and	   ¨recipient¨	   cell	   cultures	  
were	  used.	  	  PBMCs	  from	  healthy	  donors	  were	  cultured	  in	  wells	  of	  plates	  pre-­‐coated	  either	  with	  
anti-­‐CD3	   or	   anti-­‐CD3/NKG2H	   antibodies	   as	   described.	   After	   48	   hours	   of	   stimulation	   the	  
supernatant	  from	  these	  cultures	  was	  collected	  and	  frozen	  at	  -­‐20oC.	  Later,	  the	  recipient	  cultures	  
were	   prepared;	   PBMCs	   from	   healthy	   donor	   were	   purified	   and	   cultured	   in	   anti-­‐CD3	   or	   anti-­‐
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CD3/NKG2H	  antibody	  coated	  plates.	   	  Stored	  supernatant	  from	  the	  donor	  cultures	  was	  diluted	  
1:2	  or	  1:5	  in	  complete	  RPMI	  medium	  supplemented	  with	  10%	  human	  serum	  and	  then	  added	  to	  
the	  corresponding	  recipient	  culture.	  PBMCs	  stimulated	  with	   immobilized	  anti-­‐CD3	  antibody	   in	  
complete	   RPMI	   supplemented	   with	   10%	   human	   serum	   were	   used	   as	   a	   control.	   Recipient	  
cultures	  were	  maintained	  in	  a	  humidified	  incubator	  at	  37oC	  and	  5%	  CO2	  for	  48h	  until	  they	  were	  
harvested	  and	  stained	  for	  the	  surface	  CD69	  activation	  marker.	  The	  percentage	  of	  positive	  cells	  
was	  analysed	  by	  flow	  cytometry.	  Preparation	   of	   constructs	   for	   the	   expression	   of	   soluble	   CD94,	   NKG2H	   and	  HLA-­‐E	  proteins.	  
PCR	  reactions	  were	  performed	  using	  standard	  protocols	   in	  a	  final	  reaction	  volume	  of	  50	  µl	  
under	  similar	  reaction	  conditions	  employing	  Pwo	  (Roche)	  or	  Taq	  (Biotools/Roche)	  polymerase.	  
4%	  DMSO	  was	  used	  for	  some	  reactions	  to	  increase	  the	  PCR	  efficiency.	  For	  some	  amplification	  
Mg2+	  titration	  was	  also	  carried	  out,	  over	  a	  range	  of	  0.5	  mM	  to	  2.5	  mM	  in	  steps	  of	  0.5	  mM.	  
The	   amplification	   conditions	   used	   for	   the	   different	   sets	   of	   primers	   were:	   an	   initial	  
denaturation	   step	  of	   4´30´´	   at	   95oC	   followed	  by	  25/35	   cycles	  of	   denaturation	   (95oC	   for	   30´´),	  
primer	   annealing	   (55-­‐58oC	   for	   30´´),	   and	   extension	   (68oC	   or	   72oC	   for	   2´),	   followed	   by	   a	   final	  
incubation	   at	   either	   68oC	   (Pwo)	   or	   72oC	   (Taq)	   for	   7´	   to	   allow	   for	   complete	   extension.	   PCR	  
products	   were	   electrophoresed	   on	   1-­‐2%	   agarose	   and	   stained	   with	   ethidium	   bromide	   for	  
visualization.	  
	  
The	  primers	  used	  in	  all	  amplification	  reactions	  were:	  
Product	   Forward	  primer	   Reverse	  primer	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Patients	  and	  healthy	  donors.	  
A	   total	  of	  9	  patients	   (7	  males	  and	  2	   females),	  mean	  age	  73	  years	   (61-­‐85	  years),	  diagnosed	  
with	  non-­‐muscle	  invasive	  bladder	  cancer	  (NMIBC)	  were	  available	  for	  a	  pilot	  study.	  All	  patients	  
analysed	  here	  received	  intravesical	  instillations	  of	  BCG,	  starting	  with	  a	  weekly	  instillation	  for	  six	  
weeks	  followed	  by	  a	  rest	  period	  of	  two	  months	  and	  two	  weekly	  instillations	  during	  three	  years	  
(Table	  1	  and	  Scheme	  1).	  Blood	  was	  obtained	  from	  patients	  before	  each	  BCG	  instillation.	  
Informed	   consent	  was	   obtained	   from	  all	   the	   patients	   and	   the	   study	  was	   approved	   by	   the	  
local	  and	  regional	  ethical	  committees	  (CEIC	  Hospital	  Infanta	  Sofía,	  CEIC	  Hospital	  La	  Paz	  and	  CEI	  
CSIC)	  	  
Blood	  samples	  from	  a	  total	  of	  19	  healthy	  volunteers,	  11	  female	  and	  8	  male,	  with	  median	  age	  
of	   36	   years,	   were	   also	   obtained	   during	   the	   study.	   All	   subjects	   had	   no	   known	   chronic/acute	  
infections	  or	   inflammatory	  diseases	   for	  at	   least	  1	  month	  preceding	  the	  blood	  sampling.	  All	  of	  
the	   anonymous	   volunteers	   agreed	   and	   gave	  written	   consent	   to	   the	   study.	   Samples	   of	   30	  ml	  
venous	  heparinized	  blood	  were	  obtained	  from	  all	  subjects.	  
	  
Table	  1.	  Patient	  characteristics	  with	  tumour	  stage	  and	  grade.	  
	  
No	   Gender	   Age	   Tumour	  characteristics*	   Type	  of	  instillation**	  
	   	   	   	   	  
1	   M	   70	   T1G3	   BCG	  81	  
2	   M	   70	   TaG3	   OncoTICE	  
3	   M	   61	   T1G3	   BCG	  81	  
4	   M	   81	   TaG3+Cis	  multiple	   OncoTICE	  
5	   F	   85	   T1G3	   OncoTICE	  
6	   M	   73	   Ca	  in	  situ	   BCG	  81	  
7	   M	   81	   Cis	   BCG	  81	  
8	   F	   81	   T1G3	   BCG	  81	  







Scheme	  1:	  BCG	  treatment	  schedule	  in	  bladder	  cancer	  patients.	  Sample	  collection	  was	  done	  at	  first,	  third	  and	  last	  instillation	  of	  the	  first	  cycle	  and	  before	  the	  first	  and	  second	  instillation	  in	  every	  following	  cycle.	  
*	  	  Ta/T1	  indicate	  papillary	  tumors.	  Cis:	  carcinoma	  in	  situ	  
**	  BCG:	  Bacillus	  Calmette-­‐Guerin;	  BCG	  81/OncoTICE:	  BCG	  strains	  
1stcycle	   3rdcycle	  
Weeks	  





	  1	   2	   3	   6	  4	   5	   1	   2	   3	   2	  1	   3	  
B1.1	   B1.3	   B1.6	   B2.1	   B2.2	   B3.1	   B3.2	  
2ndcycle	  
…	  for	  three	  years	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HLA-­‐E	  tetramer	  production.	  
HLA-­‐E	   constructs	   for	   expression	   of	   soluble	  molecules	  were	   prepared,	   as	   described	   above,	  
using	  as	  template	  a	  plasmid	  encoding	  the	  extracellular	  domains	  of	  HLA-­‐E	  (Vales-­‐Gomez	  et	  al.	  1999).	  
A	   sequence	   recognized	   by	   the	   biotinylation	   enzyme	   BirA	   (AviTag)	   was	   introduced	   at	   the	   C-­‐
terminus	  by	  PCR.	  The	  construct	  also	  introduced	  modifications	  at	  the	  N-­‐terminus	  to	  reduce	  the	  
GC	  content	  and	  increase	  HLA-­‐E	  expression	  yield	   in	  BL21	  DE3	  bacteria.	  This	  construct	  of	  HLA-­‐E	  
(891bp)	  was	  sub-­‐cloned	  into	  pGMT7	  vector	  (Reid	  et	  al.	  1996;	  Cull	  and	  Schatz,	  2000).	  
HLA-­‐E	  tetrameric	  complexes	  were	  generated	  as	  described	  (Garboczi	  et	  al.	  1992;	  Altman	  et	  al.	  1996;	  
Fan	  et	  al.	  1996;	  O´Callaghan	  et	  al	  1998(2);	  Vales-­‐Gomez	  et	  al.	  1999).	  HLA-­‐E	  and	  β2m	  proteins	  (Garbocziet	  al.	  
1992)	  were	   overexpressed	   in	   large	   scale	   cultures	   of	   E.	   coli,	   strains	   BL21	   (DE3)	   pLysS,	   and	   the	  
protein	   accumulated	   in	   inclusion	   bodies.	   	   Briefly,	   the	   transformed	   BL21	   DE3	   bacteria	   were	  
grown	  in	  LB	  medium	  at	  37oC	  until	   the	  cultures	  reached	  an	  OD	  of	  0.6	  absorbance	  units	  at	  600	  
nm.	   At	   this	   point,	   isopropyl	   β-­‐D-­‐thiogalactoside	   (IPTG)	   was	   added	   to	   a	   0.4	   mM	   final	  
concentration	  and	  the	  cultures	  were	  incubated	  for	  additional	  4h	  at	  37oC.	  	  
The	   inclusion	   bodies	   were	   extracted	   by	   various	   rounds	   of	   DNAse	   treatment	   followed	   by	  
detergent	   washes.	   Specifically:	   bacteria	   were	   centrifuged	   at	   4000rpm	   for	   15	   min	   at	   4oC,	  
resuspended	  in	  TES	  (10	  mM	  Tris	  pH	  8,	  1	  mM	  EDTA,	  100	  mM	  NaCl)	  buffer	  and	  centrifuged	  again	  
at	   4000rpm	   for	   15	   min	   at	   4oC.	   The	   pellet	   was	   resuspended	   in	   10	   ml	   sucrose	   solution	   (25%	  
sucrose,	  50	  mM	  Tris	  pH	  8,	  1	  Mm	  EDTA,	  0.1%	  azide)	  supplemented	  with	  protease	  inhibitors	  (1	  
mM	  Leupeptin,	  1	  mM	  Pepstatin	  A)	  and	  homogenized	  very	  well.	  Lysozyme	  (20	  mg/L	  of	  culture,	  
Sigma	  Aldrich),	  was	  added	  to	  the	  sucrose/bacterial	  lysate	  mixture,	  to	  degrade	  the	  bacterial	  cell	  
wall,	  and	  this	  mix	  was	  incubated	  on	  ice	  until	  viscous	  (approximately	  30	  min).	  After	  this	  step,	  4	  
M	  MgCl2,	  DNase	  and	  RNase	  (8	  mM),	  EDTA	  (1	  mM)	  was	  added	  followed	  by	  homogenization	  and	  
incubation	   at	   room	   temperature	   until	   the	   DNA	   had	   been	   digested,	   as	   judged	   by	   decreased	  
viscosity.	   The	   mixture	   was	   centrifuged	   at	   14000	   rpm	   for	   40	   min	   at	   4oC	   and	   the	   pellet	   was	  
resuspended	   in	   a	   Triton	   X-­‐100/DOC	   solution	   [0.5%	   Triton	   X-­‐100	   (Sigma	   Aldrich),	   0.5%	   DOC	  
(Deoxycholate),	  50	  mM	  Tris	  pH8,	  100	  mM	  NaCl,	  0.1%	  Azide)	  and	  1	  mM	  DTT]	  and	  centrifuged	  at	  
4000	   rpm	   for	   40	   min	   at	   4oC.	   The	   detergent	   washes	   were	   repeated,	   with	   further	   rounds	   of	  
DNase/RNase	   treatment	   until	   the	   inclusion	   bodies	   were	   devoid	   of	   debris.	   Finally,	   after	  
centrifugation,	  the	  pellet	  was	  washed	  by	  resuspension	  in	  Tris	  buffer	  (50	  mM	  Tris	  pH	  8,	  100	  mM	  
NaCl,	  0.1%	  azide)	  and	  1	  mM	  DTT,	  and	  centrifugation,	  for	  40	  min	  at	  4oC,	  to	  remove	  detergent.	  	  
Aggregated	  protein	  purified	  from	  the	  inclusion	  bodies	  was	  solubilized	  in	  8	  M	  urea/100	  mM	  Tris	  
pH	  8/1	  mM	  DTT	  and	  spunin	  an	  ultracentrifuge	  at	  40	  000	  rpm	  for	  20	  min.	  The	  supernatant	  was	  
collected	   and	   the	   concentration	   of	   the	   protein	   was	   quantified	   using	   Bradford	   assay	  
(ThermoScientific).	  The	  purity	  of	  the	  inclusion	  body	  preparation	  was	  assessed	  by	  SDS-­‐PAGE	  and	  
staining	  with	  Coomassie	  Brilliant	  Blue	  G-­‐250.	  
Class	  I	  MHC/peptide	  complexes	  were	  refolded	  by	  dilution	  in	  vitro	  with	  a	  synthetic	  peptide	  as	  
previously	  described	  (Vales-­‐Gomez	  et	  al.	  1999).	  Refolded	  proteins	  were	  concentrated	  using	  a	  Kvick	  
Start	  cassette	  and	  purified	  by	  size	  exclusion	  chromatography	  using	  a	  Sephacryl	  S-­‐300	  column.	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Folded	  MHC	  proteins	  eluted	  within	   the	  peak	  obtained	  at	  about	  90	  ml	  after	   sample	   injection.	  
FPLC	   fractions	   containing	   folded	  peptide/MHC	   complexes	  were	  pooled,	   concentrated	  using	   a	  
Vivaspin	   concentrator	   with	   20kDa	   molecular	   weight	   cut-­‐off	   (Mwco)	   and	   exchanged	   into	  
biotinylation	   buffer	   (10	   mM	   Tris-­‐HCl,	   pH	   8)	   by	   three	   cycles	   of	   dilution	   and	   concentration.	  
Refolded	  HLA-­‐E	  heavy	  chain,	  β2m	  and	  synthetic	  peptide	  complexes	  were	  biotinylated	  using	  d-­‐
biotin	  and	  BirA	  enzyme	  (Source	  BioScience;	  GeneCopoeia),	  exchanged	  into	  20	  mM	  Tris	  (pH	  8.0)	  
and	   further	   purified	   by	   ion-­‐exchange	   chromatography	   (O´Callaghan	   et	   al.1998)	   using	   a	   HiTrap	  Q	  
Sepharose	   FF	   column.	   Correctly	   biotinylated	   fractions,	   identified	   by	   SDS-­‐PAGE	   followed	   by	  
western	   blotting	   with	   Avidin-­‐HRP,	   were	   pooled	   together	   and	   exchanged	   into	   PBS	   buffer	   by	  
membrane	  ultrafiltration	  (mwco:	  30k)	  concentrating	  the	  proteins	  to	  a	  volume	  below	  1	  ml.	  For	  
each	   peptide/MHC	   complex,	   the	   concentration	  was	  measured	   and	   aliquots	  were	   stored	   at	   -­‐
80oC	  until	  use.	  Biotinylated	  monomers	  were	  assembled	  into	  tetramers	  using	  standard	  protocols	  
(http://tetramer.yerkes.emory.edu/support/protocols).	   Briefly,	   small	   aliquots	   of	   Extravidin-­‐
phycoerythrin	   (Sigma	   Aldrich)	   were	   added	   successively	   to	   the	   biotinylated	   peptide/MHC	  
complex	   to	   ensure	   saturation	   of	   avidin-­‐binding	   sites.	   The	   HLA-­‐E	   tetramer/phycoerythrin	  
complex	  was	  then	  used	  directly	  for	  flow-­‐cytometry	  staining	  of	  whole	  human	  blood.	  
HLA-­‐E	  and	  β2m	  proteins	  were	   refolded	  with	   the	   following	   synthetic	  peptides:	  VMAPRTVLL	  
(canonical	   HLA-­‐B*0702	   leader-­‐derived	   peptide);	   the	   Mycobacterium	   tuberculosis	   derived	  
peptides,	   p68	   (VLRPGGHFL)	   p62	   (RMPPLGHEL)	   and	  p55	   (VMATRRNVL).	   The	  purified	   synthetic	  
peptides	  were	  synthesized	  by	  the	  peptide	  synthesis	  service	  of	  the	  CNB	  proteomics	  facility.	  SDS-­‐PAGE	  analyses.	  
SDS-­‐polyacrylamide	   gel	   electrophoresis	   (PAGE)	   (Electrophoresis	   running	   buffer:	   195	   mM	  
Glycine,	   24.8	   mM	   Tris	   base,	   0.1%	   SDS)	   analyses	   were	   done	   in	   reducing	   or	   non-­‐reducing	  
conditions.	   When	   the	   samples	   were	   analysed	   under	   reducing	   conditions,	   a	   2%	   SDS	   loading	  
buffer	  (125	  mM	  Tris	  pH	  6.8,	  4%	  SDS,	  20%	  glycerol	  and	  bromphenol	  blue)	  containing	  1	  mM	  DTT	  
was	   added	   to	   the	   samples	   and	   heated	   at	   100oC	   for	   3	  min.	   For	   analysis	   under	   non-­‐reducing	  
conditions	   a	   2%	   SDS	   loading	   buffer	   with	   no	   DTT	   was	   used.	   Proteins	   were	   visualized	   by	  
Coomassie	  Brilliant	  Blue	  stain	  (0.125%	  Coomassie	  blue	  R-­‐250,	  50%	  Methanol,	  10%	  Acetic	  acid)	  
by	  shake	  for	  30´-­‐1h.	  
For	  protein	  transfer	  onto	  PVDF	  (polyvinylidene	  fluoride)	  membrane	  (Immobilon-­‐P.Millipore)	  
transfer	  buffer	  (25	  mM	  Tris-­‐base,	  192	  mM	  Glycine,	  20%	  methanol)	  was	  used.	  Membranes	  were	  
blocked	  with	  5%	  milk	  in	  T-­‐TBS	  (10	  mM	  Trisbase,	  pH	  7.6,	  100	  mM	  NaCl,	  Tween20	  0.05%)	  for	  o/n.	  
Next	   day,	   membranes	   were	   washed	   three	   times	   with	   T-­‐TBS	   and	   probed	   with	   horseradish	  
peroxidase	   (HRP)-­‐conjugated	   Streptavidin	   (GE	  Healthcare)	   in	   T-­‐TBS	   for	   1h	   at	   R.T.	   Finally,	   the	  
membranes	  were	  washed	  and	  visualized	  using	   the	  Amersham	  ECL	  western	  blotting	  detection	  
kit	  (GE	  Healthcare)	  and	  X-­‐ray	  films	  (Konica	  Minolta).	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Statistical	  analysis.	  
Data	   are	   represented	   as	   the	   mean	   values,	   and	   error	   bars	   show	   Standard	   deviations.	  
Statistical	   analysis	  was	  done	  using	  GraphPad	   software	   (Prism).	  Multiple	  data	  were	   compared	  
with	  one-­‐way	  analysis	  of	  variance	   (ANOVA)	  or	   for	   two	  variables	   two-­‐way	  ANOVA.	  Studen´s	   t-­‐
test	   was	   applied	   to	   compare	   pairs	   of	   data.	   p-­‐values	   <	   0.05	   were	   considered	   statistically	  
significant	  and	  are	  indicated	  as	  follows:	  *p<0.05;	  **p<0.01;	  ***p<0.001.	  
	  List	  of	  reagents:	  
Reactive	   Supplier	   Reference	  
	   	   	  
30%	  Acrylamide/Bis	  solution	   Biorad	   161-­‐0156	  
Anti-­‐PE	  MicroBeads	   MiltenyiBiotec	   130-­‐048-­‐801	  
Biotin-­‐protein	  Ligase	   GeneCopoeia	   BIRA500	  
CFSE	   Invitrogen	   C34554	  
DMSO	   Sigma	   D2650	  
Ficoll-­‐Paque	   GE	  Healthcare	   17-­‐1440-­‐02	  
Heparin	   Sigma	   H3149	  
Human	  serum	   Sigma	   H4522	  
Leupeptin	   Calbiochem	   108975	  
Monensin	   Sigma	   M5273	  
Paraformaldehyde	   Sigma	   158127	  
Pepstatin	  A	   Calbiochem	   516481	  
PVDF	  transfer	  membranes	   MIllipore	   IPVH00010	  
RandomHexamers	   Roche	   58002113-­‐01	  
rh	  IL-­‐2	   Peprotech	   200-­‐02	  
Saponin	   Sigma	   S7900	  
SuperScript	  II	  RT	   Invitrogen	   18064-­‐022	  
T4	  DNA	  ligase	   New	  EnglandBiolabs	   M0202S	  
Tween-­‐20	   Sigma	   P5927	  
X-­‐rayfilms	   Konica	  Minolta	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Part I.  CD94/NKG2H orphan receptor 
 
1. NKG2H MOLECULE 
 
During	   the	   past	   10-­‐12	   years	   the	   expression	   and	   function	   of	   the	   CD94/NKG2A	   and	  
CD94/NKG2C	   heterodimeric	   lectin-­‐like	   receptors	   in	   NK	   and	   T	   cells	   have	   been	   the	   subject	   of	  
intensive	  study	  (Borrego	  et	  al.	  2006;	  Gunturi	  et	  al.	  2004).	  While,	  a	  series	  of	  discoveries	  have	  explained	  
several	  important	  functions	  of	  these	  receptors	  as	  well	  as	  of	  their	  cognate	  ligand	  HLA-­‐E,	  the	  first	  
and	  only	  report	  of	  the	  existence	  of	  the	  NKG2H	  protein	  comes	  from	  the	  study	  of	  Teresa	  Bellón	  
and	  her	  coworkers	   in	  1999.	  These	  workers	  studied	  a	  αβ	  CD8+	  T	  cell	   clone	   (TCC,	  K14B06)	   that	  
could	   be	   activated	   using	   either	   mAbs	   specific	   for	   CD3	   or	   CD94.	   Cell	   surface	   labelling	   and	  
immunoprecipitation	   experiments	   identified	   a	   protein	   with	  molecular	   weight	   of	   39-­‐kDa	   that	  
formed	   a	   disulphide-­‐linked	  heterodimer	  with	   CD94,	   but	  was	   neither	  NKG2A	  nor	  NKG2C.	   PCR	  
and	  cloning	  identified	  a	  novel	  cDNA	  clone,	  a	  splice	  variant	  of	  NKG2E	  that	  these	  workers	  named	  
NKG2H.	  This	  cDNA	  was	  predicted	  to	  associate	  with	  CD94	  and	  the	  adaptor	  molecule	  DAP12	  to	  
form	  an	  activating	  heterodimer.	  
Further	   progress	   in	   understanding	   the	   biology	   and	   function	   of	   the	   NKG2H	   receptor	  
(signalling,	  molecular	  interactions	  and	  ligand	  binding)	  has	  been	  seriously	  hampered	  by	  the	  lack	  
of	   monoclonal	   antibodies	   specific	   for	   the	   NKG2H	   molecule.	   When	   an	   NKG2H	   specific	   mAb	  
(MAB6549,	  R&D	  Systems)	  became	  commercially	  available,	  this	  gave	  us	  the	  opportunity	  to	  study	  
the	  NKG2H	  receptor	  in	  more	  detail.	  	  
	  
1.1 Phenotypic characterization of NKG2H+ cells in healthy donors 
Flow	   cytometry	   analysis	   of	   freshly	   isolated	  PBMCs	   from	  5	  healthy	   individuals	  was	   used	   to	  
identify	  the	  cell	  population	  expressing	  NKG2H	  at	  the	  cell	  surface.	  A	  six-­‐colour	  staining	  strategy,	  
using	  a	  combination	  of	  anti-­‐CD3,	  CD4,	  CD8,	  CD56,	  CD161	  and	  anti-­‐NKG2H	  mAbs	  was	  applied	  to	  
characterize	   NKG2H	   expression	   on	   the	   different	   PBMC	   subsets	   defined	   by	   these	   surface	  
markers.	  To	  detect	  T	  and	  NK	  cells,	  a	  lymphocyte	  gate	  was	  first	  determined	  by	  forward	  and	  side	  
scatter	  characteristics	  (Fig	  1-­‐A).	  T	  cells	  were	  detected	  by	  gating	  the	  lymphocytes	  on	  CD3+CD56-­‐	  
cells,	   while	   NK	   cells	   were	   defined	   as	   CD3-­‐CD56+	   cells.	   The	   subpopulation	   of	   NK	   cells,	   which	  
express	   higher	   levels	   of	   CD56,	   was	   gated	   as	   CD56bright	   and	   the	   subpopulation	   of	   NK	   cells	  
expressing	  lower	  levels	  of	  this	  marker	  was	  gated	  as	  CD56dim.	  The	  subpopulations	  of	  T	  cells	  were	  
defined	  as	  CD3+CD8+	  and	  CD3+CD4+	  T	  cells.	  Additionally,	  cells	  that	  co-­‐expressed	  the	  CD56	  and	  
CD3	  antigens	  (Mehta	  et	  al.	   1995)	  as	  well	  as	  the	  CD3+CD161+	   (NKT	  cells)	  subpopulation	  were	  also	  
included	   in	   the	   gating	   strategy.	   All	   these	   populations	   were	   analysed	   for	   expression	   of	   the	  



































Fig.1:	   Flow	   cytometric	   characterization	   and	   quantification	   of	   NKG2H	   expressing	   cells	   in	  




























CD4+	  T	  cells	  

























































	  	   67	  
Results	  
As	   shown	   on	   Fig.	   1-­‐B,	   NKG2H	  was	   expressed	   on	   the	   surface	   of	   low,	   almost	   undetectable	  
numbers	   of	   PBMCs,	   in	   the	   range	   between	   0,5%	   to	   1,5	   %	   of	   total	   lymphocytes.	   Further,	  
substantial	  donor	  dependent	  variations	  were	  also	  observed	  in	  the	  expression	  of	  this	  molecule.	  
The	  difference	  of	  expression	  of	  NKG2H	  receptor	  between	  the	  different	  cell	  subsets	  was	  small	  in	  
magnitude	  but	  consistently	  detected	  in	  all	  donors:	   little	  or	  no	  NKG2H	  receptor	  was	  expressed	  
by	  NK	  cells,	  either	  the	  CD56dim	  or	  CD56bright	  subsets;	  or	  by	  CD3+CD4+	  T	  cells.	  On	  the	  other	  hand,	  
the	  percentage	  of	  cells	  expressing	  NKG2H	  was	  significantly	  higher	  for	  CD3+CD56+	  and	  CD3+CD8+	  
cells,	   suggesting	   that	   the	   regulatory	   events	   controlling	   the	   expression	   of	   this	   C-­‐type	   lectin	  
receptor	  probably	  act	  differently	  on	  NK	  and	  T	  cells.	  In	  the	  light	  of	  these	  data	  it	  is	  interesting	  to	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2. CD94/NKG2H RECEPTOR AND VIRAL INFECTIONS 
 
The	   participation	   of	   both	   T	   and	   NK	   cells	   is	   necessary	   for	   effective	   defence	   against	   HCMV	  
(Mocarski	  et	  al.	  2001;	  Pass	  et	  al.	  2001;	  Fishman	  et	  al.	  2007;	  Dowd	  et	  al.	  2009;	  Pawelec	  et	  al.	  2011;	  Romo	  et	  al.	  
2011(1)).	   Patients	   with	   congenital	   HCMV	   infection	   have	   been	   shown	   to	   make	   CD8+	   T	   cell	  
responses	   (Marchant	   et	   al.	   2003;	  Gibson	   et	   al.	   2004)	  and	  expansion	  and	  differentiation	  of	  a	  specific	  
TCRγδ+	  cell	  subset	  has	  also	  been	  reported	  (Vermijlen	  et	  al.	  2010;	  Revilleza	  et	  al.	  2011).	  The	  role	  of	  NK	  
cells	   in	   controlling	   cytomegalovirus	   infection	   is	   clear	   in	   murine	   systems	   (Vidal	   &	   Lanier.	   2006;	  
Mitrović	   et	   al.	   2012;	  Miletić	   et	   al.	   2013)	  while	   for	  humans,	   a	  patient	  deficient	   for	  NK	  cells	   suffered	  
recurrent	  herpesvirus	  infections	  (Biron,	  NEJM	  1988).	  The	  indirect	  evidence	  suggesting	  a	  role	  for	  NK	  
cells	   in	   immune	   responses	   to	   HCMV	   comes	   from	   two	   sources;	   firstly,	   the	   observation	   that	  
HCMV	  has	  evolved/acquired	  multiple	  mechanisms	  of	  immune	  evasion	  that	  target	  ligands	  for	  NK	  
cell	  receptors	  (Wilkinson	  et	  al.	  2008;	  Fielding	  et	  al.	  2014)	  suggests	  that	  immune	  responses	  by	  NK	  cells	  
have	  significantly	   influenced	  the	  evolution	  of	  the	  virus.	  Secondly,	  study	  of	  the	  evolution	  of	  an	  
episode	   of	   HCMV	   infection	   in	   a	   child	   with	   a	   T-­‐B+NK+	   immunodeficiency	   has	   suggested	   that	  
human	  NK	  cells	  could	  control	  CMV	  infection	  in	  the	  absence	  of	  T	  cells,	  although	  the	  role	  of	  virus-­‐
specific	  antibodies	  was	  not	  examined	  in	  this	  case	  (Kuijpers	  et	  al.	  2008).	  
Recently	   it	   has	   been	   postulated	   that	   the	   CD94/NKG2	   lectin-­‐like	   receptors	   in	   the	   NK	   cell	  
response	  to	  HCMV	  play	   important	  roles	   in	   immunity	  HCMV.	  As	  described	   in	   the	   introduction,	  
both	   CD94/NKG2A	   inhibitory	   and	  CD94/NKG2C	   activating	   receptors	   specifically	   recognize	   but	  
differ	  in	  their	  binding	  affinity	  for	  HLA-­‐E	  that	  can	  bind	  peptide	  from	  the	  leader	  sequence	  of	  the	  
UL40	  molecule,	   stabilizing	   HLA-­‐E	   surface	   expression	   in	   HCMV-­‐infected	   fibroblasts,	   protecting	  
them	  against	  NKG2A+	  NK	  cells	  (Tomasec	  et	  al.	  2000;	  Ulbrecht	  et	  al.	  2000;	  Wang	  et	  al.	  2002;	  Heatley	  al.	  2013).	  	  
Several	   NK	   cell	   subsets,	   according	   to	   the	   expression	   of	   CD94/NKG2	   receptors	   have	   been	  
characterized	  in	  human	  peripheral	  blood:	  NKG2A+/C-­‐,	  NKG2A-­‐/C+,	  NKG2A+/C+,	  and	  NKG2A-­‐/C-­‐.	  In	  
HCMV	  seronegative	   individuals,	  NKG2A+/C-­‐	   and	  NKG2A-­‐/C-­‐	  NK	   cells	   are	  predominant	  whether	  
the	   other	   cell	   subsets	   are	   negligible.	   However,	   an	   NKG2CbrightNKG2A-­‐NKp30lowNKp46low	   cell	  
population	  has	  been	  shown	  to	  expand	  in	  HCMV	  seropositive	  individuals	  (Muntasell	  et	  al.	  2013(1)).	  
An	   increased	  proportion	  of	  NKG2C+	  NK	  and	  T	  cells	  have	  also	  been	   reported	   in	  healthy	  HCMV	  
seropositive	   children	   (Noyola	   et	   al.	   2012).	   These	   NKG2Cbright	   cells	   have	   been	   shown	   to	   be	  
functionally	   mature,	   mediating	   cytotoxicity	   and	   cytokine	   production,	   express	   perforin	   and	  
granzyme	  B	  and	  predominantly	  display	   inhibitory	  KIR	   for	  self	  HLA-­‐C	  molecules	   (Bjorkstrom	  et	   al.	  
2011;	  Bezait	  et	  al.	  2013;	  Djaoud	  et	  al.	  2013;	  Muntasell	  et	  al.	  2013(2)).	  The	  magnitude	  of	  the	  NKG2C+	  NK	  cell	  
expansion	   was	   shown	   to	   be	   quite	   variable,	   being	   undetectable	   in	   some	   HCMV+	   individuals	  
whereas	  in	  others	  it	  could	  represent	  >50%	  of	  the	  NK-­‐cell	  compartment.	  These	  NKG2C+	  NK	  cells	  
were	  shown	  to	  persist	  and	  be	  stable	  under	  steady	  state	  conditions	  during	   the	   lifetime	  of	   the	  
individual,	   leading	  to	  the	   idea	  that	  expression	  of	  NKG2C	  marks	  the	  ¨memory-­‐like¨	  cells	  of	  the	  
NK	  cell	  population	  (Min-­‐Oo	  et	  al.	  2013;	  Muntasell	  et	  al.	  2013(1)).	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Alignment	  of	  the	  NKG2H	  peptide	  with	  other	  members	  of	  the	  NKG2	  C-­‐type	  lectin	  like	  family	  
(Fig.3	  Introduction	  part)	  shows	  that	  NKG2E/H	  and	  the	  NKG2C	  family	  members	  are	  highly	  similar	  
in	  the	  amino	  acid	  sequence	  of	  the	  cytoplasmic	  and	  transmembrane	  domain	  but	  more	  divergent	  
in	   their	   extracellular	   ligand-­‐binding	   region.	   Interestingly,	   all	   three	   members	   share	   the	   same	  
charged	   lysine	   residue	   in	   the	   transmembrane	   domain	   responsible	   for	   the	   DAP12	   adaptor	  
protein	   association.	   As	   mentioned	   previously,	   the	   functional	   properties	   of	   NKG2H	   are	   still	  
unknown	   but	   given	   that	   NKG2C+	   cells	   expand	   in	   HCMV	   seropositive	   individuals	   and	   have	   a	  
possible	   role	   in	   the	   control	  of	   the	  HCMV	   infections,	   the	   structural	   similarity	  between	  NKG2H	  
and	  NKG2C	  molecules,	  made	   it	  seem	  reasonable	  to	  ask	  how	  viral	   infections,	  and	   in	  particular	  
HCMV	   infections,	  affected	  NKG2H+	  cells.	  To	  address	   this	   issue,	  we	  analysed	  the	  expression	  of	  
CD94/NKG2A,	  NKG2C	  and	  NKG2H	  receptors	  in	  peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  co-­‐
cultured	  with	  HCMV	  infected	  fibroblasts.	  	  
	  
2.1 Expansion of CD94/NKG2H+ cells in response to HCMV infected fibroblasts. 
An	  in	  vitro	  culture	  system	  for	  stimulation	  of	  PBMCs	  with	  HCMV	  infected	  fibroblasts	  has	  been	  
widely	   used	   to	   study	   cytotoxic	   T	   lymphocytes	   (CTLs)	   specific	   for	   viral	   antigens	   and	  described	  
elsewhere	  (Reusser	  et	  al.	  1991).	  We	  used	  this	  system	  to	  address	  our	  first	  objective,	  to	  establish	  the	  
effect	  of	  culture	  with	  HCMV	  infected	  fibroblasts	  on	  NKG2H	  expression	  in	  lymphocytes.	  PBMCs	  
purified	  from	  healthy	  donors	  were	  co-­‐cultured	  either	  with	  mock	  or	  HCMV	  infected	  fibroblasts,	  
as	   described	   by	   Guma	   et	   al.	   2006	  with	   the	   exception	   that	   infections	  were	   done	  with	   HCMV	  
strain	  Merlin,	  which	  is	  a	  low	  passage	  clinical	  strain.	  The	  phenotype	  of	  the	  PBMCs,	  in	  particular	  
NKG2A,	  -­‐C	  and	  –H	  expression,	  were	  compared,	  using	  flow	  cytometry,	  at	  different	  time	  points:	  
day	  3,	  day	  7	  and	  day	  10.	  	  
Three-­‐color	  immunofluorescence	  analyses	  of	  the	  PBMCs	  at	  the	  end	  of	  each	  co-­‐culture	  period	  
revelled	  a	  marked	  increase	  in	  the	  proportion	  of	  NKG2H+	  cells	  in	  PBMCs	  co-­‐cultured	  with	  HCMV	  
infected	  fibroblasts	  compared	  to	  the	  PBMCs	  co-­‐cultured	  with	  mock	  infected	  fibroblasts	  (Fig.	  2).	  
This	   increase	   in	   the	   percentage	   of	   NKG2H+	   cells	   was	   detected	   first	   at	   day	   3	   and	   further	  
expansion	  of	  these	  cells	  was	  observed	  by	  day	  7	  and	  day	  10	  (Fig.2-­‐A).	  
The	   change	  of	   the	  expression	  of	  NKG2H	   receptor	   in	   the	  different	  populations	  of	   cytotoxic	  
lymphocytes	   was	   analysed	   using	   anti-­‐CD3	   and	   anti-­‐CD56	   mAb´s	   to	   define	   NK	   and	   T	   cell	  
populations	  (Fig.	  2-­‐B	  and	  Fig.	  2-­‐C).	  Cell	  surface	  expression	  of	  NKG2H	  was	  clearly	   increased	  on	  
lymphocytes	   that	   had	   encountered	   HCMV	   infected	   cells	   comparing	   to	   the	   mock	   infected	  
controls.	   After	   7	   days,	   as	   well	   as	   after	   10	   days	   of	   cell	   culture,	   a	   significant	   increase	   of	   the	  
percentage	  of	  NKG2H	  expressing	  T	  cells,	  NK	  cells,	  both	  CD56dim	  and	  CD56hi	  subsets,	  as	  well	  as	  
CD3+CD56+	  cells	  was	  observed.	  	  
Closer	  analyses	  at	  the	  different	  time	  points	  of	  co-­‐culture	  between	  the	  PBMCs	  and	  the	  mock	  
or	   HCMV	   infected	   fibroblasts	   indicated	   that	   the	   proportion	   of	   NKG2H+	   T	   cells	   (CD3+CD56-­‐)	  
increased	  most	  during	  the	  first	  week,	  but	  by	  day	  10	  the	  numbers	  of	  these	  cells	  had	  started	  to	  
decrease.	  In	  contrast,	  the	  percentage	  of	  NKG2H+	  cells	  within	  the	  NK	  cell	  population	  (CD3-­‐CD56+)	  
continued	  to	  increase	  from	  35%	  at	  day	  7	  to	  40%	  at	  day	  10	  (Fig.	  2-­‐C).	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Fig.2:	  An	  NKG2H+	  cell	  expansion	  was	  induced	  in	  vitro	  by	  co-­‐culture	  of	  lymphocytes	  with	  HCMV	  
infected	  fibroblast.	  (A)	  Fibroblasts	  were	  mock	  or	  HCMV	  (Merlin)	   infected	  overnight,	  and	  then	  co-­‐cultured	  with	  PBMCs.	  These	  co-­‐cultures	  were	  maintained	   for	  3,	  7	  and	  10	  days,	   then	  harvested	  and	  stained	  for	  surface	  markers	  as	  described	  in	  ¨Materials	  and	  methods¨.	  A	  representative	  result	  of	  one	  healthy	  donor	  is	  shown	  for	  the	  expression	  of	  NKG2H	  in	  CD56+	  cells	  (first	  and	  fourth	  panels),	  for	  the	  expression	   of	   NKG2H	   in	   CD3+	   cells	   (second	   and	   fifth	   panels)	   and	   for	   the	   expression	   of	   NKG2H	   in	  CD3+CD56+	  cells	  (third	  and	  sixth	  panels).	  (B)	  Change	  of	  the	  cell	  surface	  expression	  of	  NKG2H	  by	  the	  different	   lymphocyte	   subsets	   after	   co-­‐culture	   with	   mock	   or	   HCMV	   (Merlin)	   infected	   fibroblasts.	  Representative	   histograms	   of	   NKG2H	   expression	   on	   the	   different	   lymphocyte	   subsets	   are	   shown;	  grey	  filled	  –	  Isotype	  control,	  grey	  line	  –	  mock	  infected	  fibroblasts,	  black	  line	  –	  HCMV	  (Merlin)	  infected	  fibroblasts.	   (C)	  Analyses	   of	   the	   percentage	   of	   NKG2H+	   cells	   expressed	   by	   CD3+CD56-­‐,	   CD3+CD56+,	  CD3-­‐CD56+,	   CD3-­‐	   CD56dim+,	   CD3-­‐CD56hi+	   after	   co-­‐culture	   with	   Mock	   of	   HCMV	   infected	   fibroblasts.	  Each	   symbol	   corresponds	   to	   the	   result	   obtained	   from	   an	   individual	   donor;	   filled	   symbols	   –	  HCMV	  seronegative,	  open	  symbol	  –	  HCMV	  seropositive.	  Mean	  data	  and	  standard	  deviations	  are	  represented,	  n=4;	  ***p<0.001.	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Results	  
2.2 CD94/NKG2H, but not NKG2A or NKG2C positive cells expand in response to 
HCMV infected fibroblasts. 
In	   parallel	   to	   the	   analysis	   of	   NKG2H	   expression,	   changes	   in	   the	   proportion	   of	   NKG2C	   and	  
NKG2A	  molecules	  on	  PBMCs	  stimulated	  with	  mock	  or	  HCMV	  (Merlin)	  infected	  fibroblasts	  were	  
also	  analysed	  (Fig.	  3).	  As	  previously	  seen,	  a	  10-­‐fold	  increase	  of	  the	  percentage	  of	  NKG2H+	  cells	  
was	   observed	   after	   co-­‐culture	   of	   PBMCs	   with	   HCMV	   infected	   fibroblast	   compared	   with	   the	  
mock	  controls,	  but	  no	  changes	  in	  the	  frequency	  of	  NKG2C	  or	  NKG2A	  positive	  cells	  between	  the	  
two	   conditions	   were	   observed.	   Given	   that	   the	   majority	   of	   our	   healthy	   donors	   were	   CMV	  
seronegative,	   these	   observations	   agree	   with	   the	   published	   data	   of	   Guma	   et	   al.	   2006	   which	  
describe	  comparable	  levels	  of	  NKG2A	  receptor	  expression	  on	  PBMCs	  after	  culture	  with	  mock	  or	  
HCMV	  infected	  fibroblast	  whereas	  expansion	  of	  NKG2C+	  cells	  was	  observed	  in	  PBMCs	  from	  6/11	  
HCMV	   seropositive	   donors	   cultured	  with	   virus	   infected	   fibroblasts,	   but	   never	   in	   PBMCs	   from	  














Fig.	  3:	  NKG2	  receptor	  expression	  in	  PBMCs	  after	  stimulation	  with	  HCMV	  infected	  fibroblasts.	  PBMCs	   from	   healthy	   individuals	   were	   co-­‐cultured	   with	   either	   mock	   or	   HCMV	   (Merlin)	   infected	  fibroblasts	   for	   3,	   7	   and	   10	   days	   (50	   U/ml	   of	   IL2	  was	   added	   after	   day	   3).	   The	   percentage	   of	   cells	  expressing	  the	  different	  NKG2	  receptors	  was	  assessed	  at	  the	  different	  time	  points.	  Day	  0	  is	  the	  point	  before	   culturing	   the	   cells	   in	   vitro.	   Mean	   data	   and	   standard	   deviations	   are	   represented,	   n=8.	   The	  proportion	  of	  NKG2H+,	  NKG2A+	  or	  NKG2C+	   cells	  detected	   in	   the	  PBMCs	   from	  8	  different	  donors,	   in	  three	  separate	  experiments	  are	  shown;	  ***p<0.001.	  	  
Given	  that	  there	  was	  a	  clear	  expansion	  of	  NKG2H	  expressing	  cells	  after	  the	  7	  days	  of	  PBMCs	  
infected	   fibroblast	   co-­‐culture,	   the	   next	   sets	   of	   experiments	   were	   analysed	   after	   7	   days	   of	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Results	  
In	   parallel,	   NKG2H	   mRNA	   expression	   by	   lymphocytes	   stimulated	   with	   mock	   or	   HCMV	  
infected	  fibroblasts	  was	  evaluated	  in	  samples	  of	  total	  RNA,	  isolated	  from	  these	  cells	  at	  different	  
time	  points.	  Surprisingly,	  no	  significant	  differences	  were	  observed	  in	  NKG2H	  mRNA	  expression,	  
suggesting	   that	   NKG2H	   surface	   expression	   must	   be	   regulated	   post-­‐transcriptionally	   and/or	  














Fig.	  4:	  Relative	  expression	  of	  the	  nkg2h	  gene	  measured	  by	  quantitative	  PCR.	  Total	  mRNA	  was	  extracted	  from	  PBMCs	  stimulated	  with	  mock	  or	  HCMV	  (Merlin)	  infected	  fibroblasts	  for	  3	  or	  7	  days	  as	  described	   in	   ¨Materials	   and	   Methods¨.	   The	   amount	   of	   NKG2H	   mRNA	   expression	   was	   normalized	  against	   the	   quantity	   of	   β-­‐actin	   mRNA	   expression	   in	   each	   sample,	   and	   related	   to	   the	   NKG2H	  expression	   in	   control,	   no	   stimulated	   cells	   (dotted	   line).	   Mean	   data	   and	   standard	   deviations	   are	  represented,	  n=4	  in	  one	  experiment.	  No	  significant	  differences	  were	  found.	  	  
	  
2.3 Contact between PBMC and HCMV infected fibroblasts is required for efficient 
expansion of CD94/NKG2H+ cells. 
In	   order	   to	   define	   the	   relative	   importance	   of	   soluble	   factors	   and	   cell:cell	   contact	   for	   the	  
expansion	   of	   the	   NKG2H+	   cells,	   PBMCs	  were	   cultured	  with	   HCMV	   (Merlin)	   or	  mock	   infected	  
fibroblasts	  either	  in	  the	  same	  chamber	  or	  in	  different	  chambers	  of	  a	  transwell	  separated	  by	  a	  
cell-­‐impermeable	   membrane	   that	   permits	   diffusion	   only	   of	   soluble	   factors.	   Under	   these	  
conditions	  a	   small	   increase	   in	   the	  percentage	  of	  NKG2H+	  cells	  was	  observed	  when	   the	  PBMC	  
were	   separated	   from	   the	   infected	   cells	  whereas	  marked	   induction	  of	  NKG2H	  expression	  was	  
observed	   only	   when	   the	   PBMC	   were	   cultured	   in	   the	   same	   chamber	   as	   the	   virus-­‐infected	  
fibroblasts	   (Fig.	   5).	   These	   data	   indicate	   that	   direct	   interaction	   between	   PBMCs	   and	   HCMV	  











































Fig.	  5:	  Direct	  contact	  with	  the	  HCMV	  (Merlin)	  infected	  fibroblasts	  is	  required	  for	  the	  expansion	  
of	  NKG2H+	  cells.	  Purified	  PBMCs	  were	  cultured	  with	  mock	  or	  HCMV	  (Merlin)	  infected	  fibroblasts	  in	  same	  chamber,	  or	  in	  different	  chambers	  separated	  by	  a	  semi-­‐permeable	  membrane	  for	  7	  days	  before	  cell	   surface	   staining.	   Mean	   data	   and	   standard	   deviations	   are	   represented,	   n=6.	   The	   proportion	   of	  NKG2H+	  cells	  in	  PBMCs	  from	  6	  different	  donors,	  in	  two	  separate	  experiments	  are	  shown;***p<0.001.	  
	  
2.4 NKG2H+ cell subset expansion in response to different HCMV strains and other 
viruses.  
HCMV	   strains	   display	   different	   levels	   of	   virulence,	   tissue	   tropism	   and	   pathogenicity	  
depending	   on	   their	   degree	   of	   adaptation	   in	   fibroblasts.	   HCMV	   strain	   Merlin	   is	   a	   minimally	  
passaged	   clinical	   strain,	   passaged	   only	   twice	   in	   vitro	   before	   the	   genome	   was	   cloned	   in	   a	  
bacterial	  artificial	  chromosome	  for	  propagation.	  The	  HCMV	  strains	  Toledo	  and	  TB/40	  are	  widely	  
used	  laboratory	  models	  of	  clinical	  strains	  whereas	  AD169	  is	  a	  highly	  passaged	  laboratory	  HCMV	  
strain.	  Clinical	  HCMV	  strains	  are	  more	  virulent	  (Elek	  et	  al.	  1974;	  Quinnan	  et	  al.	  1984;	  Plotkin	  et	  al.	  1976)	  
and	   also	   confer	   a	   stronger	   resistance	   to	   NK	   cell	   attack	   than	   the	   highly-­‐passaged	   attenuated	  
strains	  which	   produce	   only	  marginal	   effects	  with	   respect	   to	  NK	   cell	   recognition	   (Cerboni	   et	   al.	  
2000)	  suggesting	  that	  at	  least	  some	  of	  the	  mechanisms	  employed	  to	  evade	  NK	  cell	  lysis	  may	  be	  
lost	  during	  in	  vitro	  passage	  of	  this	  viruses.	  	  
To	  establish	  whether	  other	  HCMV	  strains	  than	  the	  viral	  strain	  Merlin	  could	  provoke	  the	  same	  
NKG2H	   expansion	   effect	   on	   PBMCs,	   we	   compared	   the	   effects	   on	   PBMC	   of	   co-­‐culture	   with	  
fibroblasts	   infected	   with	   strains	   AD169,	   Toledo	   and	   TB/40	   and	   the	   previously	   used	   strain	  
Merlin.	  NKG2H	  expression	  was	  checked	  at	  the	  day	  3	  and	  day	  7	  time	  points	  (Fig.	  6).	  Under	  these	  
conditions	  only	   PBMCs	   co-­‐cultured	  with	   fibroblasts	   infected	  with	   the	   viral	   strains	  Merlin	   and	  
TB/40	  were	  able	  to	  drive	  the	  expansion	  of	  NKG2H+	  cells.	  In	  contrast,	  co-­‐culture	  of	  PBMCs	  with	  
fibroblasts	  infected	  with	  the	  clinical	  strain	  Toledo	  or	  the	  highly	  passaged	  strain	  AD169	  did	  not	  










































Fig.	   6:	  HCMV	   strains	  Merlin	   and	  TB/40	  but	  not	   the	   viral	   strains	  Toledo	  and	  AD169	   infected	  
fibroblasts	  are	  capable	  to	  drive	  expansion	  of	  NKG2H+	  cells.	  hTERT	  fibroblasts	  were	  infected	  with	  different	   type	  of	  viruses	  as	  well	  as	  different	  genetic	  variants	  of	   the	  same	  HCMV	  as	   indicated	   in	   the	  legend	  of	  this	  figure.	  The	  percentage	  of	  NKG2H+	  cells	  was	  examined	  at	  day	  0	  (before	  cell	  stimulation),	  day	  3	  and	  day	  7.	  For	  HSV	  and	  Vaccinia	  the	  percentage	  of	  NKG2H+	  cells	  was	  assessed	  only	  at	  day	  7.	  Mean	  data	  and	  standard	  deviations	  are	  represented,	  n=8.	  The	  proportion	  of	  NKG2H+	  cells	  in	  PBMCs	  from	  8	  different	  donors,	  in	  three	  separate	  experiments	  are	  shown;	  *p<0.05,	  ***p<0.001.	  
	  
Similarly,	   no	   significant	   increase	   of	   the	   percentage	   of	   NKG2H+	   cells	   was	   noted	   upon	  
incubation	   of	   PBMCs	   with	   mock,	   herpes	   simplex	   virus	   (HSV)	   or	   Vaccinia	   virus	   infected	  
fibroblasts.	  Together,	  these	  data	  indicate	  that	  the	  changes	  in	  NKG2H	  expression	  associated	  with	  
virus	   infection	   depend	   not	   only	   on	   the	   type	   of	   the	   virus	   but	   also	   on	   the	   genetic	   variant	   or	  
subtype	  of	  the	  studied	  virus.	  
	  
	  
2.5 Loss of NKG2H expression after removal of PBMCs from contact with infected 
fibroblasts.  
As	  described	  above	  in	  the	  introduction	  to	  this	  results	  section,	  expansion	  of	  NKG2C+	  cells	  has	  
been	  associated	  with	  prior	  HCMV	  infection.	  These	  cells	  have	  been	  described	  to	  be	  more	  potent	  
producers	   of	   IFNγ	   and	   to	   express	   CD57,	   a	  marker	   of	   terminal	   differentiation,	   suggesting	   the	  
existence	   of	   a	   secondary	   response	   against	   CMV	   antigen	   (Foley	   et	   al.	   2012).	   Moreover,	   the	  
expansion	  of	  memory-­‐like	  NKG2C+	  NK	   cells	  was	   found	   to	  be	  persistent,	   although	   the	  basis	  of	  
this	  persistence	  is	  not	  clear	  (López-­‐Botet	  et	  al.	  2014).	  
As	  a	  first	  approximation	  to	  check	  whether	  cells	  expressing	  the	  CD94/NKG2H	  receptor	  could	  
also	  be	  classified	  as	  showing	  this	  memory	  like	  phenotype	  PBMCs	  were	  co-­‐cultured	  with	  mock	  or	  
HCMV	  (Merlin)	  infected	  fibroblasts	  for	  7	  days.	  After	  this	  time,	  the	  percentage	  of	  NKG2H+	  cells	  
was	  assessed	  and	  cells	  were	   left	   to	   rest	   in	  50	  U/ml	  of	   IL2,	   for	   four	   to	   five	  days	   in	  culture.	  As	  
usual,	  a	  clear	  expansion	  of	  NKG2H+	  cells	  was	  observed	  after	  7	  days	  of	  the	  co-­‐stimulation	  period	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(Fig.	  7).	  In	  contrast,	  once	  the	  cells	  were	  separated	  from	  the	  infected	  fibroblasts	  and	  rested	  for	  
four	   to	   five	  days	  with	   IL2,	   they	   lost	   the	  surface	  expression	  of	  NKG2H.	  These	  preliminary	  data	  
indicate	   that	   the	   expanded	   NKG2H	   expressing	   cells	   are	   not	   persistent	   over	   time	   and	   this	  






















Fig.	  7:	  Expanded	  NKG2H+	  cells	  go	  back	  to	  normal	   levels	  when	  PBMCs	  are	  not	   in	  contact	  with	  
the	   infected	   fibroblasts.	  After	   7	   days	   of	   co-­‐culture	   between	   PBMCs	   and	  mock	   or	   HCMV	   infected	  fibroblasts,	   aliquots	   of	   the	   cells	   were	   collected	   and	   stained	   for	   surface	   CD3,	   CD56	   and	   NKG2H	  molecule	  expression	  while	  the	  others	  were	   left	   to	  rest	   for	   four-­‐five	  days	  with	  50	  U/ml	  of	   IL2.	  After	  this	  period	  of	   time,	   cells	  were	   stained	  with	   anti	   CD3,	  CD56	  and	  NKG2H	  antibodies.	  Representative	  flow	   cytometry	   dot	   plots	   show	   the	   percentage	   of	   gate	   CD56+NKG2H+,	   CD3+NKG2H+	   and	  CD3+CD56+NKG2H+	  cells.	  
	  
2.6 Degranulation capacity of PBMC in response to HCMV infected fibroblasts  
Other	  data	  indicated	  that	  mAb-­‐mediated	  ligation	  of	  the	  NKG2H	  receptor	  led	  to	  increased	  T	  
cell	  death	  in	  systems	  involving	  polyclonal	  T	  cell	  activation	  (sections	  3.1	  and	  3.	  4).	  One	  testable	  
prediction	  from	  these	  data	  is	  that	  induction	  of	  NKG2H	  expression	  (and	  the	  consequent	  death	  of	  
activated	  lymphocytes)	  could	  be	  associated	  with	  weaker	  secondary	  immune	  responses.	  In	  order	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system	   involving	   the	   culture	   of	   PBMC	   with	   mock	   or	   HCMV	   infected	   fibroblasts.	   As	   NKG2H	  
receptor	  expression	  was	  seen	  to	   increase	  transiently	  at	   the	  cell	   surface	   in	   response	  to	  HCMV	  
infected	   fibroblasts,	   PBMCs	   were	   co-­‐cultured	   with	   mock	   or	   HCMV	   infected	   fibroblasts	   for	   7	  
days	   and	   then	   re-­‐stimulated	   by	   co-­‐incubation	   with	   new	   cultures	   of	   either	   mock	   or	   HCMV	  
infected	  fibroblasts	  for	  another	  48h	  (Scheme	  1	  and	  Fig.	  8).	  Lymphocyte	  activation	  was	  assessed	  
by	   examining	   the	   expression	   of	   CD107a,	   a	   degranulation	  marker,	   on	   the	   lymphocytes	   in	   the	  
culture	  after	  the	  second	  incubation.	  Allogeneic	  stimulation	  (HLA-­‐type:	  HLA-­‐A*01,	  B*08/*41,	  C*07/*17,	  
DRB1*03/*07.	   DRB3+,	   DRB4+),	   induced	   by	   the	   HLA	   antigens	   expressed	   on	   the	   fibroblasts	   led	   to	  
increased	   CD107a	   expression	   by	   T	   cells	   (CD3+CD56-­‐),	   NK	   cells	   (CD3-­‐CD56+)	   and	   effector	   cells	  
(CD3+CD56+)	  present	  in	  the	  PBMCs	  when	  cultured	  with	  mock	  infected	  fibroblasts	  (M-­‐PBMCs).	  In	  
contrast,	  the	  same	  T	  cells,	  NK	  cells	  and	  double	  positive	  cells	  degranulated	  less	  on	  exposure	  to	  
HCMV-­‐infected	  fibroblasts	   (H-­‐PBMCs)	   (Fig.	  8).	  This	  presumably	  reflects	   the	  downregulation	  of	  
HLA	  class	  I	  molecules	  and	  ligands	  for	  activating	  NK	  receptors	  that	  is	  known	  to	  occur	  after	  HCMV	  
infection	   (Wilkinson	   et	   al.2008;	   Jackson	   et	   al.	   2011).	   Secondary	   exposure	   of	   M-­‐PBMCs	   (PBMCs	  
previously	   co-­‐cultured	  with	  mock	   infected	   fibroblasts	   for	  7	  days)	   to	  mock	   infected	  allogeneic	  
fibroblast	  (MOCK	  inf.	  fibroblast	  +	  M-­‐PBMCs)	  was	  associated	  with	  an	  increase	  in	  the	  percentage	  
of	  degranulating	  T	  and	  NK	  cells	  but	  a	  decrease	  in	  the	  percentage	  of	  degranulating	  CD3+CD56+	  
cells.	  A	   round	  of	   culture	  of	   these	   same	  M-­‐PBMCs	  with	  HCMV-­‐infected	   fibroblasts	   (HCMV	   inf.	  
fibroblasts	  +	  M-­‐PBMCs)	  was	  associated	  with	  increased	  degranulation	  of	  the	  NK	  cells	  and	  double	  
positive	  cells	  but	  with	  no	  change	  in	  degranulation	  of	  the	  T	  cells	  compared	  to	  the	  degranulation	  
of	   M-­‐PBMCs	   alone.	   Secondary	   exposure	   of	   H-­‐PBMCs	   (PBMCs	   cultured	   with	   HCMV	   infected	  
fibroblasts	   for	   7	   days)	   to	   either	   mock	   (MOCK	   inf.	   fibroblasts	   +	   H-­‐PBMCs)	   or	   HCMV	   infected	  
fibroblasts	  (HCMV	  inf.	  fibroblasts	  +	  H-­‐PBMCs)	  was	  not	  associated	  with	  any	  significant	  change	  in	  
degranulation	  of	  the	  NK	  cells,	  CD3+CD56+	  cells	  and	  T	  cells	  compared	  to	  the	  degranulation	  of	  H-­‐
PBMCs	  alone	  (Fig.	  8).	  However	  a	  major	   limitation	  of	  these	  experiments	   is	  that	   it	   is	  difficult	  to	  
ascribe	   the	  effects	  observed	   to	   the	  action	  of	  NKG2H.	   The	  use	   in	   these	  experiments	  of	   F(ab)2	  
fragments	  of	  CD94	  specific	  mAbs	  would	  give	  some	  information,	  but	  since	  at	  least	  some	  of	  the	  
cells	  under	  study	  may	  also	  express	  CD94/NKG2A	  and	  CD94/NKG2C	  these	  experiments	  could	  not	  
be	   interpreted	   definitively	   and	   at	   present	   the	   preparation	   of	   F(ab)2	   fragments	   of	   the	  



































Fig.	  8:	  Degranulation	  of	  PBMCs	  to	  
mock	  or	  HCMV	  infected	  allogeneic	  
fibroblasts.	   PBMCs	   were	   co-­‐cultured	   with	   mock	   or	   HCMV	  infected	  fibroblasts	  for	  7	  days.	  Then,	  cells	   were	   collected	   and	   re-­‐stimulated	   with	   freshly	   infected	  mock	   or	   HCMV	   infected	   fibroblasts	  for	   another	   48h.	   Cell	   surface	  expression	  of	  CD107a	  was	   assessed	  after	  5h	  incubation	  period	  with	  anti-­‐CD107a	   antibody	   added	   to	   the	  media.	  Cells	  were	  co-­‐stained	  for	  CD3	  and	   CD56	   surface	   markers.	  Percentage	   of	   CD3+CD56+	   double	  positive	   cells	   (A)	   CD3+CD56-­‐	   T	   cells	  (B)	   and	   CD3-­‐CD56+	   NK	   cells	   (C)	  expressing	  CD107a	  on	  cell	  surface	  is	  presented.	   	   M-­‐PBMCs	   (PBMCs	   co-­‐cultured	   with	   mock	   infected	  fibroblasts	   for	   7	   days);	   H-­‐PBMCs	  (PBMCs	   co-­‐cultured	   with	   HCMV	  infected	   fibroblasts	   for	   7	   days);	   inf.	  fibroblasts	   (infected	   fibroblasts).	  Mean	   data	   and	   standard	   deviation	  are	   presented,	   n=2.	   *p<0.05,	  **p<0.01,	  ***p<0.001	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3. FUNCTIONAL EFFECTS OF NKG2H RECEPTOR LIGATION BY 
SPECIFIC ANTIBODY 
 
In	   the	   paper	   by	   Bellón	   et	   al.	   1999,	   NKG2H	   was	   described	   as	   possible	   partner	   forming	   a	  
heterodimer	  with	  CD94	  protein	  that	  associated	  with	  the	  DAP12	  adaptor	  molecule	  to	  transmit	  
activating	  signals.	  The	  engagement	  of	  this	  heterodimer	  expressed	  on	  the	  K14B06	  T	  cell	  clone	  by	  
anti	  CD94	  antibody,	  triggered	  both,	  early	  activation	  events	  such	  as	  Ca2+	  mobilization,	  and	  late	  
effector	  functions	  such	  as	  induction	  of	  TCR	  independent	  cytolytic	  activity	  and	  IFN-­‐γ	  production.	  
This	  observation	  was	  surprising	  since,	   in	  general,	  activating	  NK	  receptors	  expressed	  by	  T	  cells,	  
only	  act	  as	  co-­‐activators	  molecules,	  modulating	  the	  TCR-­‐mediated	  response	  but	  never	  inducing	  
cytolytic	   activity.	   Moreover,	   the	   evidence	   implicating	   NKG2H	   as	   part	   of	   an	   activating	  
heterodimer	  on	  this	  T	  cell	  clone	  was	  all	  indirect,	  thus	  the	  possibility	  that	  some	  other	  activating	  
receptor	   could	   associate	   with	   the	   CD94	   heterodimer	   and	   be	   responsible	   for	   some	   of	   the	  
observed	  effects	  could	  not	  be	  formally	  excluded.	  	  
To	  try	  and	  establish	  the	  functional	  consequences	  of	  ligation	  of	  the	  NKG2H	  receptor,	  purified	  
mAb	   specific	   for	   this	   molecule	   was	   immobilised	   on	   plastic	   and	   used	   to	   stimulate	   peripheral	  
blood	   mononuclear	   cells	   derived	   from	   healthy	   donors	   in	   the	   presence	   and	   absence	   of	  
suboptimal	  doses	  of	  a	  stimulatory	  anti-­‐CD3	  mAb.	  	  
	  
	  
3.1 	  Activation of NKG2H expressing cells markedly reduces expression of the 
activation marker CD69 by the other cells in the culture.	  
In	  general,	  optimal	  activation	  of	  T	   cells	   is	   thought	   to	   require	  at	   least	   two	   types	  of	   signals:	  
antigen	  dependent	  signals	  through	  the	  T	  cell	  receptor	  -­‐	  CD3	  complex	  and	  antigen	  independent	  
co-­‐stimulation.	  This	  combination	  of	  stimuli	  can	  be	  modelled	  in	  vitro	  using	  immobilized	  anti-­‐CD3	  
alone	  or	   in	   combination	  with	   immobilized	  anti-­‐CD28	  antibody	   to	   induce	  T	   cell	   activation	  and	  
proliferation	  (Geppert	  et	  al.	  1988;	  Thompson	  et	  al.	  1989).	  
Since	   the	  CD94/NKG2H	   receptor	  was	   found	   to	  be	  preferentially	   expressed	  on	  CD3+	   T	   cells	  
(Fig.	  1B),	  PBMCs	  were	  stimulated	  using	  a	  suboptimal	  dosage	  of	  immobilized	  anti-­‐CD3	  antibody	  
(1	   µg/ml)	   in	   combination	   with	   anti-­‐NKG2H	   antibody	   (5	   µg/ml),	   for	   48h	   or	   72h.	   PBMC	  
stimulation	  with	  either	   immobilized	  anti-­‐CD3	  antibody	  alone	  or	  a	   combination	  of	  anti-­‐CD3	   (1	  
µg/ml)	  and	  anti-­‐CD28	  (1	  µg/ml)	  antibody	  were	  used	  as	  controls.	  Simple	  visual	  inspection	  using	  
light	  microscopy	  revealed	  that	  cultures	  stimulated	  with	  anti-­‐CD3/NKG2H	  antibodies	  appeared	  
far	   less	   activated	   than	   the	   control	   cells	   after	   48h	   of	   stimulation	   and	   these	   differences	  were	  
much	  more	  pronounced	  after	  72h	   (Fig.	  9-­‐A).	  To	  confirm	  that	  cell	   cultures	  stimulated	   through	  
NKG2H	  were	  less	  activated	  than	  the	  cells	  receiving	  anti-­‐CD3	  or	  anti-­‐CD3/CD28	  stimulation,	  the	  



































Fig.	   9:	   Stimulation	   of	   PBMCs	   with	   antibodies	   directed	   to	   CD3	   and	   NKG2H	   decreases	  
lymphocyte	  activation.	   (A)	  Microscope	   images	  of	  PBMCs	   from	  two	  representative	  healthy	  donors	  incubated	   in	  plates	  pre-­‐coated	  with	   anti-­‐CD3	   (1	  µg/ml),	   the	   combination	  of	   anti-­‐CD3	  and	  CD28	   (1	  
µg/ml)	  or	  anti-­‐CD3	  and	  NKG2H	  [(1	  µg/ml)/	  (10	  µg/ml)]	  antibodies	  for	  48h	  (Donor	  1)	  or	  48h	  and	  72h	  (Donor	   2).	   (B)	   Quantification	   of	   the	   percentage	   of	   cells	   expressing	   CD69	   after	   anti-­‐CD3	   or	   anti-­‐CD3/NKG2H	  stimulation.	  Each	  symbol	  corresponds	  to	  the	  result	  obtained	  from	  an	  individual	  donor.	  Mean	  data	  are	  represented,	  n=5;	  *p<0.05.	  a	  -­‐	  anti	  
	  
Analysis	  of	  the	  flow	  cytometry	  staining	  indicated	  a	  significant	  decrease	  of	  the	  percentage	  of	  
CD69+	   cells	   in	   cultures	   stimulated	   with	   anti-­‐CD3/NKG2H	   antibodies	   compared	   to	   cells	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3.2 Activation of NKG2H expressing cells markedly reduces the proliferation of the 
other cells in the culture. 
As	  NKG2H	  stimulation	  was	  observed	  to	  impair	  T	  cell	  activation	  in	  the	  culture,	  the	  effects	  of	  
stimulation	   through	  NKG2H	  on	   the	   cell	  proliferative	   response	  were	  also	  measured.	   For	   these	  
experiments,	   purified	   PBMCs	   were	   stained	   with	   CFSE	   dye	   and	   cultured	   in	   plates	   pre-­‐coated	  
with	   anti-­‐CD3/NKG2H	   or	   anti-­‐CD3	   antibodies.	   	   The	   proliferation	   of	   the	   stimulated	   cells	   was	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These	   data	   showed	   a	   significant	   reduction	   in	   proliferation	   of	   the	   cultured	   cells	   when	  




3.3 Reduced activation of cell in the culture is characteristic for NKG2H but not for 
NKG2A or NKG2C receptor signalling. 
To	   test	   whether	   the	   observed	   reduction	   in	   T	   cell	   activation	   after	   anti-­‐CD3/NKG2H	  
stimulation	   is	  a	  characteristic	  specific	   for	  CD94/NKG2H	  receptor	  signalling,	   these	  experiments	  
were	   repeated	   using	   PBMCs	   cultured	   in	   plates	   where	   combinations	   of	   immobilized	   anti-­‐
CD3/NKG2C	  and	  anti-­‐CD3/NKG2A	  had	  been	  immobilised.	  PBMCs	  were	  once	  again	  purified	  from	  
healthy	  individuals	  and	  plated	  in	  the	  presence	  of	  anti-­‐CD3	  antibody	  or	  anti-­‐CD3	  combined	  with	  
specific	  mAb	  for	  each	  of	  the	  NKG2A,	  -­‐C	  and	  -­‐H	  receptors,	  used	  at	  the	  same	  concentration.	  The	  
percentage	  of	  cells	  induced	  to	  express	  the	  activation	  marker	  CD69,	  was	  significantly	  decreased	  
in	  the	  cell	  cultures	  where	  PBMCs	  were	  co-­‐stimulated	  with	  anti-­‐CD3	  and	  anti-­‐NKG2H	  antibody.	  
In	   contrast,	   the	   phenotype	   of	   the	   PBMCs	   stimulated	   by	   anti-­‐CD3/NKG2C	   or	   anti-­‐CD3/NKG2A	  

















Fig.	  11:	  NKG2H	  but	  not	  NKG2A	  or	  NKG2C	  signaling	   leads	  to	  reduced	  PBMCs	  activation	   in	  the	  
cell	   culture.24	  well	  plate	  was	   covered	  with	  anti-­‐CD3	   (1	  µg/ml),	   anti-­‐CD3/NKG2A	   [(1	  µg/ml)/	   (10	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3.4 Activation of NKG2H+, but not NKG2A+ or NKG2C+ cells induces apoptosis of 
other cells in the culture. 
The	  previous	  observations	  were	   surprising	   since	   they	   indicated	   that	  activation	  of	   the	  0.5	   -­‐	  
1.5%	  of	  T	  cells	  expressing	  NKG2H	  could	  modulate	  the	  activation	  of	  the	  remaining	  99.5	  –	  98.5%	  
of	  T	  cells	  that	  apparently	  did	  not	  express	  NKG2H.	  One	  possible	  solution	  to	  this	  conundrum	  was	  
the	  idea	  that	  NKG2H	  triggering	  could	  result	  the	  induction	  of	  death	  of	  other	  T	  cells.	  To	  test	  the	  
idea	   that	   the	   reduced	   proliferation	   of	   PBMCs	   after	   stimulation	   by	   anti-­‐CD3/NKG2H	   antibody	  
could	  be	  due	  to	  reduced	  cell	  survival,	  purified	  PBMCs	  were	  stimulated	  with	   immobilized	  anti-­‐
CD3	  or	  anti-­‐CD3/NKG2H	  antibodies	  for	  48h	  and	  cell	  survival	  was	  measured	  by	  Annexin	  V/	  7AAD	  


























Fig	   12:	   PBMCs	   cell	   survival	   decreases	   in	   cells	   stimulated	   by	   NKG2H,	   but	   not	   by	   NKG2A	   or	  











Annexin	  V	   7	  AAD	  
39.16	  %	   13.81	  %	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  Stimulation	   of	   PBMCs	   with	   anti-­‐CD3/NKG2A	   and	   anti-­‐CD3/NKG2C	   antibodies	   was	   also	  
carried	  out	  in	  parallel.	  Annexin	  V	  staining	  indicated	  a	  significant	  increase	  of	  cell	  apoptosis,	  when	  
activation	  of	  PBMCs	  was	  done	  in	  the	  presence	  of	  anti-­‐NKG2H	  stimuli.	  In	  contrast,	  no	  significant	  
changes	   in	  cell	  apoptosis	  were	  observed	  in	  anti-­‐NKG2A	  or	  anti-­‐NKG2C	  stimulated	  PBMCs	  (Fig.	  
12-­‐B).	  
	  
3.5 NKG2H action does not depend on soluble factor. 
The	  data	  outlined	  so	  far	  indicate	  that	  cultures	  stimulated	  with	  anti-­‐NKG2H	  antibody	  showed	  
reduced	   activation,	   a	   decreased	   proliferative	   response	   and	   an	   increased	   susceptibility	   to	  
apoptosis.	   These	   multiple	   cellular	   functions	   could	   depend	   either	   on	   soluble	   factors	   or	   they	  
could	  require	  direct	  cell	  contact.	  	  
To	  investigate	  the	  potential	  role	  of	  soluble	  factors	  released	  into	  the	  media	  after	  anti-­‐NKG2H	  
stimulation	   of	   PBMCs,	   supernatants	   collected	   from	   cell	   cultures	   after	   stimulation	  with	   either	  
anti-­‐CD3	  or	  anti-­‐CD3/NKG2H	  antibodies,	  were	  added	  at	  a	  range	  of	  different	  dilutions	  to	  a	  new	  
set	  of	  cell	  cultures.	  No	  differences	  in	  the	  induction	  of	  expression	  of	  the	  activation	  marker	  CD69	  
were	  observed	   in	  any	  of	   the	  conditions	  used	   (Fig.	  13),	   strongly	  suggesting	  that	   the	  release	  of	  
soluble	  factors	  was	  not	  responsible	  for	  the	  NKG2H	  dependent	  reduction	  in	  cell	  activation	  and	  
so,	  by	  elimination,	  cell	  to	  cell	  interaction	  is	  probably	  necessary	  for	  NKG2H	  to	  elicit	  the	  cellular	  















Fig.	  13:	  Reduced	  cell	   activation	   induced	  by	  NKG2H	  stimulation	   is	  not	  mediated	  by	  a	   soluble	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3.6 NKG2H mediated activity is not MHC class I restricted. 
As	  mentioned	  in	  the	  introduction	  MHC	  class	  I	  molecules	  are	  the	  major	  known	  ligands	  for	  the	  
C-­‐type	   lectin	   like	   CD94/NKG2	   heterodimers.	   Therefore	   the	   possibility	   that	   MHC	   class	   I	  
molecules	  could	  also	  be	   interacting	  with	  NKG2H	  was	   tested	  by	   including	  soluble	  MHC	  class	   I-­‐
specific	  blocking	  monoclonal	   antibody	   in	   the	   cultures	  where	  purified	  PBMCs	  were	   stimulated	  
with	   either	   immobilized	   anti-­‐CD3	   or	   anti-­‐CD3/NKG2H	  mAbs.	   Cell	   activation	   was	   assessed	   by	  
staining	  for	  the	  surface	  marker	  CD69	  after	  48h	  stimulation	  of	  PBMCs	  with	  immobilized	  anti-­‐CD3	  















Fig	  14:	  	  Antibodies	  to	  MHC	  class	  I	  did	  not	  recover	  the	  reduced	  cell	  activation	  seen	  after	  NKG2H	  
stimulation.	  Freshly	   purified	   PBMCs	  were	   cultured	   over	   immobilized	   anti-­‐CD3	   (1	  µg/ml)	   or	   anti-­‐CD3/NKG2H	  [(1	  µg/ml)/	  (10	  µg/ml)]	  antibodies	  for	  48h	  in	  the	  presence	  of	  purified	  MHC	  class	  I	  (10	  
µg/ml)	  antibody.	  PBMCs	  cultured	  only	  in	  the	  presence	  of	  purified	  MHC	  class	  I	  antibody	  were	  used	  as	  a	   control.	  Mean	   data	   and	   standard	   deviations	   are	   represented,	   n=2	   in	   one	   experiment.*p<0.05.	   α–	  anti.	  
	  
The	  ability	  of	  the	  cells	  being	  cultured	  in	  the	  presence	  of	  NKG2H	  antibody	  to	  be	  activated	  at	  
levels	  comparable	  with	  the	  control	  was	  not	  recovered,	  strongly	  indicating	  that	  MHC	  class	  I	  are	  
not	  involved	  in	  the	  mechanism	  of	  action	  of	  NKG2H.	  
	  
 
3.7 Strategies for the production of soluble CD94/NKG2H for use in ligand-
hunting experiments. 
In	  light	  of	  the	  previous	  experiments	  a	  key	  question	  was	  the	  identity	  of	  the	  molecule(s)	  with	  
which	   NKG2H	   might	   interact.	   The	   strategy	   chosen	   to	   address	   this	   question	   was	   to	   try	   and	  
produce	   soluble	   CD94/NKG2H	   (sCD94/NKG2H)	   protein	   that	   could	   be	   biotinylated	   and	  
assembled	   into	  tetramers	  for	  use	  as	  a	  fluorescent	  reagent	  that	  would	  permit	   identification	  of	  
cells	  and	  cell	  lines	  that	  were	  expressing	  NKG2H-­‐binding	  proteins.	  Once	  cells,	  preferably	  tumour	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cell	  lines,	  that	  express	  high	  levels	  of	  NKG2H	  ligands	  had	  been	  identified	  two	  possible	  strategies	  
to	  molecularly	  characterize	   the	  NKG2H	   ligands	  could	  be	   followed:	  1)	  expression	  cloning	  using	  
the	  fluorescent	  soluble	  NKG2H	  receptor	  preparations	  to	  identify	  and	  sort	  ligand	  expressing	  cells	  
and	  2)	   the	  production	  of	  monoclonal	  antibodies	   that	  block	  the	  binding	  of	  soluble	  receptor	   to	  
the	   immunizing	  cell	   line	  and	  that	  can	  then	  be	  used	  to	  biochemically	  characterize	  the	  putative	  
ligand	  molecules	   for	  subsequently	  molecular	  or	  proteomic	  approaches,	   to	  definitively	   identify	  
the	  NKG2H	  ligands.	  The	  laboratory	  had	  previously	  developed	  an	  in	  vitro	  system	  to	  express	  and	  
refold	  sCD94/NKG2A	  and	  sCD94/NKG2C	  heterodimers	  (Vales-­‐Gómez	  et	  al.	  1999)	  and	  so	  the	  initial	  
experiments	   aimed	   to	   reconstitute	   CD94/NKG2H	   receptor	   in	   vitro	   using	   purified,	   soluble	  
protein	   produced	   in	   Escherichia	   coli.	   A	   construct	   directing	   expression	   of	   the	   extracellular	  
portion	   of	   the	   NKG2H	   molecule	   modified	   to	   include	   an	   N-­‐terminal	   target	   peptide	   for	  
biotinylation	   by	   the	   BirA	   enzyme	   was	   designed,	   cloned	   and	   sequenced.	   However	   when	  
attempts	  were	  made	  to	  express	  this	  sNKG2H	  protein	   in	  E.	  coli	  as	   inclusion	  bodies,	  no	  protein	  











Systematic	   variation	   of	   the	   temperature	   of	   bacterial	   growth	   as	   well	   as	   changes	   in	   the	  
concentration	  and	  time	  of	  IPTG	  induction	  or	  glucose	  supplementation	  of	  the	  growing	  media	  did	  
not	  lead	  to	  any	  increase	  of	  protein	  yield.	  Similarly,	  modification	  of	  the	  N-­‐terminal	  codons	  to	  use	  
codons	   optimal	   for	   expression	   in	   E.	   coli	   also	   failed	   to	   increase	   NKG2H	   expression.	   Finally,	  
attempts	  to	  isolate	  NKG2H-­‐containing	  inclusion	  bodies	  from	  large-­‐scale	  cultures	  of	  transformed	  
bacteria	  (hoping	  to	  compensate	  for	  low	  yield	  per	  bacteria	  by	  increasing	  the	  numbers	  of	  bacteria	  
in	  the	  culture)	  were	  also	  unsuccessful.	  
Given	   the	   failure	   to	   achieve	   expression	   of	   sNKG2H	   molecules	   in	   prokaryotic	   systems,	   a	  
construct	   was	   prepared	   to	   express	   the	   extracellular	   portion	   of	   the	   NKG2H	   protein	   in	   a	  
Baculovirus	  system.	  For	  these	  experiments	  we	  used	  plasmids	  designed	  to	  secrete	  soluble	  over-­‐
expressed	   proteins	   from	   the	   infected	   cell,	   gifts	   of	   Dr.	   F	   Rodriguez	   Aguirre	   (CNB).	   However,	  
again,	  no	  success	   in	  expression	  of	  sNKG2H	  protein	  was	  achieved.	  These	  observations	  strongly	  
suggest	   that	   factors	   intrinsic	   to	   the	   NKG2H	   sequence	   like	   mRNA	   secondary	   structure,	  
limitations	  in	  the	  intrinsic	  ability	  of	  NKG2H	  to	  fold	  or	  a	  need	  for	  posttranslational	  modifications	  





Fig.	   15:	   SDS-­‐PAGE	   analyzes	   of	   purified	  
CD94	   soluble	   protein.	   CD94	   soluble	  protein	  purified	   from	  the	   inclusion	  bodies	  and	   solubilized	   in	   8	  M	  urea	  was	   analyzed	  by	   12%	   separating	   gel	   (SDS-­‐PAGE).	   	   In	  reducing	   conditions	   the	   CD94	   protein	  appears	  as	  a	  15	  kDa	  band.	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Part II.   Characterization of M. tuberculosis – peptide specific 
HLA-E restricted T cells in bladder cancer patients receiving 
BCG immunotherapy	  
 
Since	   1976,	   immunotherapy	   with	   live	   bacilli	   Calmette	   Guerin	   (BCG)	   has	   proved	   to	   be	   an	  
effective	   adjuvant	   intravesical	   treatment	   to	   prevent	   progress	   and	   relapse	   after	   transurethral	  
resection	  of	  non-­‐muscle	   invasive	  bladder	  cancer	  (Morales	  et	  al.	  1976;	  Sylvester	  et	  al.	  2002;	  Herr	  et	  al.	  
2008).	   The	   antitumor	   effect	   of	   the	   BCG	   therapy	   is	   characterized	   by	   the	   induction	   of	   a	   strong	  
innate	  immune	  response	  (Higuchi	  et	  al.	  2009)	  as	  well	  as	  T	  cell	  infiltration	  into	  the	  bladder	  (Bohle	  et	  
al.	   2003;	   Brandau	   et	   al.	   2007;	   Cooper	   et	   al.	   2009).	   One	   aspect	   of	   this	   therapy	   that	   has	   proved	  
controversial	  is	  whether	  immunity	  to	  tuberculosis	  antigens,	  is	  of	  benefit	  to	  the	  patient.	  Studies	  
evaluating	  how	  the	  appearance	  of	  PPD-­‐reactive	  T	  cells	  after	  intravesical	  therapy	  correlates	  with	  
clinical	   outcome,	   have	   given	   mixed	   results,	   including	   1)	   a	   positive	   correlation	   with	   clinical	  
response	  (Kelley	  et	  al.	  1986;	  Torrence	  et	  al.	  1988;	  Lamm	  et	  al.	  1991),	  2)	  a	  weak	  association	  (Lüftenegger	  et	  
al.	  1996)	  or	  3)	  no	  correlation	  whatsoever	  (Shinka	  et	  al.	  1990;	  Bilen	  et	  al.	  2003).	  In	  agreement	  with	  the	  
last	  set	  of	  studies,	  clinical	  trials	  to	  investigate	  the	  combined	  use	  of	  intravesical	  and	  intradermal	  
(the	  normal	  route	  of	  BCG	  vaccination)	  exposure	  to	  BCG	  showed	  no	  evidence	  that	  an	  enhanced	  
reactivity	   to	  PPD	  was	  associated	  with	  a	  better	   clinical	   response	   in	  bladder	   cancer	   (Lamm	   et	   al.	  
1991;	   Lüftenegger	   et	   al.	   1996).	   However,	   recently	   it	   has	   been	   suggested	   that	   parenteral	  
immunization	   with	   BCG	   to	   generate	   systemic	   immunity,	   before	   initiating	   intravesical	  
instillations	  could	  be	  associated	  with	  an	  improved	  response	  to	  therapy	  (Biot	  et	  al.	  2012).	  	  
In	  view	  of	  this	  contradicting	  data	  in	  the	  literature,	  it	  was	  of	  interest	  to	  revisit	  this	  issue	  taking	  
advantage	   of	   new	   knowledge	   and	   using	   newer	   technologies	   that	   allow	   a	   more	   detailed	  
characterization	  of	  M.	  tuberculosis	  –	  specific	  CD8+	  T	  cells	  induced	  after	  BCG	  instillation	  therapy	  
in	   patients	   with	   bladder	   cancer.	   Assessment	   of	   T	   cell	   functionality	   by	   cytokine	   profiling,	   in	  
addition	  to	  the	  more	  than	  100-­‐years-­‐old	  tuberculin	  skin	  test	  has	  been	  applied	  to	  indicate	  pre-­‐
exposure	  to	  Mtb	  as	  well	  as	  to	  distinguish	  patients	  with	  and	  without	  active	  disease	  (Millington	  et	  
al.	   2007;	   Caccamo	   et	   al.	   2010;	   Day	   et	   al.	   2011;	   Harari	   et	   al.	   2011;	   Sester	   et	   al.	   2011;	   Petruccioli	   et	   al.	   2013).	  	  
Additionally,	  well-­‐defined	  peptide	  epitopes	  and	  tetramers	  have	  already	  been	  used	  for	  detection	  
of	  Mtb	  specific	  T	  cells	   in	  PBMCs	  and	  also	  directly	   in	  situ,	   in	  granuloma	  tissue	  (Geluk	  et	   al.	   2000;	  
Tully	  et	  al.	  2005;	  Hohn	  et	  al.	  2007;	  Caccamo	  et	  al.	  2009).	  Recently,	  this	  finding	  has	  also	  been	  combined	  
with	  IFN-­‐γ	  and	  TNF-­‐α	  detection	  showing	  that	  at	  least	  some	  antigen-­‐specific	  Mtb-­‐specific	  T	  cells	  
produced	  IFN-­‐γ	  and/or	  TNF-­‐α	  (Li	  et	  al.	  2011)	  and	  suggests	  that	  these	  tetramer	  positive	  cells	  may	  
be	  functional	  (Bronke	  et	  al.	  2005).	  
Most	  of	  the	  MHC	  class	  I	  tetramers	  used	  in	  the	  experiments	  mentioned	  above	  are	  complexes	  
of	   HLA-­‐A*02:01	  molecules	   and	   specific	   –	   epitopes,	   derived	   from	  Mtb,	   that	   bind	   to	   this	   HLA	  
allele.	   However,	   the	   non-­‐classical	   HLA-­‐E	   protein	   has	   been	   also	   shown	   to	   present	   peptides	  
derived	  from	  Mtb,	  leading	  to	  expansion	  of	  HLA-­‐E	  restricted	  CD8+	  T	  cell	  clones	  (Heinzel	  et	  al.	  2002).	  
Thus,	   it	   seemed	   reasonable	   to	   hypothesize	   that	   the	   use	   of	   tetramers	   comprising	   of	   HLA-­‐E	  
loaded	  with	  Mtb-­‐derived	  peptide	  epitopes	  could	  be	  a	  simple	  approach	  to	  detect	  Mtb-­‐reactive	  T	  
cells	  in	  a	  wide	  variety	  of	  patients	  given	  that	  HLA-­‐E	  displays	  only	  very	  limited	  polymorphism.	  This	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approach	  was	  made	  possible	  by	  the	  characterization	  of	  a	  large	  panel	  of	  Mtb	  derived	  peptides	  
presented	  by	  HLA-­‐E	  molecules	  and	  recognized	  by	  CD8+	  T	  cells	  by	  Joosten	  et	  al.	  at	  2010.	  	  
To	  generate	   tetrameric	   complexes	  using	  peptides	  epitope	   reported	   to	  have	  a	  high	  binding	  
affinity	   for	   HLA-­‐E,	   three	   peptides,	   p55	   (VMATRRNVL)	   (HLA-­‐E/p55),	   p62	   (RMPPLGHEL)	   (HLA-­‐
E/p62)	  and	  p68	   (VLRPGGHFL)	   (HLA-­‐E/p68)	  were	  selected	  and	   refolded	  with	  HLA-­‐E	   in	  vitro	   for	  
subsequent	   assembly	   into	   fluorescent	   tetramer	   complexes	   (Fig.	   16-­‐B	   and	   Table	   1).	   We	   also	  
prepared	   a	   control	   HLA-­‐E	   tetramer,	   using	   a	   nonameric	   peptide	   derived	   from	   the	   signal	  
sequence	   of	   HLA-­‐B*0702	   (HLA-­‐E/B*07),	   that	   is	   known	   to	   strongly	   bind	   and	   induce	   surface	  
expression	  of	  HLA-­‐E	  (Fig.	  16	  and	  Table	  1)	  (Braud	  et	  al.	  1997;	  Borrego	  et	  al.	  1998;	  Braud	  et	  al.	  1998(1);	  Lee	  et	  
al.	   1998(1)(2);	   Vales-­‐Gomez	   et	   al.1999).	  Unfortunately,	  although	   the	  p55	  peptide	  was	   reported	   to	  be	  
recognized	  by	  T	  cells	  from	  Mtb-­‐exposed	  donors	  in	  an	  HLA-­‐E	  restricted	  manner	  this	  peptide	  did	  
not	   refold	   HLA-­‐E	   efficiently	   and	   so	   reactivity	   with	   this	   peptide/HLA-­‐E	   complex	   could	   not	   be	  
studied	   further.	  Once	   generated,	   these	   tetramers	  were	   first	   tested	   for	   specific	   binding	   using	  
whole	   blood	   from	  healthy	   individuals	   immunized	   or	   not	  with	   Bacillus	   Calmette	  Guerin	   (BCG)	  
vaccine	  and	  later	  tetramer	  reactivity	  with	  PBMCs	  from	  9	  bladder	  cancer	  patients	  who	  received	  
BCG-­‐instillation	  therapy	  (mean	  age	  72	  years)	  was	  studied.	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Fig.	  16:	  SDS-­‐PAGE	  analyses	  of	  recombinant	  HLA-­‐E	  soluble	  protein	  after	  refolding	  in	  vitro	  (A).	  HLA-­‐E	   soluble	   protein	   refolded	  with	  HLA-­‐B*0702	   peptide	  was	   analysed	   by	   12%	   SDS-­‐PAGE	   before	  protein	   purification	   by	   size	   exclusion	   chromatography.	   SDS-­‐PAGE	  was	   run	   in	   reducing	   conditions.	  The	  position	  and	  the	  size	  of	  the	  heavy	  chain	  (HC)	  and	  β2m	  are	  indicated.	  (B	  and	  C)	  Purification	  of	  






















HLA-­‐E	  /Peptide	  sequence	  
Size-­‐exclusion	  Chromatography	  
Ion-­‐exchange	  Chromatography	   Refolded	  monomer	  (mg)	  Peak	  Area	  /mAU*min	   Peak	  Area	  /mAU*min	  
VMAPRTVLL	  
(HLA-­‐B*0702)	   25425	   216	   0.7	  
VLRPGGHFL	  
(Mtb-­‐p62)	   182	   82	   0.18	  
RMPPLGHEL	  




Table	  1.	  Summary	  of	  the	  purification	  steps	  and	  
final	  yield	  of	  HLA-­‐E	  refolded	  monomers	  	  A	   B	   C	   D	   E	  
BP	  
Biotinylated	  protein	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1. M. tuberculosis specific CD8+ T cells in healthy individuals 
immunized or not with BCG. 
Bacillus	  Calmette-­‐Guerin	  (BCG)	  is	  a	  live	  vaccine	  derived	  from	  a	  strain	  of	  Mycobacterium	  bovis	  
that	   was	   attenuated	   by	   Calmette	   and	   Guerin	   at	   the	   Pasteur	   Institute	   after	   passaging	   for	   12	  
years	   and	   was	   first	   administrated	   to	   humans	   in	   1921	   (Grange	   et	   al.	   1983).	   Although	   all	   the	  
currently	   used	   vaccines	   are	   derived	   from	   the	   original	   BCG	   strain,	   they	   differ	   in	   their	  
characteristics	   when	   grown	   in	   culture	   and	   in	   their	   ability	   to	   induce	   an	   immune	   response	   to	  
tuberculin.	  	  
The	  possible	  existence	  of	  Mtb-­‐primed	  T	  cells	   in	  healthy	  people	  being	  vaccinated	  with	  BCG	  
should	  have	  allowed	  us	  to	  test	  for	  reactivity	  with	  HLA-­‐E	  tetramers	  loaded	  with	  M.	  tuberculosis	  
peptides	   p62	   and	   p68.	  We	   collected	   blood	   samples	   from	   6	   adult	   volunteers	   who	   had	   been	  
vaccinated	  with	  BCG	  in	  the	  first	  year	  of	  life.	  The	  average	  time	  between	  last	  vaccination	  and	  the	  
blood	  test	  was	  27	  years.	  A	  group	  of	  3	  healthy	  volunteers	  with	  no	  history	  of	  exposure	  to	  BCG	  or	  
M.	  tuberculosis	  infection	  acted	  as	  controls.	  
Flow	  cytometry	  staining	  of	  whole	  blood	  samples	  using	  HLA-­‐E/p62	  -­‐,	  HLA-­‐E/p68	  -­‐	  tetramers	  
did	  not	  detect	  BCG-­‐specific	  CD8+	  T	  cells	  in	  any	  of	  the	  healthy	  donors.	  Nevertheless,	  CD8+	  T	  cells	  
reactive	  with	  the	  HLA-­‐E-­‐	  HLA-­‐B*0702	  peptide	  could	  be	  observed	  in	  one	  of	  the	  examined	  donors	  
(Fig.	  17-­‐A).	  This	   likely	  reflects	  expression	  of	  CD94/NKG2A	  heterodimers	  by	  a	  subpopulation	  of	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Fig.	  17:	  Screening	  of	  Mycobacterium	  tuberculosis	  specific	  CD8+	  T	  cells	   in	  blood	  from	  healthy	  
volunteers	   previously	   exposed	   or	   not	   to	   the	   pathogen	   using	   tetrameric	   complexes.	   (A)	  Representative	   flow	   cytometry	   dot	   plots	   for	   tetramer	   staining	   of	   PBMCs.	   (B)	  Quantification	   of	   the	  percentage	   of	   tetramer+	   cells	   among	   CD8+	   T	   cells	   found	   in	   peripheral	   blood	   from	   healthy	   BCG	  no/vaccinated	   donors.	   Each	   symbol	   corresponds	   to	   the	   result	   obtained	   from	   an	   individual	   donor.	  Mean	  data	  are	  represented,	  n=6	  in	  one	  experiment..	  	  	  
The	  percentages	  of	  HLA-­‐E/p62	  -­‐,	  HLA-­‐E/p68	  -­‐	  and	  HLA-­‐E/B*07	  tetramer	  positive	  cells	  among	  
the	  CD8+	  T	  cells	  between	  different	  groups	  of	  donors	  did	  not	  show	  any	  significant	  difference	  (Fig.	  
17-­‐B).	   This	   result	   was	   not	   entirely	   unexpected	   as	   numerous	   results	   obtained	   in	   controlled	  
clinical	   trials	  have	  shown	  that	  BCG	  driven	  protective	   immunity	  diminishes	  with	   the	  age	  and	  a	  
booster	   tuberculosis	  BCG	  vaccine	   is	  needed	   to	   induce	  measurable	  protection	  against	   virulent	  
bacteria	  in	  adults	  vaccinated	  with	  BCG	  when	  neonates	  (Mangtani	  et	  al.	  2013).	  However	  this	  result	  
meant	  that	   there	  was	  no	  positive	  control	   for	  staining	  of	  PBMCs	  using	  these	  tetramers.	  To	  try	  
and	   increase	   the	   frequency	   of	   BCG	   reactive	   T	   cells	   before	   staining,	   PBMC	   from	   a	   vaccinated	  
individual	  were	  restimulated	  with	  live	  BCG	  for	  5	  and	  12	  days	  in	  culture,	  before	  staining	  with	  the	  
teramers,	  but	  again	  no	  convincingly	  positive	  population	  was	  identified.	  
	  
	  
2. Screening for tetramer+ cells among T cell in blood from patients 
with bladder cancer receiving instillations of live BCG   
Simultaneous	   with	   the	   above	   experiments	   a	   group	   of	   nine	   patients	   with	   bladder	   cancer	  
receiving	  BCG	  therapy	  was	  screened	  for	  the	  existence	  of	  Mtb-­‐peptide	  specific	  HLA-­‐E	  restricted	  
T	   cells	   using	   HLA-­‐E/p62	   -­‐	   and	   HLA-­‐E/p68	   -­‐	   tetramers.	   The	   characteristics	   of	   the	   patients	  
included	  in	  this	  study	  are	  presented	  in	  Table	  1	  (Materials	  and	  Methods).	  Samples	  of	  peripheral	  
blood,	  collected	  before	  each	   instillation	  as	   indicated	   in	  Material	  and	  Methods,	  were	  analysed	  
by	   flow	   cytometry	   for	   the	   presence	   of	   tetramer	   reactive	   T	   cell	   populations.	   Tetramer+	   cells	  
could	   be	   detected	   at	   frequencies	   as	   low	   as	   0.01%	   of	   gated	   cells.	   The	   observed	   range	   of	  
tetramer	  percentage	  values	  in	  this	  study	  was	  0.03-­‐0.22%	  (mean	  0.08±0.05)	  for	  HLA-­‐E/p62-­‐Tet+	  
CD8+cells,	   0.01-­‐0.07%	   (mean	   0.04±0.04)	   for	   HLA-­‐E/p68-­‐tet+	   CD8+	   cells	   and	   0.5-­‐8.7%	   (mean	  
2.3±2.8)	   for	  HLA-­‐E/B*07	   -­‐tet+	   CD8+	   cells.	  When	   the	  percentage	  of	  Mtb	   Tet+	   CD8+	   T	   cells	  was	  
analysed	   in	   detail,	   little	   correlation	   between	   the	   frequencies	   of	   tetramer+	   cells	   at	   different	  
patients	  at	  the	  same	  time	  point	  of	  BCG	  instillations	  was	  found	  (Fig.	  18).	  Further,	  no	  correlation	  
between	  Mtb	  tetramer+	  cells	  and	  the	  time	  points	  of	  instillation	  within	  the	  course	  of	  treatment	  
of	  a	  single	  patient	  was	  observed.	  However,	  in	  some	  of	  the	  patients	  a	  small	  increase	  of	  the	  HLA-­‐
E	   restricted	  T	   cells	   could	  be	  observed	  during	   the	   resting	  period,	  between	   the	   two	  courses	  of	  
BCG	   instillations.	   The	   percentage	   of	   these	   cells	   tends	   to	   drop	   again	   between	   two	   BCG	  
instillations	   in	   the	   same	   course.	   This	   observation	   might	   be	   explained	   if	   activated,	   HLA-­‐E	  
restricted	  T	  cells	  infiltrate	  into	  the	  bladder	  after	  intravesical	  instillations	  of	  live	  BCG	  and	  so	  only	  
a	   very	   low	   number	   of	   these	   cells	   can	   be	   found	   circulating	   in	   the	   blood	   stream.	   Previous	  
investigations	  have	   suggested	   that	   for	   robust	   T	   cells	   infiltration	  of	   the	  bladder	  wall	   repeated	  
instillations	  with	  live	  BCG	  were	  necessary	  (Biot	  et	  al.	  2012).	  This	  might	  also	  explain	  the	  observed 



































Fig.	   18:	  Plots	   showing	   the	   variations	  over	   time	   in	   the	  percentages	  of	  HLA-­‐E/p62	   tet+	   cells,	  
HLA-­‐E/p68	  tet+	  cells	  and	  HLA-­‐E/B*07	  tet+	  cells	  among	  CD8+	  T	  cells	  in	  bladder	  cancer	  patients	  
receiving	   therapy	   with	   live	   BCG.	   Whole	   blood	   samples	   from	   the	   patients	   were	   stained	   as	  indicated	   in	   ¨Material	   and	   Methods¨.	   For	   each	   individual	   donor	   the	   percentage	   of	  tetramer+CD8+cells	  was	   assessed	   at	   the	   different	   time	  points.	  Numbers	   in	   the	   X-­‐axis	   indicate	   the	  different	   BCG	   instillations.	   The	   blood	   sample	   was	   collected	   from	   the	   patients	   before	   each	  instillation.	  Each	  symbol	  corresponds	  to	  one	  individual	  donor.	  Inset:	  Representative	  flow	  cytometry	  dot	  plot	  of	  the	  HLA-­‐E/p62	  tet+	  CD8+	  T	  cells	  in	  one	  of	  the	  patients	  showing	  expansion	  of	  these	  cells	  at	  B6.1	  and	  B7.1	  time	  points.	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variation	  in	  the	  frequency	  of	  HLA-­‐E	  restricted	  T	  cells	  found	  in	  the	  blood	  stream	  of	  the	  patients	  
at	   the	   beginning	   of	   the	   anti-­‐bladder	   cancer	   BCG	   treatment.	   Importantly,	   the	   pre-­‐existing	  
cellular	  immunity	  towards	  PPD	  for	  the	  patients	  included	  in	  this	  study	  is	  unknown.	  Thus	  it	  is	  also	  
possible	  that	  the	  tetramer+	  cells	  detected	  in	  the	  blood	  of	  some	  of	  the	  patients	  before	  receiving	  
their	   first	   instillation	   of	   BCG	   are	  memory	   T	   cells	   generated	   during	   prior	   exposure	   to	   Bacillus	  
Calmette	  Guerin	  (BCG)	  vaccine	  or	  M.	  tuberculosis	  infection.	  Another	  possibility	  is	  that	  although	  
the	   HLA-­‐E	   binding	   peptide	   epitopes	   used	   in	   this	   study	   were	   chosen	   because	   they	   were	  
commonly	  recognized	  by	  a	  panel	  of	  Mtb	  exposed	  donors	  (Joosten	  et	  al.	  2010),	  it	  could	  be	  that	  the	  
pattern	  of	  epitopes	  recognized	  after	  intravesical	  instillation	  is	  different,	  or	  simply	  that	  although	  
HLA-­‐E	   restricted	   CD8+	   T	   cell	   responses	   are	   found	   in	  Mtb	   infection,	   these	   responses	   are	   not	  
generated	   efficiently	   in	   these	   bladder	   cancer	   patients.	   Again	   perhaps,	   the	   route	   of	  
immunization	   may	   influence	   the	   nature	   of	   the	   immune	   response	   made	   to	   BCG	   in	   these	  
patients.	  It	  should	  also	  be	  remembered	  that	  there	  was	  no	  positive	  control	  for	  the	  staining	  with	  
the	  Mtb	  tetramers	  and	  so	  the	  possibility	  that	  the	  lack	  of	  staining	  of	  the	  patient	  samples	  reflects	  
some	  problem	  (e.g.	  stability	  or	  folding)	  with	  these	  tetramers	  cannot	  be	  excluded.	  
Finally	   it	   is	   also	   interesting	   to	  note	   that	   expansions	  of	   CD8+	   T	   cells	   reactive	  with	   the	  HLA-­‐
E/B*07	  -­‐	  tetramer	  are	  observed	  in	  some	  patients	  during	  the	  course	  of	  treatment.	  Previous	  data	  
(Valés-­‐Gómez	   et	   al.	   1999)	   showed	   that	   although	   HLA-­‐E	   molecules	   loaded	   with	   the	   HLA-­‐B*0702	  
peptide	   bind	   both	   CD94/NKG2A	   and	   CD94/NKG2C	   receptor,	   the	   binding	   to	   the	   CD94/NKG2A	  
heterodimer	   is	  of	  markedly	  higher	  affinity.	  Thus	   it	  seems	  reasonable	  to	  suggest	  that	  the	  HLA-­‐
E/B*07	   tetramer	   staining	   observed	   most	   probably	   corresponds	   to	   CD8+	   T	   cells	   that	   express	  
inhibitory	  CD94/NKG2A	  receptors.	  
CD8+	  T	  cells	  that	  express	  CD94/NKG2A	  receptors	  generally	  correspond	  to	  a	  subset	  of	  CD8+	  T	  
cells	  with	   an	   activated/memory	   (CD44hi)	   phenotype	   (Braud	   et	   al.	   2003).	   Although	   naive	   CD8+	   T	  
cells	  can	  express	  CD94/NKG2A	  receptors	  after	  TCR	  engagement	  (McMahon	  et	  al.	  2002;	  Moser	  et	  al.	  
2002;	   Wojtasiak	   et	   al.	   2004;	   Zhou	   et	   al.	   2008)	   and	   CD94/NKG2A	   expression	   can	   be	   modulated	   by	  
cytokine	  treatment:	  incubation	  with	  IL-­‐21	  triggers	  CD94/NKG2A	  up-­‐regulation,	  whereas	  IL-­‐4	  or	  
TGF-­‐beta	   leads	   to	   receptor	   down-­‐regulation	   (Brady	   et	   al.	   2004;	   Gays	   et	   al.	   2005),	   TCR	   interaction	  
seems	  to	  be	  a	  prerequisite	  for	  induction	  of	  expression	  of	  CD94/NKG2A	  by	  T	  cells	  in	  vivo.	  	  
In	  parallel	  to	  this	  work,	  other	  members	  of	  the	  laboratory	  have	  studied	  the	  distribution	  of	  a	  
range	  of	  different	  markers	  expressed	  on	  the	  cell	  surface	  of	  leukocytes	  circulating	  in	  the	  blood	  of	  
these	  patients.	  Thus,	  we	  analysed	   the	  changes	   in	   the	  expression	  of	   the	  CD94	   receptor	   in	   the	  
blood	  of	  the	  studied	  bladder	  cancer	  patients	  and	  tried	  to	  correlate	  these	  data	  to	  the	  observed	  
HLA-­‐E/B*07	  –	   tetramer+	   staining	  of	  CD8+	  T	   cells.	   	   This	   analysis	  has	  proved	   to	  be	   complicated	  
since	  not	  only	  the	  percentage	  of	  CD94+	  cells	  varied	  widely	  between	  the	  different	  patients	  but	  
also	  these	  patients	  expressed	  distinct	  subsets	  of	  T	  cells,	  as	  defined	  by	  their	  CD94	  surface	  levels	  
(CD94+,	  CD94dim,	  CD94high+,	  CD94high++)	  (Fig.	  19-­‐A).	  Moreover,	  for	  technical	  reasons,	  the	  cocktail	  
of	  antibodies	  used	  for	  staining	  patient	  blood	  that	  included	  CD94,	  did	  not	  contain	  CD8	  and	  this	  
obviously	   further	   complicated	   comparison	   of	   the	   staining	   experiments	   using	   HLA-­‐E/B*07	  
tetramers	  and	  CD94	  mAb. 	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Fig.	  19:	  Expression	  of	  the	  CD94	  receptor	  on	  CD3+CD56-­‐CD4-­‐	  T	  cells	  in	  bladder	  cancer	  patients	  
receiving	   BCG	   immunotherapy.	   (A)	   Representative	   flow	   cytometry	   dot	   plots	   and	   histograms	  showing	  the	  different	  patterns	  of	  expression	  of	  the	  CD94	  receptor	  in	  the	  blood	  of	  two	  bladder	  cancer	  patients	  undergoing	  BCG	  treatment.	  (B)	  Whole	  blood	  samples	  from	  the	  patients	  were	  stained	  using	  combination	   of	   the	   following	   antibodies:	   anti-­‐CD3-­‐FITC,	   anti-­‐CD56-­‐PE,	   anti-­‐CD4-­‐PerCP/Cy5.5	   and	  CD94-­‐APC.	  For	  every	  individual	  donor	  the	  percentage	  of	  CD94dim+	  and	  CD94hi+	  cells	  among	  CD3+CD56-­‐CD4-­‐	   cells	   was	   assessed	   across	   the	   different	   time	   points.	   Numbers	   in	   the	   X-­‐axis	   indicate	   the	   time	  points	   of	   each	   BCG	   instillation.	   The	   blood	   sample	   was	   collected	   from	   the	   patients	   before	   each	  instillation.	  Each	  symbol	  corresponds	  to	  the	  result	  obtained	  from	  an	  individual	  donor.	  
Two	  NK	   cell	   subsets,	   defined	   by	   their	   level	   of	   CD94	   expression,	  were	   described	   by	   Perez-­‐
Villar	  et	  al.	  1996;	  NK	  cells	  with	  high	  levels	  of	  CD94	  corresponded	  to	  CD94/NKG2A	  expressing	  NK	  
cells	  and	  cells	  with	  low	  levels	  of	  CD94	  were	  enriched	  for	  CD94/NKG2C+	  NK	  cells.	  Similarly,	  T	  cells	  
with	   different	   levels	   of	   CD94	   expression	   have	   also	   been	   described	   (Jabri	   et	   al.	   2002).	   NKG2A	  
transcripts	  were	   specifically	   found	   in	   CD94high	   αβ+	   T	   cells,	   but	   this	   population	   also	   expressed	  
NKG2C	   and	   NKG2E	   (or	   NKG2H,	   the	   oligonucleotides	   used	   for	   PCR	   would	   not	   distinguish	  
between	  NKG2E	  and	  NKG2H).	  CD94dim	  T	  cells	  expressed	  NKG2C	  and/or	  NKG2E/NKG2H,	  but	  not	  
NKG2A	  transcripts.	  There	  are	  also	  some	  NKG2-­‐	  T	  cell	  clones	  expressing	  CD94	  homodimers	  (Jabri	  
et	  al.	  2002).	  As	  described	  for	  NK	  cells,	  redirected	  lysis	  assays,	  where	  the	  TCR	  was	  co-­‐crosslinked	  
with	   CD94,	   demonstrated	   that	   CD94+	   T	   cells	   could	   be	   divided	   into	   three	   functionally	   distinct	  
subsets	   based	   on	   the	   expression	   of	   inhibitory	   CD94high	   NKG2A	   receptors,	   activating	   CD94low	  
NKG2C/E	   receptors,	   or	   non-­‐functional	   CD94	   homodimers.	   CD94	   engagement	   in	   clones	  
expressing	  both	  inhibitory	  NKG2A	  and	  activating	  NKG2C,	  E	  resulted	  in	  TCR	  inhibition,	  thus	  the	  
inhibitory	   phenotype	   appears	   to	   be	   dominant.	   Analyses	   of	   the	   TCR	   repertoire	   expressed	   by	  
these	   clones	   revealed	   that	   commitment	   to	   inhibitory	   NKG2A	   expression	   was	   an	   attribute	  
acquired	  after	  TCR	  expression	  and	  during	  antigen	  encounter,	  whereas	  actual	  surface	  expression	  
depended	   on	   recent	   TCR	   engagement.	   CTL	   clones	   expressing	   sequence-­‐related	   TCR,	   and	   so	  
probably	   specific	   for	   the	   same	   antigens,	   invariably	   shared	   the	   same	   NKG2A	   commitment	  
suggesting	  that	  TCR	  antigenic	  specificity	  dictates	  NKG2A	  commitment,	  which	  critically	  regulates	  
subsequent	  activation	  of	  CTL	  (Jabri	  et	  al.	  2002).	  
In	  the	  experiments	  staining	  bladder	  cancer	  patients,	  some	  of	  the	  expansions	  of	  CD8+	  T	  cells	  
reactive	  with	  the	  HLA-­‐E/B*07	  -­‐	  tetramer	  could	  be	  correlated	  with	  the	  change	  of	  the	  cell	  surface	  
expression	  of	  CD94high+CD3+CD56-­‐CD4-­‐	  cells	  seen	  in	  some	  of	  the	  patients	  and	  so	  could	  illustrate	  
change	   of	   the	   levels	   of	  NKG2A+	   T	   cells	   (Fig.	   19-­‐B).	  However,	   in	   one	   of	   the	   patients	   the	  HLA-­‐
E/B*07	   -­‐	   tetramer	   staining	   displayed	   the	   same	   pattern	   of	   recognition	   of	   CD94high+CD3+CD56-­‐
CD4-­‐	   (NKG2A+)	   as	   for	   CD94dim+CD3+CD56-­‐CD4-­‐	   (NKG2C+)	   T	   cells.	   This	   could	  mean	   that	   NKG2C	  
receptor	   expressed	   on	   T	   cells	   in	   this	   patient	   is	   not	   only	   expressed	   in	   higher	   percentage	  
compared	   to	   the	   other	   patients	   but	   also	   has	   an	   increased	   affinity	   for	   HLA-­‐E/B*07	   ligand.	  
Alternatively,	   this	   staining	   could	   be	   due	   to	   CD94/NKG2A	   receptor	   expression	   that,	   for	   some	  
reason	   (e.g.	   cytokine	  modulation),	   is	   dull	   on	   the	   T	   cells	   of	   this	   individual	   at	   this	   time	   point.	  
These	   analyses	   are	   very	   complex,	   since	   CD94high	   from	   CD94dim	   subpopulation	   could	   not	   be	  
separated	   clearly	   in	   each	   patient.	  Moreover,	   in	   some	   patients	   the	   existence	   of	   CD94high++cell	  
subpopulation	   as	   well	   as	   changes	   in	   the	   percentages	   of	   these	   cells	   varied	   during	   the	   time	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course	   of	   the	   instillations	   (Fig.	   19-­‐A)	   (data	   not	   shown).	   	   As	   these	   results	   are	   from	   a	   study	  
currently	  underway,	  it	  would	  be	  interesting,	  and	  feasible,	  to	  modify	  future	  analyses	  to	  include	  
more	  markers	   like	  anti-­‐NKG2A/NKG2C/NKG2H	  antibodies	   to	  more	   fully	  characterise	  the	  CD94	  
expressing	  T	  cell	  subpopulations.	  
The	  significance	  of	  induced	  expression	  of	  immunoregulatory	  molecules	  such	  as	  CD94/NKG2A	  
on	  CD8+	  T	  cells	  is	  not	  fully	  understood,	  but	  it	  is	  generally	  thought	  that	  these	  receptors	  restrain	  
CD8+	   responses,	   so	   preventing	   T-­‐cell	   exhaustion	   in	   chronic	   infections	   and	   limiting	  
immunopathology.	  NKG2	  -­‐receptors	  has	  also	  been	  implicated	  in	  the	  cell	  survival	  of	  both	  NK	  and	  
CD8	   T	   cells.	   It	   was	   found	   that	   the	   extent	   of	   apoptosis	   in	   CD8+	   T	   and	   NK	   cells	   was	   inversely	  
related	  to	  the	  expression	  of	  CD94,	  with	  lower	  levels	  of	  apoptosis	  seen	  in	  CD94high	  cells	  after	  1-­‐3	  
days	  of	  culture.	  This	  correlation	  between	  CD94/NKG2	  expression	  and	  lower	  levels	  of	  apoptosis	  
may	   reflect	   an	   important	   role	   of	   these	   receptors	   in	   the	  maintenance	  of	   CD8+	   T	   and	  NK	   cells	  
(Lohwasser	  et	  al.	  2001;	  Gunturi	  et	  al.	  2003;	  Gunturi	  et	  al.	  2004;	  Gupta	  et	  al.	  2012).	  Moreover,	  as	  mentioned	  
above,	   expression	   of	   CD94/NKG2A	   heterodimers	   at	   the	   cell	   surface	   reflects	   recent	   TCR	  
engagement	   (Jabri	   et	   al.	   2002),	   thus	   the	   HLA-­‐E/B*07	   -­‐	   tetramer	   staining	   may	   be	   identifying	  
recently	  stimulated	  T	  cells.	  In	  the	  context	  of	  these	  cancer	  patients	  it	  is	  not	  currently	  possible	  to	  
know	   whether	   this	   expression	   of	   CD94/NKG2	   receptors	   is	   associated	   with	   a	   net	   positive	   or	  
negative	   effect,	   but	   as	   the	   study	   progresses	   it	   will	   be	   interesting	   to	   compare	   the	   clinical	  
outcome	  of	  those	  patients	  that	  have	  experienced	  CD94/NKG2A/NKG2C/NKG2H	  upregulation	  on	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CD94/NKG2H	  C-­‐type	  lectin	  like	  receptor	  complex	  and	  HCMV	  infection	  
NKG2H,	  a	  splice	  variant	  of	  NKG2E	  was	  described	  by	  Bellon	  et	  al.	  at	  1999.	  However,	   to	  our	  
knowledge,	   no	   follow-­‐up	   studies	   have	   been	   published,	   presumably	   the	   lack	   of	   a	   specific	  
monoclonal	  antibody	  is	  the	  main	  reason	  that	  has	  severely	  restricted	  progress	  in	  understanding	  
the	  immunological	  function	  of	  this	  receptor.	  In	  this	  work	  using	  a	  newly	  commercially	  available	  
anti-­‐NKG2H	  monoclonal	  antibody,	  the	  phenotypic	  properties	  and	  to	  some	  extent	  the	  functional	  
capacity	  of	  lymphocytes	  expressing	  the	  NKG2H	  receptor	  has	  been	  studied	  and	  defined.	  
NKG2H	  was	  found	  to	  be	  expressed	  at	  low	  levels	  on	  the	  surface	  of	  a	  small	  fraction	  of	  PBMCs	  
derived	   from	  healthy	  donors.	  Although	   some	  expression	  of	  NKG2H	  was	  detected	  on	  NK	   cells	  
and	  CD4+	  T	  cells,	  this	  molecule	  was	  preferentially	  expressed	  on	  CD3+CD56+	  and	  CD3+CD8+	  cells	  
implying	   that	   the	  signals	  controlling	   the	  expression	  of	  NKG2H	  receptor	  on	  the	  cell	   surface	  do	  
not	  operate	  equally	   in	  NK	  and	  T	  cell	  subsets.	   Interestingly,	  NKG2H	  protein	  was	  first	   identified	  
and	   the	   cDNA	   obtained	   from	   a	   human	   TCRαβ	   CD8+	   T	   cell	   clone	   (TCC)	   (Bellón	   et	   al.	   1999).	  
Moreover,	   both	   CD94/NKG2A	   and	   CD94/NKG2C	   NK	   cell	   heterodimeric	   receptors	   have	   been	  
described	  to	  be	  expressed	  and	  functional	  in	  αβ	  and	  γδ	  CD8+	  T	  cells	  populations	  (Poccia	  et	  al.	  1997;	  
Noppen	  et	   al.	   1998;	  Uhrberg	  et	   al.	   2001;	   Jabri	   et	   al.	   2002;	  Guma	  et	   al.	   2005;	  Moser	  et	   al.	   2002;	  Meresse	  et	   al.	  
2006).	   In	  αβ	   T	   cells	   the	   expression	  of	  NKG2A	  and	  NKG2C	   is	   different,	   so	   that	   CD94/NKG2C	   is	  
expressed	   by	   highly	   differentiated	   CD8+	   effector	   T	   cells	   whereas	   CD94/NKG2A	   is	   present	   on	  
effector	  cells	  as	  well	  as	  on	  memory	  cells	  (Arletazz	  et	  al.	  2004).	  Additionally,	  it	  has	  been	  shown	  that	  
both	   types	   of	   receptors	   are	   expressed	   at	   different	   moments	   during	   γδ	   T	   cell	   effector	  
differentiation	   and	   function	   (Angelini	   et	   al.	   2010).	   It	   remains	   to	   be	   defined	   whether	   NKG2H	  
molecule	  expression	  is	  stochastic	  or	  restricted	  to	  naive,	  memory	  or	  some	  effector	  subset	  of	  αβ	  
and/or	  γδ	  T	  cells,	  and	   if	  CD94/NKG2H	  heterodimer	  can	  be	  co-­‐expressed	  or	  not	  on	   these	  cells	  
with	  the	  other	  members	  of	  this	  receptor	  family.	  One	  note	  of	  caution	  that	  should	  be	  borne	   in	  
mind	   for	   these	   experiments	   is	   that	   currently	   only	   one	   mAb	   specific	   for	   NKG2H	   has	   been	  
described.	   This	   mAb	   was	   raised	   against	   a	   peptide	   sequence	   that	   is	   specific	   for	   NKG2H	  
(corresponds	  to	  the	  last	  23	  amino	  acids	  of	  the	  extracellular	  domain;	  TBLASTN	  search	  22nd	  July	  
2014)	   and	   as	   has	   been	   shown	   by	   the	   manufacturer,	  
(http://www.rndsystems.com/ScientificPoster_nkg1_family.aspx)	   does	   not	   stain	   NKG2A	   or	  
NKG2C	   transfectants.	   This	   observation	   was	   confirmed	   using	   RBL	   cell	   transfected	   with	   CD94,	  
CD94/NKG2A	  and	  CD94/NKG2C	  (gifts	  of	  Miguel	  López-­‐Botet,	  UPF,	  Barcelona)	  before	  beginning	  
the	  experiments	  presented	  in	  this	  thesis	  (data	  not	  shown).	  
Evidence	   is	   accumulating	   that	   indicates	   that	   HCMV	   infection	   is	   associated	   with	   a	   stable	  
reshaping	  of	  the	  repertoire	  of	  receptors	  expressed	  by	  NK	  cells,	  leading	  to	  a	  variable	  expansion	  
of	  NKG2C+	  NK	  and	  T	  cell	  subsets	  in	  HCMV	  seropositive	  healthy	  individuals	  (Guma	  et	  al.	  2004)	  and	  
aviremic	  HIV-­‐1	  infected	  patients	  (Guma	  et	  al.	  2006(2);	  Mela	  et	  al.	  2007;	  Muntasell	  et	  al.	  2013(1);	  Lopez-­‐Botet	  
et	  al.	  2014).	  The	  structural	  similarity	  between	  NKG2H	  and	  NKG2C	  suggested	  the	  possibility	  that	  
HCMV	   infection	  may	   also	   influence	   NKG2H	   expression	   by	   the	   cells	   present	   in	   the	   PBMC.	   To	  
address	   this	   idea,	   we	   stimulated	   purified	   PBMCs	   with	   HCMV	   infected	   fibroblasts;	   an	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experimental	   system	   previously	   employed	   to	   study	   virus-­‐specific	   CTLs	   (Walter	   et	   al.	   1995)	   and	  
already	  used	  to	  study	  NKG2C+	  cells	  in	  HCMV	  infection	  (Guma	  et	  al.	  2006).	  Experiments	  done	  with	  
freshly	  isolated	  PBMCs	  from	  blood	  of	  healthy	  volunteers	  showed	  an	  increase	  in	  the	  proportion	  
of	  NKG2H+	  cells	  after	  co-­‐culture	  of	   the	  PBMCs	  with	  HCMV	   infected	   fibroblasts	  similar	   to	   that	  
observed	   for	   NKG2C+	   cells.	   These	   data	   have	   been	   generated	   in	   an	   allogeneic	   environment;	  
however	   no	   changes	   in	   NKG2H	   receptor	   expression	   on	   control	   PBMCs	   incubated	  with	  mock	  
infected	   fibroblasts	  was	  observed.	   Further,	   the	   expansion	  of	  NKG2C+	   cells	   after	   co-­‐culture	  of	  
PBMC	  from	  HCMV	  seropositive	  individuals	  with	  HCMV	  infected	  fibroblasts	  has	  previously	  been	  
shown	   to	   be	   comparable	   in	   allogeneic	   and	   autologous	   systems	   (Guma	   et	   al.	   2006;	   Petersen	   et	   al.	  
2010).	  To	  what	  extent	  the	  CD94/NKG2H	  heterodimer	  is	  involved	  in	  driving	  the	  observed	  HCMV	  
induced	  T	   cell	   and	  NK	   cell	   expansion	   constitutes	  a	   relevant	  question.	   In	  PBMCs	   from	  healthy	  
donors	  the	  NKG2H	  receptor	  was	  expressed	  at	  relatively	  modest	  levels,	  preferentially	  detected	  
on	  CD8+	  T	  cells	  and	  CD3+CD56+	  double	  positive	  cells	  but	  only	  a	  minor	  proportion	  on	  NK	  cells.	  
During	   the	   period	   of	   co-­‐culture	   of	   PBMCs	  with	  HCMV	   infected	   fibroblasts	   an	   increase	   of	   the	  
percentage	  of	  NKG2H	  expressing	  T	  cells,	  CD3+CD56+	  cells	  as	  well	  as	  NK	  cells	  was	  noted-­‐	  weak	  
after	   three	  days	  and	  much	  more	  prominent	  after	  7	  days	  of	   culture.	   These	  data	  are	  easier	   to	  
reconcile	  with	  a	  model	  where	   the	   cells	  have	  acquired	  NKG2H	   receptor	   after	   exposure	  of	   the	  
PBMCs	  to	  virus	   infection	  rather	   than	  that	   the	  NKG2H+	  cells	  have	  expanded.	  However,	  NKG2H	  
specific	   expansion	   during	   HCMV	   infections	   cannot	   be	   excluded.	   Indeed	   the	   transwell	  
experiments	  (Fig.	  5)	  indicate	  that	  contact	  between	  the	  virus-­‐infected	  cells	  and	  the	  lymphocytes	  
markedly	   enhances	   the	   increase	   in	   NKG2H	   expression,	   although	   this	   could	   also	   reflect	  
enhanced	  lymphocyte	  activation	  due	  to	  cell:cell	  contact.	  
In	   parallel	   to	   the	   analysis	   of	   NKG2H	   expression,	   changes	   in	   the	   proportion	   of	   NKG2C	   and	  
NKG2A	   molecules	   on	   PBMCs	   after	   stimulation	   with	   HCMV	   infected	   fibroblasts	   were	   also	  
examined.	  Whereas	  the	  expansion	  of	  NKG2H+	  cells	  was	  consistent	  over	  multiple	  experiments	  no	  
consistent	   changes	   in	   the	   frequency	   of	   NKG2C	   and	   NKG2A	   expressing	   cells	   were	   observed.	  
According	   to	   the	   published	   data,	   NKG2C+	   cell	   expansion	   in	   vitro	   after	   exposure	   to	   HCMV	  
infected	   cells	   is	   associated	   with	   positive	   serology	   for	   HCMV	   so	   that	   it	   appears	   in	   HCMV-­‐
seropositive	   donors	   exclusively.	   As	   the	   majority	   of	   our	   healthy	   donors	   were	   HCMV-­‐
seronegative,	  the	  lack	  of	  change	  in	  the	  proportion	  of	  NKG2C+	  cells	  in	  these	  samples	  was	  to	  be	  
expected.	   In	   some	   studies,	   where	   the	   co-­‐culture	   protocol	   was	   essentially	   identical	   to	   our	  
experiments,	   no	   differences	   in	   the	   expression	   of	   the	   NKG2A	   receptor	   on	   PBMCs	   upon	   co-­‐
culture	  with	  mock	  or	  HCMV	  infected	  fibroblasts	  were	  described	  and	  the	  frequency	  of	  NKG2A+	  
cells	  appeared	  not	  to	  be	  related	  to	  HCMV	  seropositivity	  status.	  (Guma	  et	  al.	  2006;	  Lopez-­‐Verges	  et	  al.	  
2011;	  Wu	  et	  al.	  2013).	  One	  study	  has	  described	  an	  increase	  of	  functionally	  active	  CD94/NKG2A+	  NK	  
cells	  that	  occurs	  after	  24	  and	  72	  hours	  of	  addition	  of	  PBMCs	  to	  HCMV	  infected	  fibroblasts,	  but	  
an	   important	   difference	   between	   those	   experiments	   and	   the	   data	   presented	   in	   this	   thesis	   is	  
that	  these	  fibroblasts	  were	   in	   late	  stages	  of	  the	  viral	  replication	  since	  they	  had	  been	  cultured	  
for	  4	  days	  after	  the	  initial	  infection	  before	  the	  addition	  of	  PBMCs	  (Petersen	  et	  al.	  2010).	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The	  molecular	  mechanisms	   underlying	   the	   induction	   of	   NKG2H	   after	   contact	  with	   HCMV-­‐
infected	   fibroblasts	   are	   not	   clear.	   CD94/NKG2A	   expression	   has	   been	   previously	   shown	   to	   be	  
induced	   in	   T	   cells	   stimulated	  with	   IL	   -­‐12	   (Derre	   et	   al.	   2002)	   or	   upon	   TCR	   dependent	   activation	  
under	  the	  influence	  of	  IL-­‐15	  or	  TGFβ	  (Mingari	  et	  al.	  1998;	  Bertone	  et	  al.	  1999).	  Virus	  infection	  can	  also	  
induce	  the	  production	  of	   IL-­‐15	  (Ahmad	  et	  al.	  2000;	  Azimi	  et	  al.	  2000),	  a	  cytokine	  that	  plays	  a	  major	  
role	  in	  regulating	  NK	  cell	  proliferation	  and	  differentiation,	  contributing	  to	  the	  accumulation	  of	  
NK	  cells	  in	  CMV-­‐infected	  mice	  (Nguyen	  et	  al.	  2002).	  Moreover,	  an	  increased	  proportion	  of	  NKG2A+	  
lymphocytes	  were	  observed	  in	  NK	  cell	  populations	  cultured	  in	  the	  presence	  of	  IL-­‐12	  (Draghi	  et	  al.	  
2005),	  whereas	  endogenous	  IL-­‐12	  secretion	  in	  HCMV-­‐infected	  monocyte-­‐derived	  dendritic	  cells	  
(moDC)	  cultures	  has	  been	  described	  to	  induce	  NKG2A	  expression	  in	  NKG2C+	  cells	  (Saez-­‐Borderias	  
et	  al.	  2009).	  The	  transwell	  cell	  culture	  experiment	  (Fig.	  5)	  where	  PBMCs	  were	  cultured	  either	  in	  
contact	  with	  HCMV	  infected	  fibroblasts	  or	  in	  different	  chambers	  where	  only	  diffusion	  of	  soluble	  
factors	  was	  permitted	  indicated	  that	  although	  signals	   in	  the	  form	  of	  soluble	  factors	   induced	  a	  
small	  increase	  in	  the	  percentage	  of	  NKG2H+	  cells,	  contact	  between	  PBMCs	  and	  HCMV	  infected	  
fibroblast	   was	   required	   for	   efficient	   expansion	   of	   CD94/NKG2H+	   cells.	   Altogether,	   the	  
observations	  suggest	  that	  HCMV-­‐induced	  changes	  in	  the	  cytokine	  network	  may	  contribute	  but	  
are	   not	   sufficient	   to	   strongly	   drive	   increased	   NKG2H	   expression	   by	   lymphocytes	   in	   these	  
cultures.	   The	   contact	   dependence	   of	   this	   phenomenon	   could	   suggest	   the	   possibility	   of	   a	  
putative	   ligand	   expressed	   by	   HCMV-­‐infected	   fibroblasts	   able	   to	   engage	   the	   CD94/NKG2H	  
receptor.	  A	  peptide	  from	  the	  leader	  sequence	  of	  the	  UL40	  HCMV	  protein	  is	  known	  to	  preserve	  
HLA-­‐E	  expression	  in	  HCMV-­‐infected	  fibroblasts,	  protecting	  them	  from	  lysis	  by	  CD94/NKG2A+	  NK	  
cells	  (Tomasec	  et	  al.	  2000;	  Ulbrecht	  et	  al.	  2000;	  Wang	  et	  al.	  2002).	  Polymorphisms	  of	  HCMV	  UL40	  have	  
been	   shown	   to	   impact	   the	   affinity	   of	   the	   interaction	   with	   the	   inhibitory	   CD94/NKG2A	   or	  
activating	  CD94/NKG2C	  receptors	  on	  NK	  cells	  (Heatley	  et	  al.	  2013).	  Thus	  it	   is	  at	  least	  conceivable	  
that	   some	   viral	   protein,	   or	   peptide	   from	   a	   viral	   protein	   presented	   in	   the	   context	   of	   an	   HLA	  
molecule,	   could	   contribute	   to	   the	   increased	   NKG2H	   expression	   by	   T	   and	   NK	   cells	   in	   these	  
cultures.	   Another	   possibility	   is	   that	   the	  NKG2H	   receptor	   could	   react	  with	  molecular	   patterns	  
presented	  on	  infected	  cells,	  which	  are	  not	  restricted/associated	  with	  HLA.	  A	  final	  possibility	   is	  
that	   NKG2H	   expression	   is	   a	   secondary	   consequence	   of	   activation	   of	   some	   populations	   of	  
lymphocytes,	   however	   this	  model	  does	  not	   explain	  why	  only	   some	   strains	  of	  HCMV	  drive	   an	  
increase	  in	  NKG2H	  expression.	  
Each	  clinical	  HCMV	  strain	  isolated	  has	  the	  potential	  for	  a	  unique	  identity	  (Kilpatrick	  et	  al.	  1976;	  
Huang	   et	   al.	   1976),	   which	   leads	   to	   the	   hypothesis	   that	   strain	   variation,	   affects	   the	   outcome	   of	  
HCMV	   infection	   (Cerboni	   et	   al.	   2000).	   Most	   genes	   are	   highly	   conserved	   in	   sequence	   between	  
HCMV	  strains,	  but	  a	  number	  of	  genes	  predicted	  to	  encode	  membrane	  associated	  or	  secreted	  
proteins	  are	  characterized	  by	  a	  striking	  degree	  of	  variability	  (Murphy	  et	  al.	  2003;	  Pignatelli	  et	  al.	  2001;	  
Dolan	  et	   al.	   2004).	  The	  data	   in	   this	   thesis	   (Fig.	  6)	  show	  that	   the	   increased	  NKG2H	  expression	  by	  
PBMCs	  exposed	  to	  HCMV	  infected	  fibroblasts	  was	  dependent	  not	  only	  on	  the	  type	  of	  the	  virus	  
(HCMV,	  but	  not	  HSV	  or	  Vaccinia),	  but	  also	  on	  the	  strain	  of	  HCMV	  employed.	  Of	  the	  four	  HCMV	  
strains	  that	  were	  studied	  here,	  Merlin,	  Toledo,	  TB/40	  and	  AD169	  only	  HCMV	  strains	  Merlin	  and	  
TB/40	   were	   able	   to	   drive	   the	   increase	   of	   NKG2H	   expression.	   From	   the	   low-­‐passage	   clinical	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strains,	   the	   minimally	   passaged	   strain	   Merlin	   is	   considered	   to	   best	   represent	   the	   wild-­‐type	  
HCMV	   genome,	   containing	   no	   obvious	  mutations	   other	   than	   a	   single	   nucleotide	   substitution	  
that	  truncates	  the	  UL128	  gene	  (Dolan	  et	  al.	  2004).	  The	  highly-­‐passaged,	  attenuated	  strain	  AD169	  
is	   known	   to	   have	   lost	   virulence	   and	   experienced	   substantial	   alteration	   in	   its	   genome	   during	  
passage	   in	  cell	   culture	   (Elek	   et	   al.	   1974;	  Quinnan	   et	   al.	   1984)	   including	   the	   loss	  of	  a	   region	  of	  DNA	  
containing	   at	   least	   19	   ORFs	   (denoted	   UL133	   to	   UL151)	   that	   are	   normally	   found	   in	   the	   low-­‐
passage	   clinical	   isolates	   including,	   Toledo,	   TB/40	   and	  Merlin	   (Cha	   et	   al.	   1996).	   Thus	   there	   is	   a	  
possibility	  that	  some	  of	  these	  genes,	  at	  least	  in	  the	  case	  of	  TB/40	  and	  Merlin	  are	  important	  for	  
the	   increased	  NKG2H	   expression.	   It	   has	   been	   recently	   demonstrated	   that	  HCMV	   infection	   of	  
different	  monocyte-­‐derived	   cell	   types	   triggered	  different	  NK	   cell	   response	   (Romo	   et	   al.	   2011(2)).	  
Additionally,	   depending	   on	   the	   degree	   of	   adaptation	   in	   fibroblasts,	   HCMV	   strains	   display	  
different	   levels	   of	   virulence,	   tissue	   tropism,	   and	   pathogenicity.	   All	   four	   of	   the	   HCMV	   strains	  
used	   in	   these	   studies	  have	  been	   sequenced	  and	   these	  analyses	  have	   revealed	  divergences	   in	  
genome-­‐size,	   inversion,	   orientation	   and	   coding	   potential,	   even	   within	   conserved	   genes,	  
including	  nucleotide	  polymorphism,	  DNA	  strand	  composition	  asymmetry,	  and	  evolutionary	  rate	  
variation	  in	  conserved	  genes	  (Murphy	  et	  al.	  2008;	  Cunningham	  et	  al.	  2010).	  Thus	  it	  will	  not	  be	  trivial	  to	  
elucidate	   the	   key	   differences	   between	   Merlin/TB40	   and	   Toledo/AD169	   that	   underlay	   the	  
differential	  ability	  of	  these	  strains	  to	  drive	   increased	  NKG2H	  expression,	  particularly	  since	  the	  
differences	  in	  the	  ability	  of	  these	  viruses	  to	  trigger	  increased	  expression	  of	  the	  NKG2H	  receptor	  
after	  exposure	   to	  virus-­‐infected	  hTERT	   fibroblasts,	   could	   reflect	   some	  difference	   in	   the	  direct	  
interaction	  of	  a	  viral	  component	  with	  the	  NK	  cell	  or,	  some	  difference	  in	  the	  replication	  of	  these	  
viruses	   in	   fibroblasts	   that	   indirectly	  modulates	   this	   phenotype.	   For	   example,	   diversity	   in	   the	  
requirements	   for	   the	   function	  of	   some	  core	  DNA	   replication	  proteins	   involved	   in	  HCMV	  DNA	  
replication	   during	   lytic	   infection	   have	   been	   described	   between	   different	   fibroblast	   cell	   lines	  
(Goldmacher	  et	  al.	  1999;	  Skaletskaya	  et	  al.	  2001;	  Xu	  et	  al.	  2004).	  Finally,	  we	  observed	  no	  change	   in	  the	  
proportion	   of	   NKG2H+	   cells	   in	   PBMCs	   co-­‐cultured	   with	   HSV	   and	   Vaccinia	   virus	   infected	  
fibroblast	   strongly	   suggesting	   that	   the	  expansion	  of	  CD94/NKG2H	  expressing	   cells,	   at	   least	   to	  
some	  extent,	  is	  HCMV-­‐	  specific.	  	  
Interestingly,	   when	   the	   expression	   of	   NKG2H	   mRNA	   by	   the	   virus	   stimulated	   PBMCs	   was	  
analysed	   no	   correlation	   between	   transcription	   levels	   and	   surface	   expression	   of	   NKG2H	  
molecule	   was	   seen.	   This	   suggests	   that	   transcriptional	   regulation	   does	   not	   account	   for	   the	  
enhanced	   expression	   of	   NKG2H	  molecule	   and	   indicates	   as	  more	   likely	   a	   post	   transcriptional	  
and/or	  posttranslational	  regulation	  of	  NKG2H	  protein	  expression	  at	  the	  cell	  surface.	  Consistent	  
with	   this	   idea,	   recently,	   data	   have	   been	   published	   demonstrating	   the	   existence	   of	   intra-­‐
cytoplasmic	  complexes	  of	  NKG2E	  with	  CD94	  and	  DAP12	  (Orbelyan	  et	  al.	  2014).	  NKG2H	  is	  a	  splice	  
variant	  of	  NKG2E	  in	  which	  intron	  VI	  has	  not	  been	  removed	  and	  does	  not	  contain	  exon	  VII.	  Thus	  
the	  existence	  of	  NKG2H	  protein	  and/or	  CD94-­‐NKG2H-­‐DAP12	  complexes	  constitutively	  stored	  in	  
intra-­‐cytoplasmic	  pools	  that	  can	  be	  expressed	  after	  specific	  receptor–ligand	   interaction	   in	  the	  
absence	   of	   new	   gene	   expression	   might	   be	   possible	   mechanism	   of	   regulation	   of	   surface	  
expression	   of	   NKG2H.	   Experiments	   addressing	   the	  mechanisms	   involved	   in	   the	   regulation	   of	  
constitutive	  and	  inducible	  NKG2H	  expression	  need	  to	  be	  done.	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Withdrawal	  of	  PBMCs	  from	  contact	  with	  the	  infected	  fibroblast	  led	  to	  a	  rapid	  loss	  of	  NKG2H	  
expression	   supporting	   the	   idea	   that,	   under	   the	   influence	   of	  HCMV	   infection,	   CD94/NKG2H	   is	  
only	  transiently	   induced	  at	  the	  cell	  surface.	  This	  observation	  is	  consistent	  with	  the	  hypothesis	  
that	  acquisition	  of	  the	  NKG2H	  activating	  receptor	  may	  play	  a	  role	  in	  the	  regulation	  of	  T	  cell	  and	  
NK	  cell	   responses	  during	   the	  acute	  phase	  of	  virus	   infection	  so	   that	  on	  apparent	   resolution	  of	  
HCMV	   infection,	  NKG2H	  expression	   is	   no	   longer	  necessary	   and	   the	   receptor	  disappears	   from	  
the	   cell	   surface.	  However,	   a	   recent	   report	   suggests	   that	  HCMV	   independently	   affects	   the	  NK	  
and	  T	  cell	  compartments	  (Bengner	  et	  al.	  2013),	  thus	  the	  possibility	  that	  NKG2H	  molecule	  may	  play	  
different	  roles	  in	  individual	  cell	  subsets	  should	  not	  be	  excluded.	  	  
In	  order	  to	  assess	  the	  functional	  capacity	  of	  PBMCs	  after	  co-­‐culture	  with	  infected	  fibroblasts	  
CD107a	  degranulation	  assays	  to	  measure	  NK	  (Alter	  et	  al.	  2004)	  and	  T	  cell	  (Kannan	  et	  al.	  1996;	  Bossi	  et	  
al.	  1999;	  Betts	  et	  al.	  2003)	  cytotoxicity	  were	  performed.	  The	  increased	  percentage	  of	  CD107a+	  cells	  
in	  PBMCs	  stimulated	  with	  mock	  infected	  fibroblasts	  was	  due	  to	  allogeneic	  responses	  made	  by	  
the	  donor	  PBMCs	  towards	  the	  HLA-­‐mismatched	  fibroblasts	  and	  includes	  responses	  of	  both	  allo-­‐
reactive	   T	   cells	   (Lindahl	   et	   al.	   1977;	   Kalil	   et	   al.	   1983;	   Nieda	   et	   al.	   1985;	   Suchin	   et	   al.	   2001)	   and	  NK	   cells	  
(Ciccone	  et	  al.	  1992(1)(2);	  Colonna	  et	  al.	  1992;	  Colonna	  et	  al.	  1993).	   It	  has	  been	  previously	  proposed	  that	  
the	  presence	  of	  cross-­‐reactive	  anti-­‐viral	  T	  cells	  may	  contribute	  to	  a	  less	  controllable	  and	  easily	  
magnified	  immunological	  response	  to	  allogeneic	  stimulations	  and/or	  viral	  reactivation	  (Gamadia	  
et	  al.	  2004;	  Elkington	  et	  al.	  2005;	  Rist	  et	  al.	  2009;	  Morice	  et	  al.	  2010).	  According	  to	  our	  data,	  neither	  CD3-­‐
CD56+	  NK	  cells	  nor	  CD3+CD56-­‐	  T	  cells	  or	  CD3+CD56+	  cells	  previously	  exposed	  to	  HCMV	  infected	  
fibroblasts	  were	   primed	   for	   enhanced	   reactivity	   towards	   the	  HLA-­‐allo-­‐antigens	   on	   the	  mock-­‐
infected	   cells	   or	   the	   HCMV	   infected	   fibroblasts	   on	   a	   second	   exposure	   to	   viral	   antigens.	   In	  
contrast,	  T	  cells	  previously	  exposed	  to	  mock	   infected	  fibroblasts	  showed	  enhanced	  responses	  
to	  those	  same	  fibroblasts	  on	  secondary	  challenge,	  but	  responded	  very	  poorly	  to	  HCMV-­‐infected	  
fibroblasts.	  NK	  cells	  primed	  by	  culture	  on	  mock	  infected	  fibroblasts	  showed	  a	  marked	  increase	  
in	   their	  degranulation	   to	  HCMV	   infected	   cells	   (and	  a	   smaller	   increase	   towards	  mock	   infected	  
fibroblasts).	   According	   to	   our	   data,	   the	   exposure	   of	   PBMCs	   to	   HCMV	   infected	   fibroblasts	  
triggered	   an	   increase	   in	   the	   proportion	   of	   NKG2H+	   cells	   for	   both	   T	   and	   NK	   cells,	   thus	   one	  
interpretation	  of	  these	  data	  is	  that	  the	  increased	  expression	  of	  NKG2H	  has	  different	  effects	  on	  
T	   and	  NK	   cells;	   inhibition	  of	   T	   cell	   activation,	   but	   enhancement	  of	  NK	   cell	   stimulation.	   These	  
experiments	  are	  however	  very	   complex,	   since	  HCMV	   infection	  will	  downregulate	  MHC	  class	   I	  
expression	  –	  probably	  affecting	  the	  priming	  of	  alloreactive	  T	  cells	  and	  HCMV	  infection	  will	  also	  
lead	   to	   the	   downregulation	   of	   multiple	   ligands	   for	   activating	   receptors	   of	   NK	   cells	   again	  
affecting	   the	   activation	   of	   these	   cells.	   Indeed	   HCMV	   infection	   protects	   allogeneic	   fibroblasts	  
from	  NK	  cell	  recognition	  (Valés-­‐Gómez	  et	  al.	  2003;	  Wilkinson	  et	  al.	  2008).	  Moreover	  at	  present	  no	  firm	  
conclusions	   can	   be	   made	   about	   the	   role	   of	   NKG2H	   in	   the	   phenomena	   observed.	   Thus,	   this	  
experiment	   needs	   to	   be	   repeated	   and	   improved.	   A	   first	   step	   would	   be	   to	   include	   F(ab)2	  
fragments	   of	   blocking	   CD94	  mAbs	   and	   ideally	   an	  NKG2H	  mAb.	   An	   additional	   complication	   is	  
that	  modification	  of	  the	  currently	  available	  NKG2H-­‐specific	  mAb,	  by	  labelling	  with	  Alexa	  488,	  PE	  
or	  biotin,	   leads	  to	  loss	  of	  reactivity	  (data	  not	  shown),	  presumably	  reflecting	  the	  presence	  of	  a	  
lysine	   residue	   in	   the	   antigen-­‐combining	   site	   of	   this	   mAb	   that	   is	   targeted	   by	   the	   labelling	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chemistry.	  The	  absence	  of	  a	  directly	  labelled	  NKG2H-­‐reactive	  mAb	  renders	  impossible	  the	  study	  
of	  NKG2H-­‐expressing	  lymphocytes	  in	  experiments	  where	  blocking	  antibodies	  are	  used.	  
To	   further	   explore	   the	   functional	   consequences	   of	   NKG2H	   engagement	   for	   cells	   that	  
endogenously	  express	  this	  receptor,	  we	  compared	  the	  effects	  of	  stimulation	  of	  purified	  PBMCs	  
with	   anti-­‐CD3,	   anti-­‐NKG2H	   and	   anti-­‐CD3/NKG2H	   antibody	  mixes	   immobilized	   on	   plastic.	   The	  
experimental	   set-­‐up	   used:	   anti-­‐NKG2H	   antibody	   stimulation	   in	   the	   presence	   and	   absence	   of	  
suboptimal	  doses	  of	  stimulatory	  anti-­‐CD3	  antibody	  allowed	  the	  detection	  of	  both	  enhancement	  
and	  reduction	  of	  the	  stimulation	  triggered	  by	  CD3	  cross-­‐linking.	  Under	  these	  conditions	  NKG2H	  
ligation	  resulted	  in	  a	  profound	  inhibitory	  effect	  on	  T	  cell	  activation	  in	  these	  cultures.	  This	  was	  
confirmed	  by	   the	  evaluation	  of	  expression	  of	  early	   activation-­‐associated	  marker	  CD69,	  which	  
appeared	   to	   be	   significantly	   lower	   on	   stimulation	   of	   PBMCs	   after	   NKG2H	   receptor	   ligation.	  
Moreover,	   this	   inhibitory	   effect	   was	   specific	   for	   NKG2H	   receptor	   signalling	   as	   stimulation	   of	  
PBMCs	  with	  either	  anti	  CD3/NKG2A	  or	  anti-­‐CD3/NKG2C	  antibody	  mixes	  resulted	  in	  comparable	  
levels	  of	  expression	  of	  CD69	  as	   the	  PBMCs	  receiving	  control	  anti-­‐CD3	  stimulation	  only.	  These	  
data,	   together	  with	   the	   flow	   cytometry	   observation	  of	   preferential	   expression	  of	   the	  NKG2H	  
receptor	  on	  CD3+	  cells,	   implies	  a	  possible	  negative	  regulation	  of	  T	  cell	  activation	  mediated	  by	  
NKG2H	  receptor	  signalling.	  This	  observation	  is	  particularly	  striking	  since	  NKG2H	  is	  expressed	  by	  
only	  a	  small	  fraction	  of	  all	  the	  T	  cells	  in	  the	  culture	  that	  could	  respond	  to	  CD3	  cross-­‐linking.	  
Experiments	   using	   culture	   supernatants	   collected	   after	   anti-­‐CD3/NKG2H	   stimulation	   of	  
PBMCs	   revealed	   that	   the	   suppressive	  activity	   could	  not	  be	  accounted	  by	   secretion	  of	   soluble	  
factor(s)	  from	  NKG2H	  stimulated	  cells.	  This	  requirement	  for	  cell	  contact	  for	  NKG2H	  to	  mediate	  
inhibition	   suggests	   that	   these	   cells	   act	   directly	   on	   other	   T	   cells	   to	   prevent	   activation.	  
Simultaneous	  CD3/NKG2H	  receptor	   ligation	   suppressed	   the	  proliferation	  of	   the	  PBMCs	   in	   the	  
culture	  and	  the	  NKG2H-­‐dependent	  suppression	  could	  be	  shown	  to	  be	  due	  to	  the	  induction	  of	  T	  
cell	  apoptosis.	  The	  simplest	   interpretation	  of	   these	  observations	   is	   that	   the	  subsets	  of	  T	  cells	  
that	   express	   NKG2H	   exert	   a	   negative	   effect	   on	   T	   cell	   activation,	   leading	   to	   the	   subsequent	  
induction	  of	  cell	  apoptosis.	  It	  is	  still	  not	  clear	  whether	  this	  effect	  is	  mediated	  by	  upregulation	  of	  
NKG2H	  expression	  after	  TCR-­‐stimulated	  activation	  followed	  by	  NKG2H	  ligation	  and	  cell	  intrinsic	  
inhibition	  or	  whether	  the	  lymphocytes	  that	  express	  NKG2H	  prior	  to	  stimulation	  become	  able	  to	  
inhibit	   the	   activation	   of	   other	   T	   cells	   in	   trans.	   Either	   scenario	   would	   explain	   the	   failure	   of	  
multiple	  attempts	  to	  expand	  populations	  of	  T	  cells	  enriched	  for	  NKG2H	  expression	  using	  either	  
FACS	  or	  MACS	  based	  cell	  sorting,	  with	  or	  without	  single	  cell	  cloning	  followed	  by	  growth	  of	  the	  
purified	  NKG2H+	  T	  cells	  in	  vitro	  in	  the	  presence	  of	  irradiated	  autologous	  PBMCs,	  supplemented	  
with	   exogenous	   IL-­‐2	   or	   combinations	   of	   IL-­‐2	   and	   the	   mitogen	   PHA	   (data	   not	   shown).	  
Alternatively	   it	  cannot	  be	  excluded	  that	   the	  proliferative	  capacity	  of	  NKG2H+	  T	  cells	   is	   limited	  
and/or	  that	  specific	  co-­‐/stimuli	  and/or	  cytokines	  are	  necessary	  to	  enable	  these	  cells	  to	  divide.	  
Such	  regulation	  has	  not	  been	  observed	  for	  other	  activating	  NKR	  such	  NKG2C	  (Guma	  et	   al.	   2005;	  
Meresse	   et	   al.	   2006)	   but	   however,	   it	   would	   be	   reminiscent	   of	   some	   features	   of	   the	   CTLA-­‐4/B7	  
regulatory	  loop	  (Perkins	  et	  al.	  1996).	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It	  is	  interesting	  to	  note	  that	  the	  CD94/NKG2H	  receptor	  was	  described	  as	  binding	  the	  adaptor	  
molecule	  DAP12.	  Although,	  DAP12	  was	   initially	  described	   in	  NK	  cells	   in	  humans	  expression	  of	  
the	   adaptor	  molecule	   by	   T	   cells	  was	   initially	   somewhat	   controversial.	   However,	   CD4+CD28-­‐	   T	  
cells	  that	  express	  both	  DAP12	  and	  activating	  KIR	  have	  been	  described	  in	  patients	  suffering	  from	  
chronic	   inflammatory	  diseases	   (Snyder	   et	   al.	   2003;	   van	  Bergen	  et	   al.	   2004).	  Furthermore,	   in	  spite	  of	  
DAP12	  being	  first	  thought	  of	  as	  an	  ITAM-­‐containing	  adaptor	  molecule	  for	  activating	  receptors	  it	  
has	   subsequently	   been	   shown	   that	   the	   function	   of	   DAP12	   is	   more	   complex	   than	   originally	  
thought.	   DAP12	   associated	   receptors	   can	   downregulate	   TLR-­‐dependent	   responses	   in	  
macrophages	  as	  well	  as	  CD16-­‐dependent	  responses	  in	  NK	  cells	  (Hamerman	  et	  al.	  2005;	  Hamerman	  et	  
al	   2006).	   Similarly,	  DAP12	  down-­‐modulates	   the	   cytokine	  production	  by	  plasmacytoid	  dendritic	  
cell	  (pDC)	  in	  vivo	  during	  murine	  cytomegalovirus	  infection	  (Sjolin	  et	  al.	  2006)	  and	  DAP12-­‐deficient	  
B	   cells	   are	   hyper-­‐responsive	   after	   stimulation	   with	   anti-­‐IgM	   or	   CpG,	   suggesting	   that	   DAP12-­‐
coupled	   receptors	   negatively	   regulate	   B	   cell-­‐mediated	   adaptive	   immune	   responses	   (Nakano-­‐
Yokomizo	   et	   al.	   2011).	   It	   has	   been	   proposed	   that	   the	   cellular	   response	   signalled	   by	   DAP12	  
(activation	  or	  inhibition)	  varies	  in	  function	  of	  the	  avidity	  of	  the	  interaction	  between	  the	  DAP12-­‐
associated	   receptor	  and	   its	   ligand	   (Turnbull	   et	   al.	   2007).	   It	   is	  also	  worth	  noting	   that	  our	   findings	  
differ	   from	   those	   reported	   by	   Bellón	   et	   al.	   1999	   because	   in	   their	   work	   aggregation	   of	   the	  
putative	  CD94/NKG2H	  heterodimer	  expressed	  on	  a	  T	  cell	  clone	  triggered	  cytotoxicity	  and	  IFN-­‐γ	  
production	   in	   a	   TCR-­‐independent	  manner.	   This	   discrepancy	  might	   simply	   reflect	   that	   in	   their	  
experiments	  mAb	  mediated	   cross-­‐linking	  of	   CD94	   receptor	  was	  used	   and	   the	  presence	  of	   an	  
activating	   NKG2C	   molecule	   on	   the	   clone	   was	   never	   excluded,	   whereas	   in	   our	   experiments	  
stimulation	  of	  NKG2H	  by	  a	  specific	  monoclonal	  antibody	  was	  applied.	  It	  is	  also	  possible	  that	  the	  
responses	  of	  a	  single	  T	  cell	  clone	  selected	  for	   long-­‐term	  growth	  in	   in	  vitro	  culture	  may	  not	  be	  
representative	  of	  the	  full	  spectrum	  of	  responses	  of	  freshly	   isolated	  peripheral	  blood	  T	  cells	   in	  
short-­‐term	  culture.	  In	  summary	  then,	  it	  is	  possible	  that	  NKG2H	  can	  exert	  either	  stimulatory	  or	  
inhibitory	   effects	   on	   T	   cells	   and	   perhaps	   the	   level	   of	   receptor	   cross-­‐linking	   is	   extremely	  
important	  for	  generating	  negative	  signalling.	  Further	  experiments	  will	  be	  required	  to	  determine	  
the	   important	  factors	   influencing	  NKG2H-­‐mediated	   interactions	  with	  other	  cells,	   including	  the	  
level	   and	   type	   of	   NKG2H	   ligand	   expression,	   the	   expression	   of	   cofactors,	   and	   the	   ratio	   of	  
interacting	  cells.	  
Given	  that	  the	  best	  characterized	  CD94/NKG2	  heterodimers	  expressed	  by	  NK	  cells	  recognize	  
HLA-­‐E	  molecules	  loaded	  with	  nonapeptides	  derived	  from	  HLA-­‐class	  I	  signal	  sequences	  (Borrego	  et	  
al.	  1998;	  Braud	  et	  al.	  1998;	  Lee	  et	  al.	  1998;	  Llano	  et	  al.	  1998)	  one	  obvious	  candidate	  ligand	  for	  the	  NKG2H	  
receptor	   would	   be	   HLA-­‐E.	   However	   Bellón	   et	   al.	   1999	   have	   reported	   that	   the	   TAP-­‐deficient	  
mouse	  cell	  line	  RMA-­‐S	  when	  transfected	  with	  HLA-­‐E	  cDNA	  (Borrego	  et	  al.	  1998)	  and	  cultured	  in	  the	  
presence	  of	  peptides	  that	  stabilize	  HLA-­‐E	  on	  the	  surface	  was	  not	  recognized	  by	  the	  T	  cell	  clone	  
expressing	  NKG2H.	  Similarly,	  in	  the	  experiments	  described	  in	  this	  thesis,	  addition	  of	  an	  anti-­‐HLA	  
class	  I	  mAb	  (HP-­‐1F7),	  which	  detects	  all	  classical	  and	  nonclassical	  HLA	  class	  I	  molecules	  including	  
HLA-­‐E	  (Pérez-­‐Villar	  et	  al.	  1997;	  Lee	  et	  al.	  1998;	  Takao	  et	  al.	  2010),	  failed	  to	  recover	  the	  activation	  of	  the	  
PBMCs	   in	   the	   cultures	   stimulated	   with	   anti-­‐CD3/NKG2H	   antibodies.	   Finally,	   although	   it	   was	  
suggested	  that	  the	  splice	  variant	  NKG2H,	  would	  behave	  identically	  to	  NKG2E	  and	  probably	  bind	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to	  HLA-­‐E	  with	   similar	   affinity	   (Kaiser	   et	   al.	   2005)	   so	   far,	   there	   are	  no	  data	   that	  demonstrate	   an	  
interaction	  between	  HLA-­‐E	  and	  NKG2H.	  In	  aggregate	  therefore,	  the	  available	  data	  suggest	  that	  
it	   is	   possible	   that	   NKG2H	   recognizes	   and	   binds	   molecules	   that	   are	   not	   related,	   at	   least	   to	  
conventional	   HLA-­‐E-­‐leader	   peptide	   loaded	   complexes.	   However,	   to	   date	   all	   attempts	   to	  
produce	  soluble	  NKG2H	  molecules,	  which	  would	  greatly	  facilitate	  the	  search	  for	  possible	  ligands	  
for	  this	  receptor,	  have	  been	  unsuccessful.	  Difficulties	   in	  expression	  and	  refolding	  of	  wild	  type	  
intact	  ectodomain	  of	  NKG2E	  molecule	  have	  also	  been	  documented	  (Kaiser	  et	  al.	  2005)	  thus	  new	  
strategies	  to	  achieve	  high	  level	  expression	  of	  this	  gene	  in	  vitro	  are	  required	  in	  order	  to	  generate	  
the	  reagents	  needed	  to	  try	  and	  define	  the	  ligand(s)	  for	  this	  receptor.	  	  
	  
HLA-­‐E	   tetramer	   guided	   detection	   of	  Mycobacterium	   tuberculosis	   –	   specific	  
CD8+	  T	  cells	  in	  bladder	  cancer	  patients	  receiving	  BCG	  therapy.	  
Although	  immunotherapy	  by	  intravesical	  instillation	  of	  live	  bacilli	  Calmette	  Guerin	  (BCG)	  has	  
proved	  to	  be	  an	  effective	  treatment	  for	  non-­‐muscle	  invasive	  bladder	  cancer	  (Morales	  et	  al.	  1976;	  
Sylvester	  et	  al.	  2002;	  Herr	  et	  al.	  2008)	  the	  mechanism	  of	  action	  of	  intravesical	  BCG	  therapy	  is	  still	  not	  
well	  understood,	  although	  it	  is	  clear	  that	  the	  induction	  of	  a	  strong	  innate	  immune	  response	  as	  
well	  as	  T	  cell	  infiltration	  into	  the	  bladder	  are	  important.	  As	  discussed	  previously,	  one	  aspect	  of	  
this	   therapy	   that	   has	   proved	   particularly	   controversial	   is	   whether	   immunity	   to	   tuberculosis	  
antigens	   is	  of	  benefit	   to	  the	  patient;	  why	  should	  an	   immune	  response	  to	  a	  bacterium	  lead	  to	  
elimination	  of	  a	  tumour	  cell?	  It	  has	  been	  speculated	  that	  the	  pathogen	  invades	  the	  cancer	  cells	  
and	   once	   inside	   leads	   to	   their	   destruction,	   perhaps	   by	   stimulating	   some	   form	   of	   antitumor	  
immunity	  (Redelman-­‐Sidi	  et	  al.	  2014).	  An	  alternative	  view	  is	  that	  exposure	  to	  BCG	  stimulates	  a	  non-­‐
specific	   inflammatory	   response	   that	   somehow,	   perhaps	   by	   altering	   the	   balance	   of	   cytokine	  
production,	   indirectly	  potentiates	  the	  generation	  of	  effective	  anti-­‐tumour	  immunity	  (Redelman-­‐
Sidi	   et	   al.	   2014).	   If	   the	  hypothesis	  ¨immune	  responses	  to	  BCG	  benefit	   the	  patient¨	   is	  valid,	   then	  
rounds	  of	   treatment	  with	  BCG	   instillation	   are	   likely	   to	   be	   associated	  with	   an	   enhanced	  Mtb-­‐
specific	  adaptive	   immune	  response.	  The	   importance	  of	  non-­‐classically	   restricted	  T	  cells	   in	   the	  
host	  response	  to	   infection	  with	  M.Tuberculosis	  has	  already	  been	  addressed	  (Heinzel	  et	  al.	  2002),	  
however	   the	   possible	   role	   of	  M.Tuberculosis	   –	   HLA-­‐E	   -­‐	   restricted	   T	   cells	   induced	   in	   bladder	  
cancer	  patients	  after	  BCG	  instillation	  therapy	  has	  not	  been	  addressed.	  Using	  Mtb-­‐p62	  and	  Mtb-­‐
p68	   HLA-­‐E	   tetramers	   we	   screened	   nine	   bladder	   cancer	   patients	   receiving	   BCG	   therapy	   for	  
possible	  Mtb-­‐peptide	  reactive	  T	  cells.	  Our	  data	  demonstrate	  low	  frequencies	  of	  tetramer+	  cells	  
in	  the	  peripheral	  blood	  from	  these	  patients	  although	  in	  some	  of	  them,	  detectable	  levels	  could	  
be	   observed	   during	   the	   period	   of	   rest	   for	   two	  months.	   The	   frequencies	   of	   tetramer	   reactive	  
cells	  detected	  are	  comparable	  to	  other	  systems	  where	  tetramers	  have	  been	  used	  to	  visualize	  
antigen-­‐specific	  T	  cells.	  However,	  it	  might	  be	  expected	  that,	  the	  numbers	  of	  tetramer	  stained	  T	  
cells	  could	  vary	  over	  time,	  perhaps	  decreasing	  during	  the	  two	  months	  rest	  phase	  and	  increasing	  
after	  the	  rounds	  of	  instillation	  of	  BCG	  and	  such	  a	  relationship	  was	  not	  observed.	  Obviously,	  for	  
ethical	  reasons,	  in	  these	  experiments	  the	  staining	  was	  done	  using	  peripheral	  blood	  lymphocytes	  
and	  if	  activated	  HLA-­‐E	  restricted	  T	  cells	  infiltrate	  into	  the	  bladder	  after	  intravesical	  instillation	  of	  
live	  BCG	  then	  it	  might	  not	  be	  surprising	  that	  only	  a	  very	  low	  percentage	  of	  these	  cells	  could	  be	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found	   circulating	   in	   the	   bloodstream	   and	   that	   the	   kinetics	   of	   their	   appearance	   does	   not	  
coincide	  with	  the	  application	  of	  the	  therapy.	  Another	   factor	  to	  take	   into	  account	   is	   that	  even	  
though	  the	  HLA-­‐E	  restricted	  epitopes	  used	  in	  this	  study	  were	  commonly	  recognized	  by	  donors	  
exposed	   to	  Mtb	   (Joosten	   et	   al.	   2010),	   it	   could	   be	   that	   the	   pattern	   of	   epitopes	   recognized	   after	  
intravesical	   BCG	   instillation	   is	   different	   or	   that	   intravesical	   instillation	   of	   BCG	   does	   not	  
efficiently	  prime	   systemic	  T	   cell	   responses.	   Finally,	   the	  BCG	  vaccination	   status	  of	   the	  bladder	  
cancer	  patients	   is	  currently	  not	  known,	  thus	   it	   is	  possible	  that	  the	  tetramer+	  cells	  detected	   in	  
the	  blood	  of	  some	  of	  the	  patients	  before	  receiving	  their	  first	  instillation	  of	  BCG	  are	  memory	  T	  
cells	  generated	  due	   to	  exposure	   to	  Bacillus	  Calmette	  Guerin	   (BCG)	  vaccine	  or	  M.	  tuberculosis	  
infection.	  
Although	  HLA-­‐E	  is	  considered	  to	  be	  a	  highly	  conserved	  molecule,	  the	  recognition	  and	  binding	  
of	  certain	  Mtb	  derived	  peptides	  was	  shown	  to	  be	  diverse	  and	  the	  capacity	  of	  these	  peptides	  to	  
be	  presented	  and	  trigger	  a	  response	  by	  CD8+	  T	  cells	  was	  donor	  related	  (Joosten	  et	  al.	  2010).	  	  In	  our	  
study,	  we	  used	  only	  2	  from	  69	  predicted	  and	  characterized	  Mtb-­‐derived	  peptides	  to	  generate	  
recombinant	  HLA-­‐E-­‐peptide	  complexes	   in	  vitro.	  A	   larger	   study,	  where	   the	   same	   technology	   is	  
applied,	  but	  including	  additional	  HLA-­‐E	  binding	  Mtb-­‐derived	  peptides	  is	  required.	  Extending	  the	  
analysis	  to	  include	  more	  bladder	  cancer	  patients,	  with	  known	  PPD	  status,	  would	  also	  increase	  
the	  possibilities	   to	  discover	   and	   characterize	   the	   significance	  of	  Mtb-­‐peptide-­‐HLA-­‐E	   specific	   T	  
cells	   after	   BCG	   instillation	   as	   a	   biomarker	   for	   treatment	   outcome	   in	   bladder	   cancer	   patients	  
receiving	  BCG	  therapy.	  In	  this	  context,	  it	  is	  worth	  pointing	  out	  that	  the	  prognostic	  significance	  
of	  the	  expression	  of	  HLA-­‐E	  by	  bladder	  cancer	  cells	  is	  not	  very	  well	  characterized.	  In	  contrast	  to	  
HLA-­‐G,	  less	  information	  is	  available	  regarding	  HLA-­‐E	  expression	  by	  malignant	  cells	  (Wischhusen	  et	  
al.	  2007).	  In	  surgically	  removed	  malignant	  lesions,	  HLA-­‐E	  expression	  is	  increased	  in	  glioblastoma,	  
carcinomas	   of	   colon	   and	   ovary,	   lymphoma	   and	   melanoma	   (Lee	   et	   al.	   2003;	   Chang	   et	   al.	   2005;	  
Wischhusen	  et	  al.	  2007;	  Campoli	  et	  al.	  2008).	  As	  immune	  recognition	  of	  a	  cancer	  cell	  depends	  not	  only	  
on	   the	   level	  of	   tumour	  MHC	  class	   I	  expression,	  but	  also	  on	   the	  molecular	  mechanisms	  which	  
cause	   alterations	   in	   the	   MHC	   class	   I	   expression	   (Aptsiauri	   et	   al.	   2013),	   then	   even	   if	   HLA-­‐E	   is	  
expressed	  by	  the	  bladder	  cancer	  cells	  the	  ability	  of	  these	  molecule	  to	  bind	  and	  express	  at	  the	  
cell	  surface	  Mtb	  peptides	  after	  BCG	  treatment	  could	  be	  altered.	  
Lastly,	   the	   failure	   to	   detect	   enhanced	   Mtb-­‐tetramer	   reactivity	   could	   simply	   reflect	   that,	  
although	  HLA-­‐E	   restricted	   CD8+	   T	   cell	   responses	   are	   found	   in	  Mtb	   infection,	   these	   responses	  
may	   not	   be	   generated	   efficiently	   in	   these	   bladder	   cancer	   patients.	   In	   this	   regard,	   this	   study	  
might	   be	   indicating	   that	   the	   concept	   of	   an	   important	   role	   for	   BCG	   specific	   antigen	   MHC-­‐
restricted	   response	   as	   a	   key	   mechanism	   of	   BCG	   mediated	   anti-­‐bladder	   cancer	   immunity	   is	  
erroneous.	  An	   important	  caveat	  to	  this	  conclusion	   is	  the	   lack	  of	  a	  really	  good	  positive	  control	  
for	   the	  Mtb-­‐tetramer	  staining.	  However,	  data	   from	  other	  members	  of	   the	  group	  suggest	   that	  
the	  interaction	  of	  BCG	  with	  PBMC	  leads	  to	  NK	  cell	  activation	  and	  enhanced	  tumour	  cell	  killing	  
by	   these	   activated	   NK	   cells,	   and	   these	   observations	   are	   consistent	   with	   data	   from	   murine	  
models	  demonstrating	  a	  key	  role	  for	  NK	  cells	  in	  immune	  responses	  to	  bladder	  cancer	  (Brandau	  et	  
al.	  2001).	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It	   is	   also	   interesting	   to	   note	   that	   expansions	   of	   CD8+	   T	   cells	   reactive	   with	   the	   HLA-­‐E/B7	  
tetramer	  were	  observed	   in	   some	  patients	  during	   the	  course	  of	   treatment.	  The	  expectation	   is	  
that	  this	  tetramer	  will	  bind	  with	  highest	  affinity	  to	  CD94/NKG2A	  heterodimers	  (Valés-­‐Gómez	  et	  al.	  
1999).	   Thus	   the	   staining	  with	   this	   tetramer	  probably	   corresponds	   to	  CD8+	  T	   cells	   that	  express	  
inhibitory	   CD94/NKG2A	   receptors.	  When	   the	   changes	   in	   cell	   surface	   expression	   of	   the	   CD94	  
molecule	  on	  T	  cells	  in	  the	  blood	  from	  these	  patients	  was	  analysed	  and	  the	  attempt	  was	  made	  
to	  relate	  these	  data	  to	  the	  HLA-­‐E/B*07	  tetramer+	  staining	  of	  CD8+	  T	  cells.	  Significant	  variability	  
between	   the	   different	   donors	   both	   in	   the	   percentage	   of	   cells	   expressing	   CD94	   as	   well	   as	  
variation	  in	  the	  populations	  of	  T	  cells	  expressing	  different	  amounts	  of	  the	  CD94	  molecule	  on	  the	  
cell	   surface	   was	   found.	   Different	   levels	   of	   expression	   of	   CD94	   on	   T	   and	   NK	   cell	   clones	   has	  
previously	   been	   shown	   to	   correspond	   to	   expression	   of	   inhibitory	   (CD94high	   αβ+	   T	   cells	   are	   all	  
NKG2A+)	  and	  activating	  (CD94dim	  T	  cells	  either	  express	  NKG2C	  and/or	  NKG2E	  or	  NKG2H	  or	  lack	  
transcripts	  altogether)	  CD94/NKG2	  heterodimers	  (Perez-­‐Villar	  et	  al.	  1996;	  Jabri	  et	  al.	  2003).	  However	  
analyses	  of	   the	  bladder	   cancer	  patients	   revealed	   that	   some	  of	   the	  patients	  maintained	  other	  
subpopulations	  e.g.	  CD94high++,	  while	   in	  others	   it	  was	  not	  possible	  clearly	  to	  separate	  CD94high	  
from	   CD94dim	   subpopulation.	   Thus,	   although	   some	   degree	   of	   correlation	   between	   the	  
expansions	  of	  CD8+	  T	  cells	  reactive	  with	  the	  HLA-­‐E/B*07	  -­‐	  tetramer	  and	  the	  change	  of	  the	  cell	  
surface	  expression	  of	  CD94high+CD3+CD56-­‐CD4-­‐	  cells	  could	  be	  seen	  in	  some	  of	  the	  patients,	  the	  
complexity	  of	  the	  data	  analyses	  and	  the	  small	  sample	  size	  make	  it	  difficult	  to	  make	  any	  strong	  
conclusion	  just	  now.	  	  
The	  significance	  of	  induced	  expression	  of	  immunoregulatory	  molecules	  such	  as	  CD94/NKG2A	  
on	  CD8+	  T	  cells	  is	  not	  fully	  understood,	  but	  it	  is	  generally	  thought	  that	  these	  receptors	  restrain	  
CD8+	  responses.	  While	  negative	  regulation	  of	  CTL	  responses	  may	  be	  beneficial	  in	  infections	  by	  
preventing	  T-­‐cell	  exhaustion	   in	  chronic	   infections	  and	   limiting	   immunopathology	   it	  might	  also	  
be	  the	  case	  that	  limitation	  of	  the	  immune	  response	  in	  cancer	  does	  not	  lead	  to	  a	  good	  outcome;	  
one	   possible	   analogy	  might	   be	   the	   role	   of	   inhibitory	   molecules	   such	   as	   CTLA-­‐4	   and	   PD-­‐1	   in	  
modulating	   immune	   responses	   in	   melanoma	   and	   other	   cancers	   (Kyi	   &	   Postow,	   2014).	   Another	  
example	   is	   cervical	   cancer-­‐infiltrating	   CD8+	   T	   lymphocytes,	   which	   express	   increased	  
CD94/NKG2A	   levels	   compared	   with	   peripheral	   blood	   CD8+	   T	   cells	   and/or	   normal	   cervix-­‐
infiltrating	  CD8+	  T	  lymphocytes.	  Such	  increased	  expression	  of	  inhibitory	  NKRs	  could	  be	  triggered	  
via	  IL-­‐15	  or	  TGF-­‐β	  mediated	  mechanisms	  and	  probably	  abrogates	  the	  antitumor	  cytotoxicity	  of	  
the	   tumour	   infiltrating	   lymphocytes	   (Sheu	   et	   al.	   2005).	   An	   increased	   frequency	   of	   CD94	   and	  
NKG2A	  expression	  by	  tumour	   infiltrating	   lymphocytes	  compared	  to	  peripheral	  blood	  T	  cells	   in	  
human	   endometrial	   carcinoma	  may	   also	   shape	   the	   cytotoxic	   response	   of	   these	   CD8+	   T	   cells,	  
which	  may	  again	  suggest	  a	  possible	  mechanism	  of	  tumour	  escape	  from	  host	  immunity	  (Chang	  et	  
al.	   2005).	   In	   the	   context	   of	   the	   group	   of	   bladder	   cancer	   patients	   studied,	   it	   is	   not	   currently	  
possible	   to	   know	  whether	   this	   putative	   restraint	   of	   immune	   responses	   has	   a	   net	   positive	   or	  
negative	  effect,	  but	  it	  is	  particularly	  striking	  that	  CD8+	  T	  cells	  of	  only	  a	  subset	  of	  patients	  seem	  
to	   express	   CD94/NKG2A	   since,	   while	   BCG	   therapy	   leads	   to	   tumour	   clearance	   and	   patient	  
survival	   in	  around	  70%	  of	  patients	   the	  tumours	  of	  around	  30%	  of	  patients	  do	  not	  respond	  to	  
this	   therapy.	   Thus	   it	   will	   be	   interesting	   in	   future	   analyses	   to	   include	   anti-­‐NKG2A/NKG2C	   or	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NKG2H	  antibody	  together	  with	  the	  other	  T	  cell	  surface	  markers,	  which	  could	  probably	  help	  to	  
further	  classify	  patients	  and	  especially	  compare	  the	  clinical	  outcome	  of	  those	  patients	  that	  have	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The	  studies	  on	  the	  NKG2H	  receptor	  have	  shown:	  
1. In	   the	  peripheral	  blood	  of	  healthy	   individuals,	   the	  CD94/NKG2H	  receptor	   is	  expressed	  on	  
low	  numbers	  of	  circulating	  lymphocytes,	  principally	  on	  CD3+CD56+	  and	  CD3+CD8+	  cells.	  
2. The	  frequency	  of	  NKG2H+	  cells	  increases	  when	  PBMCs	  are	  co-­‐cultured	  with	  HCMV	  infected	  
fibroblasts.	   No	   significant	   changes	   in	   the	   percentages	   of	   NKG2A	   or	   NKG2C	  expressing	   T	  
cells,	  NK	  cells,	  and	  CD3+CD56+	  cells	  were	  observed	  after	  culture	  of	  PBMCs	  with	  the	  virally	  
infected	  fibroblasts.	  	  
3. The	   elevated	   proportion	   of	   NKG2H	   expressing	   cells	   produced	   by	   contact	   with	   HCMV	  
infected	  fibroblasts	  is	  not	  associated	  with	  increased	  levels	  of	  mRNA	  for	  NKG2H.	  Therefore,	  
the	  surface	  expression	  of	  NKG2H	  is	  most	  likely	  regulated	  post-­‐transcriptionally	  and/or	  post-­‐
translationally.	  	  
4. The	  increase	  in	  the	  frequency	  of	  NKG2H+	  cells	  depends	  on	  the	  type	  and	  genetic	  variant	  of	  
the	  virus.	  	  
5. Direct	  contact	  between	  the	  lymphocytes	  and	  the	  HCMV	  infected	  fibroblasts	  is	  required	  for	  
optimal	  induction	  of	  NKG2H+	  cells.	  The	  increased	  fraction	  of	  NKG2H	  expressing	  cells	  is	  not	  
stable	  over	   time	  since	  NKG2H	  expression	   is	   lost	  after	   separation	  of	  PBMCs	   from	   infected	  
fibroblasts.	  	  
6. Stimulation	  of	   cells	  via	  NKG2H,	  but	  not	   through	   the	  NKG2A	  or	  NKG2C	  receptors,	   induces	  
apoptosis	   and	   notably	   reduces	   the	   activation	   and	   proliferation	   of	   the	   other	   cells	   in	   the	  
culture.	  
7. The	   NKG2H	   dependent	   reduction	   of	   cell	   culture	   activation	   does	   not	   depend	   on	   soluble	  
factors	  or	  recognition	  of	  MHC	  class	  I	  molecules.	  	  
The	   studies	   using	   peptide/HLA-­‐E	   complexes	   to	   analyse	   the	   PBMCs	   of	   bladder	  
cancer	  patients	  have	  shown:	  
8. The	  frequencies	  of	  HLA-­‐E/p62	  and	  HLA-­‐E/p68	  tetramer+	  CD8+	  T	  cells	  in	  the	  peripheral	  blood	  
from	  9	  bladder	  cancer	  patients	  receiving	  BCG	  immunotherapy	  are	  low.	  	  
9. An	  expansion	  of	  CD8+	  T	  cells	  reactive	  with	  HLA-­‐E/B*07-­‐tetramer	  could	  be	  observed	  in	  some	  
bladder	   cancer	   patients	   during	   the	   course	   of	   treatment	  with	   live	   BCG.	   Once	   the	   clinical	  
outcome	  of	  these	  patients	   is	  resolved	  it	  will	  be	  possible	  to	  evaluate	  whether	  there	   is	  any	  
relationship	  between	  these	  changes	  and	  response	  to	  therapy.	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Conclusiones	  
Los	  estudios	  sobre	  el	  receptor	  NKG2H	  han	  mostrado:	  
1. En	   sangre	   periférica	   de	   individuos	   sanos	   el	   receptor	   CD94/NKG2H	   se	   expresa	   en	   un	  
porcentaje	  bajo	  de	  células	  CD3+CD56+	  y	  CD3+CD8+.	  
2. La	   frecuencia	   de	   células	   NKG2H	   positivas	   aumenta	   tras	   el	   co-­‐cultivo	   de	   PBMCs	   con	  
fibroblastos	   infectados	  con	  HCMV.	  Sin	  embargo,	  no	  se	  observan	  cambios	  significativos	  en	  
los	  porcentajes	  de	  células	  T,	  NK	  ni	  CD3+CD56+	  que	  expresan	  NKG2A	  o	  NKG2C	  tras	  el	  mismo	  
co-­‐cultivo	  usando	  sangre	  periférica	  de	  donantes	  seronegativos	  para	  HCMV.	  
3. La	  elevada	  proporción	  de	  células	  expresando	  NKG2H	  que	  se	  observa	  tras	  el	  contacto	  con	  
fibroblastos	  infectados	  con	  HCMV	  no	  se	  asocia	  con	  niveles	  elevados	  de	  mRNA	  para	  NKG2H.	  
Por	   lo	   tanto,	   la	   expresión	   en	   superficie	   de	   NKG2H	   probablemente	   esté	   regulada	   por	  
modificaciones	  post-­‐transcripcionales	  y/o	  post-­‐traduccionales.	  
4. El	   incremento	  en	   la	  frecuencia	  de	  células	  NKG2H	  positivas	  depende	  del	  tipo	  y	   la	  cepa	  del	  
virus.	  
5. Se	   requiere	   contacto	   directo	   entre	   los	   linfocitos	   y	   los	   fibroblastos	   infectados	   por	   HCMV	  
para	   la	   inducción	   óptima	   de	   células	   NKG2H	   positivas.	   El	   incremento	   en	   la	   fracción	   de	  
células	  que	  expresan	  NKG2H	  no	  es	  estable	  con	  el	  tiempo,	  y	   la	  expresión	  se	  pierde	  tras	   la	  
separación	  de	  los	  linfocitos	  y	  los	  fibroblastos	  infectados.	  
6. La	  estimulación	  de	  células	  a	  través	  de	  NKG2H	  pero	  no	  NKG2A	  o	  NKG2C	  induce	  apoptosis	  y	  
reduce	  notablemente	  la	  activación	  y	  la	  proliferación	  de	  otras	  células	  en	  el	  cultivo.	  
7. La	   reducción	   de	   la	   activación	   en	   el	   cultivo	   celular	   dependiente	   de	   NKG2H	   no	   requiere	  
factores	  solubles,	  ni	  el	  reconocimiento	  de	  moléculas	  MHC	  de	  clase	  I.	  
Los	  estudios	  utilizando	  complejos	  péptido/HLA-­‐	  para	  analizar	  PBMCs	  de	  pacientes	  de	  cáncer	  
de	  vejiga	  han	  mostrado:	  
8. La	  frecuencia	  de	  células	  T	  CD8+,	  positivas	  para	   los	  tetrámeros	  HLA-­‐E/p62	  y	  HLA-­‐E/p68,	  es	  
baja	  en	  sangre	  periférica	  de	  nueve	  pacientes	  de	  cáncer	  de	  vejiga	  recibiendo	  inmunoterapia	  
con	  BCG.	  
9. Se	   observa	   una	   expansión	   de	   células	   T	   CD8+	   reactivas	   con	   el	   tetrámero	   HLA-­‐E/B*07	   en	  
algunos	  de	   los	  pacientes	  de	  cáncer	  de	  vejiga	  a	   lo	   largo	  del	  tratamiento	  con	  BCG.	  Una	  vez	  
que	   se	   conozca	   la	   respuesta	   a	   la	   terapia	   de	   cada	   paciente	   será	   posible	   evaluar	   si	   existe	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